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Abstract 
Many human diseases are related to a disturbed balance of intracellular pro- and 
antioxidants, in favour of the pro-oxidants. This event is called Oxidative Stress (OS). 
The latter is characterised, for instance, by elevated levels of reactive species and 
diminished concentrations of antioxidants. 
The development of multifunctional redox modulators, which are able to exploit the 
pre-existing redox imbalance in abnormal cells promises new treatments for those 
diseases. Whilst healthy cells remain mostly unaffected, cell death in such abnormal 
cells is induced preferentially via apoptosis. 
Based on this notion, the first part of the present work describes the development of 
new redox modulators based on quinones and chalcogens. The compounds 
synthesised were investigated in detail regarding their toxicity and their redox-
modulating and anti-inflammatory properties in various cell culture assays. These 
show high effiency and selectivity and hence represent a promising class of new 
multifunctional agents. 
The second part of this work addresses the synthesis and analytical characterisation 
of potential redox modulators based on porphyrins. Hence 12 hitherho unknown 
selenium-containing metal-free porphyrins were synthesised and extensively studied 
using UV/VIS spectroscopy, mass spectrometry and different NMR-techniques. 
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Kurzfassung 
Viele menschliche Krankheiten weisen ein gestörtes Gleichgewicht der 
intrazellulären Pro- und Antioxidantien zugunsten der Pro-oxidantien auf. Diese als 
Oxidativer Stress (OS) bezeichnete Erscheinung ist u.a. durch erhöhte 
Konzentrationen an reaktiven Spezies und verminderte Konzentrationen an 
Antioxidantien charakterisiert. 
Die Entwicklung multifunktioneller Redox-Modulatoren, welche mit den intrazellulären 
Anzeichen von unter OS-leidenden Zellen interagieren können, verspricht neue 
Behandlungsmöglichkeiten für solche Krankheiten. Während gesunde Zellen 
unbeeinflusst bleiben, wird in betroffenen Zellen der Zelltod, vorzugsweise über 
Apoptose, eingeleitet. 
Auf dieser Idee beruhend beschreibt der erste Teil der vorliegenden Arbeit die 
Entwicklung neuer chinon- und chalkogenhaltiger Redox-Modulatoren. Die 
synthestisierten Verbindungen wurden umfassend bezüglich ihrer Toxizität und ihrer 
redox-modulierenden und anti-entzündlichen Eigenschaften in diversen Zellkultur-
Versuchen untersucht. Diese chalkogenhaltigen Chinone zeigen hohe Effizienz und 
Selektivität und repräsentieren somit eine neue Klasse vielversprechender 
Wirkstoffe. 
Der zweite Teil der Arbeit befasst sich mit der Synthese und analytischen 
Charakterisierung potentieller Redox-Modulatoren auf der strukturellen Grundlage 
von Porphyrin. Hierfür wurden 12 neue Selen-haltige metallfreie Porphyrine 
synthetisiert und umfassend mittels UV/VIS Spektroskopie, Massenspektrometrie 
und unterschiedlichen NMR-Techniken untersucht. 
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1. Introduction 
1.1 Oxidative Stress 
1.1.1 Definition and causes 
The term ‘Oxidative Stress’ (OS) describes the disturbed balance of the pro- and 
antioxidant systems, leading to an increase of the oxidising processes [1]. Mostly, 
under conditions of OS, a lowered capacity of antioxidant defences accomplished by 
increased cellular concentrations of oxidative stressors, like reactive oxygen species 
(ROS), reactive nitrogen species (RNS), reactive nitrogen oxygen species (RNOS), 
and free metal ions is observed [2, 3]. 
In order to reconstitute a suitable homeostasis, endogenous antioxidant systems 
consisting of enzymes as well as non-enzymatic antioxidants and also radical 
scavengers are expressed and regulated. Under prolonged conditions, OS may lead 
to irreparable membrane damage, altered enzyme function and the loss of genomic 
stability [1, 4]. OS is not only a feature of the natural ageing process, it is also 
involved in a large number of human diseases including neurodegenerative 
disorders, inflammatory diseases, cardiovascular diseases and even various types of 
cancer [5]. In many cases, OS itself is not the cause for the affection yet it is rather a 
side-effect of a genetic mutation. 
1.1.2 Reactive Species 
Reactive species are molecules that on the one hand play an important role in redox 
signalling [6], but on the other hand can also lead to severe damage of lipids, 
proteins and DNA, thus disturbing or altering their functions [2, 7]. Reactive species 
are classified into ROS, RNS, RONS and reactive sulfur species (RSS) as well as 
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labile metal ions (e.g. copper and iron). The oxygen-based ROS either contain an 
oxygen-centred radical such as the superoxide radical anion O2•-, the hydroxyl radical 
HO•, alkoxyl radicals RO• and peroxyl radicals ROO•, or they contain a nonradical 
derivative of molecular oxygen like singlet oxygen 1O2, peroxides R2O2, 
hydrogenperoxide H2O2 or hypochlorous acid HOCl. Reactive nitrogen species 
include nitric oxide •NO, peroxynitrite ONOO- and nitrogendioxide •NO2 (most RNS 
can also be considered as RONS). As long as a certain amount is not exceeded, 
reactive species act as important mediators in redox signalling. For example, •NO is a 
strong vasodilator and neurotransmitter, however, reactive species may also 
contribute to considerable damage due to interaction with proteins, enzymes or even 
oxidation of the DNA or lipids [4, 8-10]. 
ROS can enter the body exogenously, for example due to environmental influences 
such as smoking, air pollutants or exposure to UV-irradiation [1, 2, 5]. ROS are also 
formed by endogenous processes, predominantly by NADPH oxidases, xanthine 
oxidase, nitric oxide synthase (NOS) and the mitochondrial electron transport chain 
[11-13]. Since mitochondria consume 85 - 90 % of the oxygen utilised by the cell [3, 
14], ROS are naturally occuring side products of the respiratory chain located at the 
inner membrane of mitochondria [7, 11, 15]. The stable and freely diffusable H2O2 is 
considered to be the most important ROS. It is formed via the dismutation of the 
superoxide radical anion (Equation 1.1), which itself is produced mainly by the one-
electron reduction of O2 by the mitochondrial electron transport chain [3, 16]. 
Superoxide radical anions are generated ‘by mistake’ via the donation of single 
electrons, which should rather be passed down a chain of membrane protein 
complexes to a terminal electron acceptor, to O2, giving rise to the formation of O2•- 
(Equation 1.2) [17]. 
Equation 1.1:  2 O2•- + 2 H+  H2O2 + O2 
Equation 1.2:  O2 + e-  O2•- 
The generation of ROS can also be induced by other ROS: Via uncoupling the 
endothelial NOS (eNOS) by ONOO-, •NO production is switched to O2•− production 
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leading to increased production of mitochondrial ROS. H2O2 activates the production 
of O2•− by phagocytic and nonphagocytic NADPH (nicotinamide adenine dinucleotide 
phosphate) oxidases, which catalyse the transfer of electrons from NADPH to O2 via 
their Nox subunit [12]. NADPH oxidase consists of cytosolic and membrane-bound 
components [1, 18] and its activation in macrophages and other phagocytic cells 
during phagocytosis or upon stimulation with various stimuli may lead to the 
‚respiratory burst’ [19]. That oxidative burst not only provides microbicidal activity, but 
also plays an important role in redox signalling [13, 20]. 
H2O2 is able to modulate the function of proteins, mostly by modifying their thiol 
groups at cysteine residues in the presence of catalysis [19]. Since elevated levels of 
H2O2 are toxic to cells, its intracellular concentration is regulated via H2O2-reducing 
enzymes like catalases, peroxiredoxins and glutathione peroxidases (see chapter 
1.1.4.1) in vivo. These enzymes catalyse the reaction of H2O2 to non-toxic products. 
The principal RNS is nitric oxide •NO, which plays an important role in redox 
signalling. It is generated in cells by NOS such as the neuronal NOS (nNOS), 
endothelial NOS (eNOS) and the inducible NOS (iNOS), which is responsible for the 
generation of •NO in macrophages [8, 10, 21]. The metabolism of •NO leads to the 
formation of many other RNS, including the rapid reaction to peroxynitrite (Equation 
1.3), nitrite (Equation 1.4) or nitrate (Equation 1.5). 
Equation 1.3: •NO + O2•-  ONOO- 
Equation 1.4: 4 •NO + O2 + 2 H2O  4 NO2- + 4 H+ 
Equation 1.5: HbIIO2 + •NO  HbIII + NO3- 
Oxyhemoglobin or Oxymyoglobin (HbIIO2) catalyse the reaction of •NO to nitrate as 
its primary decomposition product in vivo [8]. Furthermore RNS as well as ONOO- 
are able to react with thiols [22], for example leading to S-nitrosothiols, thiyl radicals 
or sulfenic acids, which may cause further damage to the cell [23]. 
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1.1.3 Diseases related to Oxidative Stress 
A range of human diseases is related to the disturbed intracellular balance of pro- 
and antioxidants and thus the occurrence of OS. These diseases range from 
neurodegenerative diseases such as Alzheimer’ Disease to various types of cancer 
including chronic lymphocytic leukaemia (CLL), and inflammatory diseases, such as 
rheumatoid arthritis (RA). 
During cellular homeostasis, a balance between proliferation and cell death (mostly 
by apoptosis) is maintained. Cancer includes a variety of different diseases, in which 
cells grow and vigorously proliferate without control. Cancer cells exhibit genetic 
instability and elevated ROS levels. In most types of cancer, tumour suppressor 
protein p53 shows increased mutations or even loss of function, in advanced cancer 
stages in particular [7]. Cancer spreads through the body via the bloodstream or 
lymphatic vessels and thus invades adjacent tissues. The increased growth and 
spreading of malignant cells may lead to the destruction of healthy tissue and the 
generation of tumours. CLL is the most common type of leukaemia and affects B-cell 
lymphocytes [24]. Healthy B-cells originate in the bone marrow and develop in the 
lymph nodes. They act as a defence against infection by the production of antibodies. 
In contrast, CLL cells grow out of control and accumulate in the bone marrow and 
blood, where they crowd out healthy blood cells. CLL mostly affects older people 
(age over 50 years) and is characterised by swollen lymph nodes and eventually 
anaemia and infections. Whilst peripheral mononuclear blood cells (PBMC) maintain 
an intracellular balance, CLL cells show significantly higher ROS levels [25]. That 
circumstance can be exploited as part of therapeutic approaches [7].  
In contrast, RA is a chronic inflammatory and autoimmune disease characterised by 
painful swollen joints, particularly those of hands, feet, elbows, and knees. RA affects 
approximately one percent of the European population, mostly women [14]. It seems 
that various factors, such as defective immune cells and certain viruses, play a role in 
RA, but the initiating event in RA is currently still unknown. Macrophages are widely 
distributed in the peripheral and lymphoid system since they are part of the body’s 
defence system [26] and play an important key role in inflammatory diseases, like 
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sepsis, atherosclerosis [27], or also RA. During the process of RA, the synovial 
membrane, which consists of macrophage- and fibroblast-like cells, expands (see 
Figure 1.1). Macrophages mediate pro-inflammatory cytokines and inflammatory 
mediators, such as interleukin-1β (IL-1β), tumour necrosis factor α (TNF-α) and •NO 
[28, 29]. The chemokine secretion triggers the recruitment of many immune and 
inflammatory cells into the affected area. The accumulation, activation, differentiation 
and persistence of these cells in the affected tissue trigger the autoimmune process. 
The recruited inflammatory cells contribute to degradation of cartilage and bone 
through the release of proteolytic enzymes, ROS and RNS, such as •OH, O2•- or •NO, 
which themselves generate secondary ROS and RNS [30, 31].  
 
Figure 1.1: Schematic display of a human joint affected by RA, adopted from [32]. Details of the 
genesis and courses of RA are provided in the text. 
The reduction of the number of activated macrophages as well as the inhibition of 
activation signals are considered as promising therapeutic approaches against 
inflammatory diseases [29]. The urgent need for new anti-inflammatory drugs with 
selective pharmacology and less toxicity faces problems like side effects, delivery 
problems and cost of manufacture [33]. 
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1.1.4 Natural defence systems against OS 
There are several ways how a healthy cell can react towards OS. It possesses an 
enzymatic defence system made up of enzymes such as catalase (CAT), glutathione 
peroxidise (GPx), superoxide dismutase (SOD) and peroxiredoxin (Prx) as well as 
non-enzymatic exogenous substrates like ascorbic acid, α-tocopherole and 
glutathione (GSH). 
1.1.4.1 Antioxidant enzymes 
There are a number of antioxidant enzymes which detoxify reactive to non-hazardous 
species. The intracellular content of these enzymes differs depending on the cell type 
and the general status of the individual cell. In the following section a selection of 
antioxidant enzymes is shortly discussed. 
Oscar Loew discovered in 1900 the first antioxidant enzyme, the iron-containing CAT 
[34], which is generally found in peroxisomes [19] and catalyses the dismutation of 
H2O2 to water and oxygen O2 (Equation 1.6) [35]. 
Equation 1.6: 2 H2O2  2 H2O + O2  
The exact mechanism of transforming H2O2 into H2O is yet still unknown, but the 
oxidation of Fe3+ to an oxoferrylgroup (Fe=O) is suspected to be involved in the 
process [36]. 
SOD, which catalyses the dismutation of superoxide radical anions to H2O2 and O2 
(see Equation 1.1), occurs in three forms in humans: SOD1, which is found in the 
cytosol and SOD3, which is found extracellularly, whereby both contain zinc and 
redox active copper. In contrast, SOD2, which contains manganese, is present in the 
mitochondria [13, 16, 37, 38]. 
The selenoprotein GPx requires the substrate GSH to reduce hydroperoxides such 
as H2O2 to water or alcohol, respectively (Equation 1.7) [35]. 
Equation 1.7: H2O2 + 2 GSH  GSSG + 2 H2O 
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Until now, five different GPx isoforms have been identified in the human body [39]. 
GPx1, which prefers H2O2 as substrate, is found in the cytoplasm of nearly all 
mammalian tissues and is thus the most abundant form of the selenium-containing 
enzymes [40]. 
Prx also reduce H2O2, with Prx1, Prx2, Prx3 and Prx5 using cellular thiols like 
thioredoxin (Trx) to detoxify H2O2 (Equation 1.8) [35]. Prx4 can also use GSH instead 
and Prx6 exclusively uses GSH [34]. 
Equation 1.8: H2O2 + Trx-(SH)2  H2O + Trx-(SS) 
1.1.4.2 Endogenous antioxidants 
In contrast to regenerative antioxidant enzymes, endogenous antioxidants have to be 
used stochiometrically. 
Originally, antioxidant research once comprehended the use of antioxidants in 
important industrial processes, later the prevention of the oxidation of unsaturated 
fats became its focus [41]. Within the identification of vitamins A, C, and E as 
antioxidants, biochemical events and related processes scavenging reactive species 
came into focus of antioxidant research. The latter was oriented strongly at natural 
occurring compounds, such as polyphenols, which have attracted attention due to 
their antimicrobial, antiviral and also anticancer activities, or also curcumin, which 
gained attention for its anti-inflammatory and antioxidant effects [15]. 
Antioxidants can be classified into hydrophilic and hydrophobic substances as well as 
into endogenous antioxidants (which are generated by the organism itself) and 
exogenous antioxidants (which have to be taken up, for example by nutrition). The 
water-soluble antioxidants like GSH (Figure 1.2) or α-lipoic acid (Figure 1.2) react 
with oxidants in the cell cytosol and the blood plasma. The lipid-soluble antioxidants 
like α-tocopherol (Figure 1.2) act in lipid compartments and thus protect cell 
membranes from lipid peroxidation. 
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Figure 1.2: Selection of antioxidants: glutathione, α-tocopherol, α-lipoic acid and ascorbic acid. 
The cellular redox buffer GSH (L-γ-glutamyl-L-cysteinylglycine, Figure 1.2) is a 
cysteine containing tripeptide and its concentration in eukaryotic systems is in the 
millimolar range [19, 42]. To maintain cellular constituents in their reduced states, 
GSH works in concert with enzymatic systems (Figure 1.3). Hence, H2O2 is reduced 
to H2O via the enzymatic reaction with GPx, which requires GSH as a substrate. 
Alternatively, damaging radicals (R•) can also be scavenged directly. 
 
 
Figure 1.3: Reaction scheme for the detoxifying redox mechanisms involving glutathione. 
Details are provided in the text. 
GSH itself is regulated in the reduced form by the NADPH-dependent enzyme 
glutathione reductase (GR), which catalytically reduces the oxidised glutathione 
disulfide (GSSG) to GSH. The reversibility of the oxidation and reduction of the thiol 
group in GSH facilitates the prevention of the accumulation of oxidants or radicals. In 
its role as a substrate for the seleno-enzyme GPx, GSH drives the reduction of H2O2 
and other peroxides to water and alcohol. 
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In the group of vitamin E, the radical-scavanger α-tocopherol (Figure 1.2) plays the 
most important role, because it protects membranes from oxidation by reacting with 
lipid radicals produced in the lipid peroxidation chain reaction. The oxidised  
α-tocopheroxyl radicals produced can be recycled back to the reduced form through 
the reduction by other antioxidants, like ascorbate and thiols [1]. 
α-Lipoic acid (LA, Figure 1.2) is a radical scavenger which can regenerate consumed 
antioxidants like vitamin C, vitamin E and glutathione. Naturally occuring LA is found 
as a prosthetic group in keto acid dehydrogenase complexes of mitochondria [43]. LA 
is absorbed from the diet, and able to cross the blood-brain barrier. It is transported, 
taken up by cells and tissues and reduced intracellularly to dihydrolipoic acid [44] and 
acts as a co-enzyme in a number of enzymatic reactions [45]. 
1.1.4.3 Exogenous antioxidants 
Ascorbic acid (Figure 1.2) is an example for an antioxidant which has to be taken up 
by nutrition. The redox catalyst ascorbic acid is able to terminate chain radical 
reactions caused by reactive species by transferring an electron, leading to 
semidehydroascorbate, which is relatively unreactive and does not cause any 
damage [46]. 
1.1.5 Strategies for the treatment of oxidatively stressed cells 
There are several possibilities to target OS. If the antioxidant defence system is 
lowered by insufficient supply with antioxidants, dietary supplementation may 
affirmate relief. But still, most studies in this area and their results are controversal. 
The different therapeutic approaches are even more complicated. Predominantly, the 
basic thought to target OS in the living cell is based on the fact that a healthy cell 
possesses another level of oxidants in contrast to an abnormal cell. In cancer cells, 
elevated levels of ROS are observed. This circumstance can be exploited for the 
selective treatment of these abnormal cells, whereas leaving the unaffected cells 
unaltered [7, 47]. The keynote of this selective treatment is the thought, that when 
reaching a certain redox threshold, complicated mechanisms leading to apoptotic cell 
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death are induced (see Figure 1.4). By treatment with either a ROS-generating drug, 
an inhibitor of antioxidant systems or an intelligent catalytic agent the intracellular 
disturbed redox balance can be modified further via elevating the existing ROS-levels 
over a critical threshold. 
 
Figure 1.4: Different possible therapeutic approaches to target cells suffering from OS adopted 
from [48]. Whilst normal cells provide a balanced equilibrium between pro- and antioxidants, 
cancer cells possess elevated intracellular ROS-levels. The elevation of these ROS-levels over 
a certain critical threshold may induce processes leading to cell death. 
Doxorubicin [7, 49, 50] (Figure 1.5), β-Lapachon [51] and its derivates such as 
deoxynyboquinone [44] are examples for drugs, which are able to push the already 
existing ROS levels further. These ROS-generating agents do not necessarily have 
to be specific by themselves, because the unaffected cell still does not reach the 
critical redox threshold where cell death is induced. In contrast, a cell suffering from 
OS reaches that critical level and as a result, cell death is induced. 
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Figure 1.5: Chemical structures of agents used for therapeutical approaches to target OS. 
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Another approach for selective treatment interferes with essential antioxidative 
defence systems. The SOD-inhibitor 2-methoxyestradiol (Figure 1.5), for example, 
prevents the detoxification of ROS [7, 52], resulting in an ‘overwhelming’ 
concentration of O2•- and its follow-on products [47]. The appropriate redox damage 
to a non-cancerous cell caused by such inhibitors is generally considered as modest. 
Other compounds are able to convert the existing ROS into even more damaging 
ROS, like the extremely toxic hydroxylradical •OH. Yet others ‘intelligent’ redox 
modulators are able to exert a SOD- or GPx-like activity. In particular organotellurium 
compounds such as 4,4’-dihydroxydiphenyltelluride (Figure 1.5) act as potent GPx-
mimics and thus are able to use H2O2 for the oxidation of tellurium. During this 
process these agents also oxidise thiols rather than consuming the sacrificial GSH 
[53], which in turn can drive the cells affected into apoptosis. 
The circumstances leading to cell death may be much more complex and are not yet 
fully understood. The group of Prof. Jacob has been working in the research area of 
the development of these above mentioned ‘intelligent’ redox modulators as well as 
‘sensor/effector’ molecules for several years. During the last years, studies with the 
organotellurium compounds investigated pointed towards certain selectivity of these 
compounds for cells which suffer from OS (see also chapter 1.2), and thus the term 
‘sensor/effector’ molecule has been coined for these compounds. 
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1.2 State of the art 
1.2.1 Quinone-containing xenobiotics 
Some xenobiotics can enhance the generation of ROS via redox cycling. These 
redox cyclers, like the 1,4-naphthoquinone-containing junglone, form free radical 
intermediates by accepting electrons from biological sources. These intermediates 
can then transfer these electrons onto O2 to generate O2•- under the regeneration of 
the original compound [54]. 
Quinones represent a group of xenobiotics, which are on the one hand able to 
generate ROS and on the other hand, cause the depletion of antioxidants in cells. 
Certain quinones are potent electrophiles and also able to react with thiol groups in 
proteins as well as GSH [54]. Quinones can be reduced enzymatically to 
semiquinones, which themselves can be reduced to hydroquinones (Figure 1.6). 
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Figure 1.6: Reaction scheme for the redox cycling of quinones as exemplified with junglone 
adopted from [34]. Quinones can be reduced to semiquinones or hydroquinones. 
The original quinone can be regenerated by molecular oxygen under the release of 
the superoxide radical anion. To facilitate the reduction of the quinone NADPH or 
NADH may be used (as long as present in the cell in sufficient amounts) [34]. 
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During the last couple of years, benzoquinone-derivatives have gained considerable 
attention as potential antitumour agents. The derivative 2,5-diaziridinyl-3-
(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1), for instance, is a novel 
antitumour candidate that is currently in Phase I clinical trials [55]. 
1.2.2 Chalcogen-containing redox modulators 
Although being discovered early in 1782 and 1817 by the Swedish chemist Jöns 
Jakob Berzelius [39, 56] and by the Austrian chemist Franz-Joseph Mueller von 
Reichenstein [53], respectively, selenium and tellurium did not gain much attention in 
Biology since they were both considered to be toxic for a long time. In the 1950s 
selenium was identified as an essential trace element [57]. Researchers found that a 
deficiency in selenium can be related to diverse biochemical disturbances as well as 
certain diseases. In particular, people living in regions with insufficient supply of 
selenium, like the region of north-eastern China, develop selenium-dependent 
deficiency symptoms, such as loss of hair, anaemia, disruption of growth and 
osteogenesis. The increased endemic occurrence of Keshan and Khasin-Beck 
disease is reported in that particular region, too [40]. Keshan disease is known to not 
only being caused by selenium-deficiency, but rather by low GPx1 activity, a family 
history of the disease and living in an endemic area [58]. Here, the selenocysteine-
containing selenoproteins (such as GPx) play an important role in the living organism 
and regulate many essential processes, including antioxidant defence systems.  
The antioxidant and anticarciogenic effects of selenium-containing compounds and 
enzymes remain an often discussed topic [2, 56, 59]. In order to act against 
selenium-deficiency, several approaches to provide the organism with the trace 
element have been considered. In the field of synthetic antioxidants, mimics of 
antioxidant enzymes, such as 2-phenyl-1,2-benzisoselenazol-3(2H)-one (also known 
as ebselen, Figure 1.7), have received a certain attention. Detailed studies during the 
last decades identified ebselen as a potential anti-inflammatory antioxidant [60-63]. 
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Figure 1.7: Reaction scheme for possible mechanism for the GPx-mimicking activity of ebselen 
as proposed by Sarma and Mugesh, adopted from [56]. 
There are several possible redox cycling processes, describing how ebselen may 
exhibit its GPx-like activity. Ebselen could be oxidised by reactive species like H2O2 
to the selenoxide derivative a (cycle A). The reaction of the selenoxide with a thiol 
RSH, leading to the formation of a thiolseleninate b, can be followed by another 
reaction with thiol under the release of seleninic acid c and disulfide RSSR. 
Intramolecular rearrangement may recover ebselen. Alternatively, ebselen could be 
cleaved by a thiol group to form the selenyl sulfide d first. That species is able to 
react with another thiol group leading to ebselen selenol e (cycle B), which may 
reduce H2O2 via entering in possible mechanism as described in cycle A. The 
disproportion of the selenyl sulfide d may produce the corresponding disulfide and 
diselenide f (cycle C), which itself also can be oxidised by H2O2 [56]. 
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In contrast to selenium, tellurium is still considered exotic from a pharmacological 
perspective. The rather complex tellurium-compounds (3E)-4-chloro-3-[dichloro(4-
methoxyphenyl)tellanyl]-2-methylbut-3-en-2-ol (RT-04, not shown) and trichloro- 
(dioxoethylene-O,O’)-tellurate (AS101, Figure 1.8) have been studied rather 
extensively in a biological context. A kind of ligand exchange facilitates the majority 
of biological activities, for instance, the inhibitory action found against various 
cysteine proteases is due to ligand exchange of the chloride ligands against the thiol 
group of the active site cysteine residue of the protease (Figure 1.8), thus leading to 
the inactivation of the protease [53]. As a result cell death may be induced, 
preferentially via apoptosis. 
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Figure 1.8: Reaction scheme for the possible ligand exchange mechanisms of the tellurium-
containing agent AS101, adopted from [53]. 
Similarly, selenocysteine-containing proteins like glutathione peroxidase or 
thioredoxin reductase, although being less abundant than cysteine-containing 
proteins, could be affected in the same way (Figure 1.8), thus leading to the inhibition 
of these selenoenzymes and thus the increase of OS, which may also result in cell 
death. 
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1.2.3 Multifunctional agents which target Oxidative Stress 
Although ebselen as well as AS101 are still under intensive investigation, in the 
meantime attention has been focused on the design of multifunctional agents (Figure 
1.9), which combine several redox modulating properties. Since OS is a multistressor 
event, these properties are pivotal and essential for potential new drugs for the 
treatment or employment of OS. 
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Figure 1.9: Structures of different multifunctional redox modulators, previously synthesised in 
the Jacob group. The core structures are based on 1,4-naphthoquinones and nitrogen-
containing macrocycles like porphyrin or triazanonan. 
In 2003, Jacob and co-workers combined a chalcogen with a quinone in the 
organotellurium compound 2-(phenyltelluryl)-3-methyl-1,4-naphthoquinone (Figure 
1.9, compound A) in order to increase OS-targeting efficiency. Compound A was 
proposed to act in a redox cycle quasi combining the beneficial properties of 
compounds like junglone and ebselen (Figure 1.10). The organotellurium-catalyst on 
the one hand can be oxidised via reactive species such as H2O2, and on the other 
hand can be reduced to the hydroquinone [64]. 
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Figure 1.10: Scheme for the redox cycle of compound A as proposed in [64]. 
The electrochemical, in vitro and cell culture analysis of compound A pointed towards 
the development of a new class of potential redox catalysts, Implying the idea of the 
so called biochemical ‘sensor-effector molecules’ [64, 65] these molecules might be 
able to effectively, yet selectively, affect certain types of cancer cells whilst being 
mostly non-toxic towards differentiated cells. 
During the last five years multifunctional agents able to act as redox modulators have 
been designed. The attachment of a selenium-containing moiety to a nitrogen-
containing macrocycle provided compounds, which were also able to provide metal-
binding properties, as demonstrated for 1-[3-(phenylseleno)propyl]-1,4,7-triaza-
cyclononane (Figure 1.9, compound B) and the protoporphyrin IX-derivative (Figure 
1.9, compound C) [66]. The organoselenium compound B also revealed promising 
activities against the parasitic fungus Trichophyton rubrum and furthermore 
counteracted the cytotoxic effects exerted by H2O2 on HL-60 cells [67, 68]. This 
antioxidant effect was already observed in mouse fibroblasts exposed to UVA 
irradiation [66, 69]. Yet, the rather complex mechanisms leading to cell death are not 
fully clarified. 
At the same time multicomponent-reactions (Passerini or Ugi-reaction) were also 
used to combine several redox-active moieties in one molecule (Figure 1.9, 
compound D). Among the agents investigated, compounds bearing a selenium-atom 
attached to a quinone were the most promising agents [70] against cancer cell lines. 
The organoselenium-compound D (Figure 1.9) in particular exhibited promising 
results in a screen of different cancer cell lines and now requires further investigation 
concerning the biochemical mode(s) of action. 
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1.3 Porphyrins 
1.3.1 Introduction and nomenclature 
Porphyrins belong to the group of tetrapyrrols, which play a central role in essential 
processes in nature. The heme group, which contains a protoporphyrin IX (PPIX), is 
part of various important enzymes. The H2O2-detoxifying enzyme CAT, hemoglobin 
and myoglobin as managers for oxygen transport and oxygen storage in the blood, 
as well as cytochrom P450 being responsible for the electron and energy transfer are 
only a few examples of enzymes containing a porphyrin as key molecule. Since 
Küster in 1912 proposed the macrocycle consisting of four pyrrols [71], many 
biochemical processes in which the heterocyclic tetrapyrrols are involved were 
identified and analysed in detail. 
Tetrapyrrols can be classified depending on the type of bridge between the pyrrol 
units. That bridge can either be a methine- or a methylenbridge. The reduction of 
porphyrin provides chlorins, bacteriochlorins, isobacteriochlorins, porphyrinogens, 
phlorins and 5,15-porphodimethens (Figure 1.11). 
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Figure 1.11: Structures of important tetrapyrrols. 
According to IUPAC-rules the ring atoms in the porphyrin structure are numbered 
from 1 to 24 and the positions 5, 10, 15 and 20 are called meso-positions, the 
positions 2, 3, 7, 8, 12, 13, 17 and 18 are called β-positions and the positions  
1, 4, 6, 9, 11, 14, 16 and 19 are called α-positions (Figure 1.12). 
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Figure 1.12: Nomenclature of the porphyrin structure according to IUPAC-rules. 
Accordingly, porphyrins can also be classified into β- and meso-porphyrins. Most 
biosynthetically formed porphyrins are β-substituted porphyrins, whereas meso-
porphyrins are used as their synthetically derived equivalent models. 
1.3.2 Properties, occurrence and applications of porphyrins 
Porphyrins follow the [4n+2]-Hückel rule for aromatic compounds, thus 18 of the  
22 π-electrons of the porphyrin are part of the aromatic ring. Via reduction of the 
porphyrin, the appropriate aromatic cyclic conjugated systems of chlorins, 
bacteriochlorins and isobacteriochlorins can be derived. In contrast, reduction to 
phlorin, 5,15-porphodimethen and to porphyrinogen causes the loss of the aromatic 
system (Figure 1.11). 
The four nitrogen atoms of the tetrapyrrol ring are able to complex metal ions, e.g. 
PPIX is able to bind metals like iron. Hemoglobin, myoglobin and cytochrom P450 are 
examples of enzymes which contain a PPIX-subunit and are only three of the several 
natural occurring porphyrin-metal complexes with biochemical significance. 
Porphyrins not only play an important role in the fields of catalysis and dyes, the 
photoactive properties of porphyrins also allow their use as photosensitizers in 
photodynamic therapy (PDT). Additional to chemotherapy, surgery and radiation 
therapy, the medical technique of PDT is one of the major cancer therapies in order 
to selectively ablate abnormal tissue [72]. The combination of a non-toxic 
photosensitizer, a light source and oxygen results in the production of ROS [73]. 
These ROS in turn lead to the stimulation of different redox signalling pathways 
resulting in apoptosis or necrosis of the abnormal tissue. Therefore the affected 
tissue is either exposed to a photosensitizer or the latter is administered systemically 
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and the tissue is locally exposed to light in order to facilitate the selective damage of 
the target area. Especially cancerous tissues tend to accumulate photosensitizers, a 
specific behaviour which turns it easily accessible for PDT treatment [74]. 
1.3.3 Synthetic considerations 
Due to their excellent applicability as simplified biological models for their naturally 
occurring, but rather complex relatives, the synthesis of naturally occurring 
assembling tetrapyrrols is still an interesting as well as an ambitious aim. The 
synthesis of non-symmetrical β-porphyrins, in particular, is mostly related to intensive 
purification and low yields. In contrast, the symmetrical meso-porphyrins can be 
synthesised rather easily. Either pyrrol, bilane or dipyrromethane can be used for the 
condensation reaction to form a porphyrin (Figure 1.13). Depending on the structure, 
the synthesis of the pyrrol-containing building blocks themselves might become 
rather complicated and thus requires several reaction as well as purification steps. 
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Figure 1.13: Reaction scheme for different synthetic approaches for the synthesis of 
porphyrins. Details for the different methods are provided in the text. 
In contrast, porphyrin can also be formed in a one pot reaction via mixing different 
aldehydes with four equivalents of pyrrol. One equivalent of pyrrol reacts with the 
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aldehyde under formation of 2-pyrrolmethanol, which reacts further with a second 
equivalent of aldehyde to dipyrromethane. Analogous subsequent steps provide the 
bilancarbeniumion and subsequent cyclisation provides the porphyrinogen, which is 
oxidised to porphyrin. As early as in 1935, Rothemund successfully performed the 
condensation reaction between aldehyde and pyrrol [75, 76]. 
Later on, in 1967, Adler et al. found that performing the condensation reaction under 
acidic conditions provides better yields [77]. The so-called Adler-Longo-cyclisation is 
performed in boiling propionic acid and the subsequent oxidation to porphyrin is 
realised by oxygen from the air. Due to the acidic conditions, however, the use of that 
procedure was strictly limited, since no acid-sensitive substances could be used. The 
separation of the cyclisation and oxidation step, as developed by Lindsey et al. in the 
1980s, expanded the number of accessible porphyrins (Figure 1.14) [78]. 
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Figure 1.14: Reaction scheme for the synthetic formation of a porphyrin via the Lindsey 
method. Four eq. of aldehyde are reacted with 4 eq. of pyrrol under the formation of 
porphyrinogen, which is subsequently oxidised to porphyrin. 
Under mild conditions, such as room temperature and a solvent which can be 
removed easily (e.g. dichloromethane), pyrrol and aldehyde are mixed together. After 
addition of borontrifluoretherate (BF3 • 2 H2O) or trifluoroacetic acid (TFA) oxidation is 
triggered by addition of 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) or 2,3,5,6-
tetrachloro-p-benzoquinone (p-chloroanil). Using this reaction, yields up to 50 % can 
be achieved [79]. 
Depending on the ratio of the different aldehydes, many possible side products can 
be formed in addition to the desired product. These mixtures are not separated 
without problems, especially in the case of non-symmetrical porphyrins. Step by step 
formation of a porphyrin starting from 2,5-disubstituted pyrrols or 
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dipyrromethanederivatives may on the one hand allow more selectivity by avoiding 
the formation of such undesired side products but on the other hand may result in the 
need for additional different reactions steps using mostly expensive starting 
materials, thus also resulting in reduced yields. 
1.4 Objective of the present work 
Increasing detailed information about the biochemical events in diseases associated 
with the concurrent occurrence of OS facilitates the design of new compounds which 
can be used in the therapy of such diseases. The overall aim of the present work was 
to develop promising multifunctional redox catalysts, which effectively employ and/or 
reduce OS in human diseases such as rheumatoid arthritis or cancer. 
Based on the previous success of Prof. Jacob’s group in the area of sensor-effector 
molecules, a new generation of multifunctional redox catalysts combining a quinone 
with a chalcogen-containing moiety were synthesised. In order to investigate certain 
structure-activity relationships of these organochalcogenic compounds, a set of 
suitable compounds either bearing a 1,4-benzoquinone or a 1,4-naphthoquinone 
moiety was chosen. Both kinds of quinones were supposed to enhance the 
generation of ROS via redox cycling as well as cause the depletion of antioxidant 
defence systems [54]. 
A selection of the compounds synthesised was investigated in a cell culture model, 
using RAW 264.7 cells, in order to investigate the anti-inflammatory as well as the 
antioxidant properties of the compounds synthesised. First of all, the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) assay was performed in order 
to obtain initial information about the toxicity of the compounds. More in-depth 
studies including the investigation of the cell death induced were conducted including 
apoptotic studies (caspase-3-assay and staining of cell nuclei with DAPI (4,6-
diamidino-2-phenylindole)). Additionally, the anti-inflammatory and antioxidant 
properties of the compounds were investigated using the MTT assay, Griess assay 
and a specific ROS assay. ECIS (electric cell-substrate impedance sensing)-based 
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studies to investigate effects on cell proliferation were also performed. At the same 
time, the compounds synthesised were also tested by collaborative partners in 
different models using cancer cells (CLL cells) or yeast (BY4742).  
A further part of the present work deals with the design of new selenium-containing 
porphyrins. Diverse synthetic approaches were developed to combine various OS-
targeting properties with the ability to complex metal ions. Therefore different 
synthestic procedures were developed. 
1.5 Synthetic considerations 
1.5.1 Multifunctional agents based on quinone 
Based on the previous results in the development of sensor/effector compounds 
produced by Prof. Jacob’s group [64, 65], the compilation of a set of structurally 
similarly compounds was anticipated. In the subsequent biological assays, structure-
activity relationships were investigated. Analoga, which differ in the chalcogen atom 
(S, Se, Te) were considered, and their different biological effects were compared. All 
products synthesised had to possess a high purity in order to be tested in biological 
assays.  
For this present work, several multifunctional redox agents combining two or more 
redox-active parts in one molecule were synthesised. Since OS is a multicomponent 
event, the combination of several redox centers was pivotal, and agents able to 
interact with various ingredients of OS were expected to be more effective compared 
to agents with a single target. Three different quinones were chosen as basic 
structures of the target molecules: 1,4-benzoquinones, 1,4-naphthoquinones, and 
benzo[b]thiophen-4,7-diones. Although structurally very close to each other, a 
different biological behaviour due to the reactivity, size of the molecule and polarity 
was expected. 
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Figure 1.15: Reaction schemes for the synthesis of monosubstituted and disubstituted  
1,4-naphthoquinones. Details concerning the underlying mechanisms are provided in the text. 
An overview over the syntheses of compounds based on 1,4-naphthoquinone is 
provided in Figure 1.15. The reduction of a diphenyldichalcogen derivatives led to the 
formation of a very nucleophilic species, a chalcogenolate. This strong nucleophile 
caused a nucleophilic substitution reaction at the halogenated  
1,4-naphthoquinone under formation of the desired product. Consequently, the 
chalcogen-containing moiety was directly connected to the quinone. 2-Bromo-3-
methyl-1,4-naphthoquinone was used as starting material for the syntheses of the 
mono-substituted 1,4-naphthoquinones, which differed in their substituents in para-
position: H, OH or OMe (Figure 1.15 A). Reaction of dihalogenated  
1,4-naphthoquinones with diphenyldichalogenides resulted in the formation of the 
appropriate disubstituted 1,4-naphthoquinones (Figure 1.15 B). These were expected 
to exhibit, due to their additional chalcogen-containing moiety, a different biological 
behaviour compared to their monosubstituted analoga. 
The 1,4-benzoquinones were of particular interest, since 1,4-benzoquinone-
derivatives, such as ubiquinone or thymoquinone are known to exhibit antioxidant 
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and redox-modulating properties [80], [81], thus the combination of a  
1,4-benzoquinone with a catalytically active chalcogen was expected to be intriguing 
concerning a potential anti-inflammatory, antioxidant or redox-modulating property. 
The series of the 1,4-benzoquinones differed in the kind and in the position of the 
substituents which were directly bond to the quinone. Therefore, appropriate  
1,4-benzoquinones were firstly brominated and in a second step reacted in a 
nucleophilic substitution reaction, in the same manner as described above for the 
1,4-naphthoquinones (Figure 1.16). 
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Figure 1.16: Reaction scheme for the synthesis of 1,4-benzoquinones. Details are provided in 
the text. 
As in case of the 1,4-naphthoquinones, mono-substituted 1,4-benzoquinones as well 
as disubstituted 1,4-benzoquinones were anticipated. Similar to the  
1,4-naphthoquinones, a set of compounds which differed in the chalcogen atom 
(selenium and tellurium) was desired. 
Bioisosteric approaches open the way to structurally close compounds, which could 
exert a different biological behaviour, or in best case, even improve the bioactivity. 
Benzo[b]thiophene-4,7-diones are currently under investigation concerning their 
antitumour effects [82, 83] and are thus very interesting bioisosteric relatives of  
1,4-naphthoquinones. These compounds offered the possibility to investigate the 
influence of the position of the chalcogen-containing moiety, since 
benzo[b]thiophene-4,7-diones can be modified easily on the one hand at the quinone 
ring and on the other hand at the thiophene ring (Figure 1.17). 
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Figure 1.17: Reaction scheme for the synthesis of benzo[b]thiophene-4,7-diones. Details are 
provided in the text. 
The phenylseleno moiety can either be directly connected to the quinone (as in the 
case of the 1,4-naphthoquinones and 1,4-benzoquinones) or it can be connected to 
the thiophene ring via an alkyl chain. The appropriate benzo[b]thiophene-4,7-diones, 
which were used as starting materials, were synthesised according to literature 
procedures. 
1.5.2 Multifunctional agents based on porphyrin 
Selenium-containing porphyrins have already gained attention regarding their 
biological activities, such as their antibacterial properties [84]. In 2008 Jacob et al. 
published the synthesis of selenium-containing macrocycles such as a 
protoporphyrin IX derivative (Figure 1.9, chapter 1.2.3) and investigated the catalytic 
activity of these antioxidant compounds. Binding of Cu2+, Fe2+ and Fe3+ caused 
significant changes to the compound’s UV/VIS absorption spectra, but the thiophenol 
assay indicative of a GPx-like catalytic activity only showed a slight increase of the 
initial rate [66]. Due to notable solubility problems, the biological investigation of that 
particular porphyrin derivative was strictly limited. 
Following that initial work, the aim of this second part of the present work was to 
develop different methods to synthesise a selenium-containing porphyrin, which 
bears various functionalities able to react with diverse ingredients of OS. The 
preliminary problems concerning the extensive purification of the desired compounds 
might be avoided by using meso-tetraarylporphyrins instead of β-porphyrins as 
synthetic targets. Different methods including the modification of monofunctionalised 
tetraarylporphyrins, the synthesis of quinone-containing selenoporphyrins and 
nucleophilic substitution reactions were developed. Poor overall yields should be 
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avoided by using reactions based on only a few reactions steps, favouring the 
formation of a major product and only few side-products. Despite the fact that the 
Lindsey method is related to intensive purification of the mixture of the porphyrins 
formed, that one pot synthesis was favoured against the step by step synthesis of a 
porphyrin, which mostly requires more than five different reaction steps. Afterwards, 
the reaction of a selenium-containing precursor with the appropriate macrocyle was 
performed. Furthermore the initial problems concerning the solubility of the 
compounds should be solved by the presence or attachment of water-soluble 
moieties.  
As part of this project, easily accessable tetraarylporphyrins bearing different 
functionalities like an amino group, a carboxyl group or a hydroxyl group were 
synthesised and coupled to a selenium-containing precursor. In order to narrow down 
the number of potential porphyrin-containing starting materials, monofunctionalised 
tetraphenylporphyrins were chosen as starting materials. Compared to 
tetrafunctionalised porphyrins, the synthesis of monofunctionalised porphyrins was 
more difficult, yet it provided porphyrins with a moderate molecular weight, what 
might be advantageous for possible applications in vivo. The coupling methods were 
limited by the availability of the selenium-containing precursor and its sensitivity 
towards the reaction conditions. (Thus the idea to use a selenium-containing 
aldehyde and pyrrol in a condensation reaction to form a porphyrin was not found 
suitable since selenium could be oxidised to seleniumoxide during the oxidation 
required to convert the porphyrinogen to porphyrin.) In Figure 1.18 an overview over 
the porphyrin- and the selenium-containing precursors, which were coupled 
subsequently with each other, is provided. 
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Figure 1.18: Reaction scheme representing different coupling methods using 
monofunctionalised tetraarylporphyrins as starting materials for the synthesis of a selenium-
containing porphyrin. 
For porphyrins 22-24 easy coupling methods including amide coupling and ether 
synthesis were selected. Additionally the N-alkylation of an anime yielding porphyrin 
25 was supposed to be used. Despite the fact that compound 25 bears a lipophilic 
alkyl chain, due to the positive charge this compound was expected to be water-
soluble. 
Since quinones are principally active as modulators of OS-related cellular states, 
quinone-containing porphyrins are of particular interest. Therefore quinone-
containing selenoporphyrins were chosen as second synthetic target. The quinone 
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part can either be coupled to a porphyrin or can also form a part of the porphyrin, for 
example as substituent in meso-position. The coupling can be performed using 
monofunctionalised tetraarylporphyrins and an appropriate quinone-containing 
reaction partner (Figure 1.19) leading to amidoporphyrins 26 and 27. 
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Figure 1.19: Reaction scheme for the synthesis of a selenium-containing porphyrin using the 
amide coupling method starting from a quinone-containing acid and an aminoporphyrin. 
Alternatively, the quinone can already be a part of the porphyrin. Literature research 
highlighted the rather interesting porphyrin 28, which offers several possibilities for 
further modifications at the quinone part. For instance, the brominated quinone 29 
may react with diphenyldiselenide in a nucleophilic substitution reaction (Figure 1.20, 
pathway a.) leading to the formation of selenoporphyrin 30. Alternatively, oxidative 
decarboxylation (Figure 1.20, pathway b.) or aminoalkylation (Figure 1.20, pathway 
c.) using easy accessable selenium-containing precursors might be used to modify 
the quinone. Both reactions were expected to result in the more amphiphilic 
porphyrins 31 and 32, since the alkyl chain is likely to be lipophilic. Compared to 
porphyrin 30, the chalcogen is located far from the porphyrin core and thus 
porphyrins 31 and 32 were expected to behave biologically different compared to 
porphyrin 30. 
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Figure 1.20: Reaction scheme for different approaches for the synthesis of selenium-
containing porphyrins using a porphyrin bearing a quinone in meso-position. The quinone part 
can be modified via bromination followed by nucleophilic substitution reaction (a), oxidative 
decarboxylation (b) or aminoalkylation (c). 
Another approach to form selenoporphyrins exploits the electronic effects of the 
substituent in para-position of the phenyl part of pentasubstituted tetraarylporphyrins. 
The fluorine atoms in 5,10,15,20-tetra-(pentafluorophenyl)porphyrin (PFPP) pull the 
electrons of the phenyl part, resulting in more positive carbons. That turns PFPP into 
a fertile target for nucleophilic substitution reactions. Amines and hydroxyls are 
known to easily substitute the fluorines in para-positions of PFPP. Thus, an approach 
using the selenium-containing precursor 3-(phenylselanyl)propane-amine was 
expected to substitute at the para-fluorine as well (Figure 1.21). 
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Figure 1.21: Reaction scheme for the nucleophilic substitution reaction of PFPP with a 
selenium-containing amine. 
As already mentioned, phenylselenolate is a strong nucleophile, which can be used 
directly as a nucleophile in a nucleophilic substitution reaction. Therefore, 
diphenyldiselenide was reduced with sodiumborohydride under the formation of 
phenylselenolate. That species should be able to substitute the fluorine in PFPP, 
leading to a porphyrin bearing a selenium atom that is enclosed by two aromatic 
rings, which increase the chemical (and metabolic) stability of the selenium (Figure 
1.22). 
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Figure 1.22: Reaction scheme of the nucleophilic substitution reaction of PFPP with 
diphenyldiselenide. 
The different synthetic approaches should provide a wide variety of structurally 
related but still diverse selenoporphyrins, which could be tested concerning their 
biological properties. In general, all desired selenoporphyrins were expected to be 
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chemically stable. In the case of the porphyrins which bear an alkyl chain, the 
molecules might even exhibit a somewhat amphiphilic character. That property might 
affect the permeability of these high molecular weight molecules through biological 
membranes. Additionally the hemoglobin-like structure as well as the amide-bond (as 
in porphyrins 22, 23, 26 and 27) implied a similarity to the endogenous substance 
hemoglobin and thus might facilitate the uptake into the organism. Due to the 
properties of the nitrogen cavity all selenoporphyrin targets were expected to exhibit 
strong metal binding properties, which subsequently might even lead to a SOD-like 
activity. Additionally, due to the presence of a selenium atom, a GPx-like catalytic 
activity was also expected. The structures of the porphyrins synthesised were 
confirmed using NMR spectroscopy, mass spectrometry and UV/VIS spectroscopy. 
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2. Results and discussion 
2.1 Syntheses of multifunctional agents based on quinones 
2.1.1 1,4-Benzoquinones 
Based on the previous results of the group [68, 85], which pointed towards a certain 
activity of compounds which posses a direct bond between the chalcogen and the 
quinone, a number of 1,4-benzoquinone-containing organochalcogen compounds 
was successfully synthesised. Their synthesis was performed via the nucleophilic 
substitution reaction of the appropriate brominated 1,4-benzoquinone and a 
dichalcogenide using the modified procedure which was developed for the synthesis 
of the 1,4-naphthoquinones (and is described in detail in chapter 2.1.2). The 
structures and purities of the compounds were confirmed with NMR spectroscopy, 
mass spectrometry and high performance liquid chromatography (HPLC). All  
1,4-benzoquinones synthesised contained at least one phenylseleno- or one 
phenyltelluro-group which was directly connected to the quinone. The chemical 
stability, which was pivotal for the use of the compounds in biological assays, was 
afforded by the aromatic residue next to the chalcogen; hence the compounds should 
not decompose easily. Selenium and tellurium are redox active elements, enabling 
the compounds to undergo several redox reactions (depending on the oxidation state 
of the chalcogen and on the reaction conditions) and to exhibit catalytic activity. 
Since the molecules synthesised were comparably small, the position and kind of the 
substituents (hydrogen, methyl group, methoxy group) in α- or β-position to the 
quinone C=O group might be crucial for the biological properties. Thus minor 
structural differences could exert a huge effect on the biological activity, with the 
structure isomers 1 and 2 being of particular interest. 
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In Figure 2.1 provides an overview over the 1,4-benzoquinones synthesised. 
Compounds 1-4 and 6-11 have not been reported in the literature before and some of 
them were published as part of this project by the Jacob group in 2010 and 2012 [47, 
86]. 
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Figure 2.1: Structures of chalcogen-containing 1,4-benzoquinones which were synthesised as 
part of this thesis. 
Unfortunately, the tellurium-containing analoga 9, 10 and 11 to the selenium-
containing 1,4-benzoquinones 1, 2 and 3 tended to decompose quickly as 
ascertained by analytical methods. Furthermore, although using purified starting 
materials and performing different purification methods or repeated column 
chromatography, the compounds 5-8 in the end did not possess an adequate purity 
to be tested in biological assays and consequently were not included further in these 
studies. 
2.1.2 1,4-Naphthoquinones 
The synthesis of some of the 1,4-naphthoquinone-containing compounds was 
already published in 2003 by Jacob and co-workers [64, 65] as a modified version of 
Sakakibara’s [87] synthesis. At that time, the appropriate dichalcogenide was 
reduced with sodiumborohydride and reacted with 2-bromo-3-methyl-1,4-
naphthoquinone in ethanol for 3 h. After work-up and column chromatography, yields 
between 2 % and 9 % were achieved. 
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As part of this work, the synthetic procedure was modified, resulting in yields of over  
97 %. These modifications included the change of the solvent. After a few attempts, a 
mixture of THF/water was identified as suitable solvent. Sodiumborohydride was 
dissolved in water and added to a solution of the dichalcogenide in THF. As soon as 
the mixture became colourless, the appropriate bromide, dissolved in THF, was 
added and the progress of the reaction was monitored via TLC. This meticulous 
monitoring allowed termination of the reaction before undesired side-products were 
generated. As soon as the spot of the starting material disappeared (after 
approximately 15 to 30 min after the start of the reaction), the reaction mixture was 
quenched with aqueous ammoniumchloride and extracted with ethylacetate. 
Removal of the solvent and subsequent column chromatography yielded the desired 
compounds in high purities and high yields. Apart from the significantly better yields, 
the modified synthesis had the advantages of being cheap, easily performed and, 
due to the mild reaction conditions; considerably less side-products were formed. In 
Figure 2.2 an overview over the compounds which were synthesised according to 
this method is provided. 
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Figure 2.2: Structures of chalcogen-containing 1,4-naphthoquinones which were synthesised 
as part of this thesis. 
The modified synthesis for the hitherto unknown compounds 15 and 21 was 
published 2010 [47]. Although some of the compounds were already known from a 
chemical perspective, little was known to date regarding their biological activities. 
Thus a detailed biological investigation of these compounds in different cell culture 
assays regarding their toxicity as well as their redox-modulating and anti-
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inflammatory properties was chosen as objective of the present work. The latter 
included the estimation of structure-activity relationships, for example by determining 
the effect of the substituent in para-position of the phenyl ring. Additionally, the 
impact of the specific kind of substitution (monosubstitution and disubstitution) was 
investigated. 
2.1.3 Benzo[b]thiophene-4,7-diones 
Benzo[b]thiophene-4,7-diones as the bioisosteric relatives of 1,4-naphthoquinones 
are of particular interest. These compounds recently gained considerable attention 
and are currently under investigation regarding their anti-tumour effects [82, 83, 88]. 
In case of the synthesis of the anticipated benzo[b]thiophene-derivatives, insuperable 
problems were faced. The synthesis of the benzo[b]thiophene-4,7-diones was started 
from 3,6-dimethoxy-2-nitro-benzaldehyde. The formation of the thiophene ring was 
afforded by the reaction of the aldehyde with methyl thioglycolate. That subsequent 
oxidation provided the desired benzo[b]thiophene-4,7-diones. The following reactions 
at the quinone or at the side-chain should provide chalcogen-containing 
benzo[b]thiophene-4,7-diones (Figure 2.3 A). 
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Figure 2.3: Reaction scheme for the synthesis of benzo[b]thiophene derivatives. Details 
concerning the different reactions are provided in the text. 
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Yet despite the fact that the amidation of 4,7-dimethoxybenzo[b]thiophene-2-
carboxylic acid was performed in the presence of different coupling-reagents, such 
as N-methyl morpholine (NMM) and ethylchloroformiate or dicyclohexylcarbodiimid 
(DCC), the desired compound could not be generated. Neither did the bromination of 
methyl-4,7-dioxo-4,7-dihydrobenzo[b]thiophene-2-carboxylate provide the desired 
brominated product. 
As a comparison, another thiophene derivative was coupled to a selenium-containing 
precursor. But different attempts to couple 3-aminobenzo[b]thiophene-2-carboxylic 
acid with the appropriate 4-(phenylselanyl)butanoic acid did not result in the the 
desired product (Figure 2.3 B). 
Although structurally related to each other, benzo[b]thiophene derivates often differ 
considerably in their chemical reactivity from 1,4-naphthoquinones. The former 
neither underwent coupling reactions nor brominations. The synthesis of the desired 
derivatives was unsuccessful and thus not followed up further. 
2.2 Biological evaluation of the quinone-based compounds 
2.2.1 Selection of suitable redox agents 
For this present work, many redox agents combining a quinone moiety with a 
chalcogen group have been synthesised (1-21). Both redox centres are pivotal for 
the ability of the compound to interfere with the cellular aspects of OS: Quinones are 
generally able to generate ROS, whereas the catalytically active chalcogen is usually 
able to use ROS. Thus, the biochemical behaviour of the compounds was 
investigated in cell culture assays. In order to apply the redox catalysts synthesised 
in cell culture, several requirements had to be fulfilled. 
First of all, the redox catalyst had to be present in a high purity (>97 %) in order to 
ensure, that the observed effects were exclusively caused by the applied substance 
itself or by its metabolites - and not by any impurities. Since the tellurium-containing 
benzoquinones 9-11 did not exhibit that high purity, they could not be included in cell 
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culture assays. Hence the anticipated comparison of the biological behaviour of the 
compounds differing in the chalcogen atom was indeed possible for the  
1,4-naphthoquinones, but not for the 1,4-benzoquinones. 
The second requirement concerned solubility. The test compounds had to be highly 
soluble in a solvent, which was suitable for the use in cell culture. The compounds 
were neither soluble in water nor in cell culture medium, but DMSO was found to be 
a proper solvent. The compounds were found to be stable in DMSO, they neither 
preticipated nor changed their appearance when being dissolved in the solvent. 
Therefore, 50 mM stock solutions of the redox catalysts in DMSO were prepared and 
kept at -28 °C for a maximum of two months. The working solutions were prepared 
freshly from the stock solutions and used only once. For all assays, an appropriate 
solvent control was also performed. The highest concentration used in the assays 
(0.2 % DMSO) did not affect any of the cells tested. Compounds 6-8 were neither 
soluble in DMSO (nor ethanol) and thus could not be included in the biological 
assays. In order to make sure that no interactions between the catalyst and some of 
the reagents used in the assay occured, appropriate controls for each assay were 
performed. 
Figure 2.4 shows the compounds which were chosen for investigations in cell culture 
assays (compounds bq and nq served as chalcogen-free references). 
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Figure 2.4: Selection of compounds synthesised which fulfil the requirements to be used in 
biological assays. These compounds were investigated in different biological test systems. 
2.2.2 Selection of the cell line 
Macrophages play an important key role in inflammatory diseases, such as 
rheumatoid arthritis. Therefore the reduction of the number of activated macrophages 
as well as the inhibition of activation signals are considered as promising therapeutic 
approaches against inflammatory diseases [29]. 
RAW 264.7 cells are a murine macrophage-like cell line, established from a tumour 
which was induced in a mouse by injection of Abselon Leukaemia Virus  
(A-MuLV) [89, 90]. The nearly round, monocytic cells are commonly used in 
metabolic, inflammatory and apoptotic studies. The adherent cell line is rather 
sensitive and can differentiate under treatment with certain stimuli into macrophages. 
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Some of the compounds synthesised were also investigated by collaborative groups 
(e.g. the group of Dr. Marco Herling, Cologne) using different biological techniques to 
investigate the effects of the compounds on cancer cells. Therefore compounds 14 
and 20 were studied in blood-derived CLL cells and PBMC (peripheral blood 
mononuclear cells), which served as healthy control. CLL and PBMC cells differ in 
their intracellular ROS levels, a circumstance which can be exploited for potential 
therapeutical purposes [25]. 
2.2.3 Thiophenol assay 
In order to confirm the expected GPx-like catalytic activity of the synthesised 
organochalcogen compounds, the thiophenol assay was performed for compounds 5, 
12-15, and 18-21. This assay determines the ability of a compound to catalyse the 
reduction of peroxides in the presence of thiols. Increased rates of disulfide 
formation, which can be measured spectrophotometrically, are indicative of catalytic 
activity. 
The thiophenol (PhSH) assay was initiated via addition of 2 mM H2O2 to a methanolic 
thiophenol solution (1 mM) in the presence of 100 µM compound and the resulting 
formation of diphenyldisulfide (PhSSPh) was followed spectrophotometrically for  
25 min. Initial rates were calculated for the first 5 min of the reaction. 
The compounds investigated exhibited a significant effect on disulfide formation. 
Ebselen, which was used as a control, increased the initial rate of the reaction  
by 1.87-fold. Compounds 20 and 21 were able to exceed that catalytical effect:  
A 2.15-fold increased initial rate of disulfide formation was found for compound 20 
and a 1.95-fold increase for compound 21 (Table 2.1). The tellurium-containing 
compounds 14 and 15 increased the initial rate rather modestly, compound 14, for 
instance, resulted in an increased 1.54-fold rate. Even the sulfur-containing 
compounds exhibited a certain catalytic activity: compound 12 increased the initial 
rate to 1.69-fold. 
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In general, no correlation between the kind of chalcogen (S, Se, Te) and the catalytic 
activity was found, but selenium-containing compounds seemed to increase the initial 
rates to a higher extent than the benchmark ebselen. 
Table 2.1: Initial rates of disulfide-formation in the presence of the test compounds as 
determined by the thiophenol assay. 
compound normalised initial PhSSPh rate ± experimental error 
Ebselen 1.87 ± 0.09 
5 2.05 ± 0.10 
12 1.69 ± 0.08 
13 2.00 ± 0.10 
14 1.54 ± 0.08 
15 1.42 ± 0.07 
18 1.46 ± 0.07 
19 1.85 ± 0.09 
20 2.15 ± 0.11 
21 1.95 ± 0.10 
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2.2.4 MTT assay 
In order to investigate the effects of the compounds on the cell viability, the MTT 
assay using RAW 264.7 cells was performed. The MTT assay is a colorimetric assay 
for measuring the metabolic activity of enzymes that reduce the membrane-
permeable MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) to a 
non-water-soluble formazan dye (Figure 2.5), which accumulates in the cells. After 
lysis of the cells with DMSO, the absorbance of the purple formazan which dissolves 
in DMSO can be measured spectrophotometrically at λ = 550 nm [91]. 
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Figure 2.5: The chemistry behind the MTT assay: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide is reduced by mitochondrial reductases to the purple formazan. This 
reaction proceeds only in metabolically active, i.e. living cells. 
Since MTT can only be reduced to formazan by living, metabolically active cells, the 
absorbance can be correlated directly to cell viability. The experiment was also 
followed visually via microscope to notice any optical changes in the shape of the 
cells. A preliminary experiment (negative control) showed that the compounds which 
are redox active and hence in theory interfere with MTT reduction did not interact 
with any of the ingredients of the MTT assay. 
To investigate the toxicity of the test compounds and convey first structure-activity 
relationships, cells were incubated for 24 h with the test compounds in different 
concentrations (from 2.5 µM to 100 µM). Cell viability was determined by the MTT 
assay and the resulting half maximal inhibitory concentrations (IC50) were calculated. 
The appropriate solvent control containing 0.2 % DMSO had no statistically 
significant effect on cell viability (see Figure 2.6). Thus all calculated cell viabilities of 
the cells treated with test compounds are expressed relative to the control containing  
0.2 % DMSO. In order to investigate the biological behaviour of the compounds in the 
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presence of OS, cells were co-incubated with the compounds and H2O2. In a 
preliminary experiment a concentration of 30 µM H2O2 was shown to reduce cell 
viability to around 50 % and thus this concentration was chosen to be used to 
simulate the event of OS. The viabilities of the cells co-incubated with the 
compounds and H2O2 are expressed relative to the control containing 30 µM H2O2 
and 0.2 % DMSO, which did not significantly differ from cells only treated with 30 µM 
H2O2 (Figure 2.6). Thus, 0.2 % DMSO did not influence cell viability and hence was 
proven to be a suitable solvent. 
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Figure 2.6: MTT assay in RAW 264.7 cells for untreated cells, cells treated with 0.2 % DMSO, 
cells treated with 30 µM H2O2 and cells co-treated with 30 µM H2O2 and 0.2 % DMSO. Data show 
cell viabilities as means of 10 experiments, error bars represent SE. 
Untreated RAW 264.7 cells appeared nearly round and generally of similar size 
(Figure 2.7 A). In contrast, when cells were treated with active test compounds, they 
changed their round appearance to a bulky shape with nearly round excrescences at 
the outer cell membrane (Figure 2.7 B). Under treatment with the active compounds 
at high concentrations in particular, progressive shrinkage of these cells was 
observed. Cells seemed to literally ‘fall apart’ into small membrane-bound pieces. As 
shown in Figure 2.7 B, in particular the number of cells treated with active 
compounds at high concentrations was reduced significantly and remains of dead 
cells were found in the supernatent medium. The above-mentioned round 
excrescences might be interpreted as the first hint for an involvement of 
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subsequently induced apoptotic pathways, which ultimately resulted in cell death. 
These observations also fit to the optical appearance of apoptosis [92]. In contrast, 
necrosis is usually characterised by ‘blown up’ cells and their uncontrolled loss of the 
cellular contents, which leads to persisting tissue changes [93] and local 
inflammation [94]. 
A 
 
B 
Figure 2.7: Representative microscopic pictures of RAW 264.7 cells investigated in MTT 
assays. A: cells treated with 0.2 % DMSO (serving as control) for 20 h. B: cells treated with  
1 µM of compound 20 for 20 h. 
In the MTT assay a concentration-dependent toxicity was observed for all 
compounds tested. At lower concentrations of 2.5 µM, 5 µM, 7.5 µM and 10 µM, most 
of the test compounds did not exhibit a strong toxicity (cell viabilities around 75 %), 
whereas at a concentration of 25 µM all compounds reduced cell viability to 
approximately 50 % or lower. At a concentration of 100 µM all test compounds 
reduced cell viability significantly to less than 40 %. Observations of concentrations 
lower than 25 µM in particular were considered to be of certain interest, since a 
potential drug candidate should be applied at low concentrations, thus focus was laid 
on that low concentration range and compounds active within that range. 
First of all, the effect of the chalcogen atom (S, Se, Te) was investigated. Results 
indicated that the tellurium-containing compounds in general exhibited a strong 
toxicity, whereas the selenium- and sulfur-containing compounds showed moderate 
cell viabilities at the same concentration (Figure 2.8). For example, at a concentration 
of 10 µM, the selenium-containing compound 19 (Figure 2.8 A) exhibited a cell 
viability of 80 %, the sulfur-analogue compound 18 (Figure 2.8 B) a comparably or  
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Figure 2.8: MTT assay in RAW 264.7 cells. A: Cells treated with compound 19, B: cells treated 
with compound 18, and C: cells treated with compound 20. Data show cell viabilities after 24 h 
as means of three independent experiments and error bars represent SE. Significances are 
expressed relative to the appropriate control. 
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slightly lower cell viability of 68 % and the tellurium-analogue compound 20 (Figure 
2.8 C) a reduced cell viability of below 25 %. Hence to investigate dose-
dependencies, the tellurium-containing compounds had to be applied at lower 
concentrations. The tellurium-containing compounds 14-16 and 20, in particular, 
already exhibited a strong toxicity from a concentration of 400 nM onwards, reducing 
cell viability significantly (see appendix). The estimated IC50-values of the tellurium-
containing compounds were in the sub-micromolar range (see Table 2.2), 
numerically between 0.16 µM and 1.20 µM. In general, the selenium-containing 
compounds exhibited higher IC50-values compared to their sulfur-analoga. Both 
chalcogens exhibited much higher IC50-values than the appropriate tellurium-
analoga. For example, the selenium-containing compound 5 exhibited the highest 
observed IC50-value of 37.3 µM and the tellurium-containing compound 16 exhibited 
the lowest estimated IC50-value, with a value of 0.16 µM. In Table 2.2 the calculated 
IC50-values for the compounds investigated are summarised. 
The IC50-values of the disubstituted 1,4-benzoquinones 1-3 were found to be in the 
same range as the chalcogen-free reference compound bq (24.1 µM). In contrast, 
the monosubstituted compound 4 exhibited a lower IC50-value (4.5 µM) and 
compound 5 exhibited a higher IC50-value (37.3 µM). The surprisingly low activity of 
compound 5 still remains somewhat mysterious. Possibly, compound 5 was not as 
membrane-permeable as the other compounds. In case of compound 4, the effect 
might have been related to the monosubstitution. 
In general, all disubstituted compounds (no matter whether the basic structure was 
provided by 1,4-benzoquinone or 1,4-naphthoquinone) exhibited higher IC50-values 
when compared to their appropriate monosubstituted species. For example, the 
monosubstituted compound 13 exhibited an IC50-value of 7.7 µM whereas the 
disubstituted species compound 19 exhibited an IC50-value of 20.3 µM. 
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Table 2.2: calculated IC50-values of the different test compounds after 24 h incubation in the 
absence or presence of H2O2, as determined by MTT assay in RAW 264.7 cells. 
compound chalcogen IC50 ± SE [µM] in the  
absence of H2O2 
IC50 ± SE [µM] in the  
presence of 30 µM H2O2 
1 Se 20.5 ± 1.08 21.4 ± 1.26 
2 Se 21.1 ± 1.04 19.4 ± 1.07 
3 Se 20.9 ± 1.05 23.4 ± 1.06 
4 Se 4.5 ± 1.06 3.3 ± 1.10 
5 Se 37.2 ± 1.34 35.4 ± 1.35 
bq  24.1 ± 2.02 20.0 ± 1.06 
nq  8.2 ± 1.10 7.7 ± 1.07 
12 S 4.5 ± 1.12 3.1 ± 1.42 
13 Se 7.7 ± 1.35 10.0 ± 1.15 
14 Te 0.3 ± 0.09 0.4 ± 0.10 
15 Te 1.2 ± 0.11 3.93 ± 0.13 
16 Te 0.16 ± 0.07 0.26 ± 0.08 
17 Se 9.2 ± 1.07 7.2 ± 1.26 
18 S 12.2 ± 1.09 14.3 ± 1.08 
19 Se 20.3 ± 1.06 19.5 ± 1.13 
20 Te 0.3 ± 0.09 0.2 ± 0.04 
In contrast to the 1,4-benzoquinones, the 1,4-naphthoquinones differed in their IC50-
values from the IC50-value of their chalcogen-free reference nq (menadione) in both 
directions. In contrast to the other 1,4-naphthoquinones, menadione does not have a 
substituent in position 3, and thus nq is able to participate intracellularly in Michael-
additions [95]. Such quinone-based Michael-acceptors may cause the alkylation of 
nucleophilic sites on peptides, proteins or even nucleic acids. The products of the 
Michael-addition can significantly compromise cellular integrity and function [96]. 
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Hence there is a major difference chemically as well as biochemically between the 
Michael-acceptor nq on the one hand and our compounds on the other. Furthermore, 
the presence of a chalcogen atom had an impact on the biological behaviour. 
The selenium-containing compounds 13 and 17 as well as the tellurium-containing 
compounds 14, 15 and 16 were chosen to investigate the effect of the substituent in 
the para-position of the phenyl ring attached to the chalcogen atom. In the series of 
the selenium-containing compounds, the methoxy-substituent in compound 17  
(IC50 = 9.2 µM) exerted a protective effect compared to the para-hydrogen in 
compound 13 (IC50 = 7.7). In contrast, the methoxy-group in compound 16  
(IC50 = 0.16 µM) resulted in a more toxic effect than the para-hydrogen in compound 
14 (IC50 = 0.3 µM) or the hydroxyl-group in compound 15 (IC50 = 1.2 µM) as 
substituent for the tellurium-containing compounds. Nevertheless since the  
IC50-values for both series were still in a very close range, these interpretations 
concerning the structure-activity relationships may not be statistically relevant and 
thus may not be very meaningful. 
For the simulation of OS, cells were co-incubated with H2O2 and the compounds. 
H2O2 readily enters the cell where it induces the production of other ROS and pro-
inflammatory cytokines such as TNF-α and thus directly activates the OS-dependent 
intracellular signalling pathways [97]. In order to compare the cell viabilities of the 
cells treated with test compounds only and the cells co-treated with test compounds 
in the presence of 30 µM H2O2, the solvent-control containing 30 µM H2O2 and 0.2 % 
DMSO was set at 100 % viability. In the presence of H2O2, compounds might (but do 
not necessarily have to) exhibit different effects than in the absence of H2O2. The 
presence of H2O2 might result in comparably increased cell viability due to certain 
antioxidant effects of the compounds, or in decreased cell viability due to the 
generation of more toxic species derived from the compound in the presence of 
ROS, such as selenoxides, telluroxides or other ROS. The IC50-values for cells co-
treated with compounds and H2O2 are provided in Table 2.2. In general, IC50-values 
in the presence of H2O2 differ in both directions from the IC50-values in the absence 
of H2O2. Below, some effects are discussed in more detail. 
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The highest significant effect under the condition of OS was observed for compound 
1 (Figure 2.9). Cells treated with 5 µM and 7.5 µM of the selenium-containing 
compound 1 exhibited relative differences of 35 % (5 µM) and 18 % (7.5 µM) in the 
cell viabilities in the absence or presence of 30 µM H2O2. Thus, at these two 
concentrations, compound 1 seemed to ‘use’ the presence of H2O2 to induce cell 
death. That selectivity of compound 1 towards cells suffering from higher intracellular 
ROS levels could be exploited for a therapeutic use. Compounds 4 and 5 exhibited 
that effect to a lower extent at concentrations from 2.5 µM to 25 µM (see appendix). 
Interestingly, an extraordinary effect was observed at a concentration of 5 µM. The 
cell viability for cells treated with 5 µM of compound 1 was higher than the cell 
viability for cells treated with 2.5 µM of compound 1. This somewhat counter-intuitive 
concentration-dependent effect was also observed for the 1,4-benzoquinones 3 
(Figure 2.10) and 2 (Figure 2.11) at the concentrations of 5 µM and 10 µM. The  
1,4-naphthoquinones 18 and 19 also exerted this effect at a concentration of 5 µM. 
Since this effect was observed at a certain concentration, it seemed like the induction 
of complex intracellular actions was related to that particular concentration, being 
expressed in consequently higher cell viabilities. Concerning compounds 1, 2 and 3, 
this effect makes these compounds even more interesting. Whilst exerting a 
somehow protective effect in healthy cells, cell viability of cells suffering from 
elevated levels of ROS is reduced dramatically. This points towards a certain 
selectivity of compounds 1-3 and could result in high efficiency concerning the use in 
therapeutic treatments of diseases related to OS. 
Interestingly, from a concentration of 15 µM onwards, a very different behaviour from 
the lower concentrations was observed. The cell viability of cells co-incubated with 
compound 1 and H2O2 was higher than the cell viability of the cells incubated with 
compound 1 alone. All test compounds investigated inverted the effect of the cell 
viabilities at a certain concentration. In general, at a concentration of 100 µM, all 
compounds exhibited higher cell viabilities in the presence of 30 µM H2O2, possibly 
pointing towards a certain ROS-protecting effect. 
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Figure 2.9: MTT assay in RAW 264.7 cells treated with compound 1 for 24 h. A: the solvent 
control containing 0.2 % DMSO was set at 100 % viability. Significances are expressed to the 
appropriate solvent control. B: the same set of data, yet the solvent control containing  
0.2 % DMSO and 30 µM H2O2 was set at 100 % viability. Using this representation, the change of 
H2O2 as enhancer of cell death to protective effects at a concentration of around 20 µM is 
clearly visible. Significances are expressed to the appropriate cell viabilities at a certain 
concentration. Data show means of three independent experiments and error bars represent 
SE. 
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Figure 2.10: MTT assay in RAW 264.7 cells treated with compound 3 for 24 h. A: the solvent 
control containing 0.2 % DMSO was set at 100 % viability. Significances are expressed to the 
appropriate solvent control. B: the same set of data, yet the solvent control containing  
0.2 % DMSO and 30 µM H2O2 was set at 100 % viability. Significances are expressed to the 
appropriate cell viabilities at a certain concentration. Data show means of three independent 
experiments and error bars represent SE. 
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Figure 2.11: MTT assay in RAW 264.7 cells treated with compound 2 for 24 h. A: the solvent 
control containing 0.2 % DMSO was set at 100 % viability. Significances are expressed to the 
appropriate solvent control. B: the same set of data, yet the solvent control containing  
0.2 % DMSO and 30 µM H2O2 was set at 100 % viability. Significances are expressed to the 
appropriate cell viabilities at a certain concentration. Data show means of three independent 
experiments and error bars represent SE. 
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Figure 2.12: MTT assay in RAW 264.7 cells treated with compound 13 for 24 h. A: the solvent 
control containing 0.2 % DMSO was set at 100 % viability. Significances are expressed to the 
appropriate solvent control. B: the solvent control containing 0.2 % DMSO and 30 µM H2O2 was 
set at 100 % viability. Significances are expressed to the appropriate cell viabilities at a certain 
concentration. Data show means of three independent experiments and error bars represent 
SE. 
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Compound 13 was the only compound that exhibited that kind of ROS-protective 
effect at all investigated concentrations (see Figure 2.12). Thus, compound 13 might 
be a potential antioxidant against ROS-induced OS. The strongest effect was 
observed at a concentration of 7.5 µM. At that concentration, cell viabilities were 
increased by 14 %. From a chemical point of view, selenium could have been 
oxidised to a selenium oxide-derivative and thus may have counteracted or 
‘neutralised’ the toxic effects of H2O2. The beneficial role of selenium is an often 
discussed topic, but in that case it remains unclear, why compound 13 was the only 
selenium-compound exhibiting that ROS-protective effect in all concentrations 
investigated. (Most compounds also showed that effect at the higher concentrations 
applied, but these concentrations were not considered as biologically relevant.) 
In summary, the tellurium-containing compounds 14-16 and 20 exhibited a strong 
toxicity against RAW 264.7 cells in general, whereas the selenium- and sulfur 
analoga showed rather moderate toxicities. The IC50-values of the tellurium-
containing compounds were in the submicromolar range. This result identified 
macrophages as new prime targets of such tellurium-based redox agents and thus 
may provide new potential agents for the therapy of inflammatory diseases. In case 
findings can be confirmed in other cell lines and in more complex systems (e.g. in a 
mouse-model) the activity against macrophages at concentrations below 1 µM may 
ultimately be rather interesting, as it may provide a new way to target macrophages, 
which contribute to inflammation, with considerable precision. Compared to previous 
results obtained in human Daudi and in human Jurkat cells, the strong toxicity at a 
low concentration range could be confirmed. Yet the tellurium-containing compounds 
did not cause a huge difference in the cell viabilities in the absence or presence of 
H2O2 in previous studies as now observed for the 1,4-benzoquinones. The cell 
survival of Jurkat cells treated with 100 nM of compound 14 was reduced from 67 % 
to 28 % upon addition of 50 µM H2O2 [65]. In RAW 264.7, cell viability of cells treated 
with 200 nM of compound 14 was reduced from 69 % to 61 % upon addition of 30 µM 
H2O2 (see appendix). Nonetheless, the concentration-dependent tendency to reduce 
cell viability of cells under OS was confirmed and the use of different cell lines may 
explain these numerical differences. 
2. Results and Discussion 
   
 - 68 - 
The selenium- and the sulfur-containing compounds did not show any chalcogen-
depended tendencies. Only vague hints were obtained concerning possible structure-
activity relationships. Tendencies in the IC50-values point towards less toxic effects 
for the disubstituted species. The strongest and somehow selective, ROS-depended 
toxic effect was observed for the selenium-containing 1,4-benzoquinone compound 1 
at a concentration of 5 µM, where cell viability was reduced in the presence of H2O2 
by 35 %. The strongest ROS-protecting effect was observed for the selenium-
containing 1,4-naphthoquinone compound 13 at a concentration of 7.5 µM with an 
increased cell viability in the presence of H2O2 by 14 %. 
2.2.5 Caspase-3 assay 
Based on the findings in the MTT assay, the most interesting, i.e. compounds 1-3, 5, 
16 and 20 were chosen to be tested in the caspase-3 assay in order to investigate 
the mode of the cell death induced. The 1,4-benzoquinone-containing compounds  
1-3 and 5 showed significant differences in the cell viabilities (at low concentrations 
applied) in the absence or presence of H2O2, and the 1,4-naphthoquinone-containing 
compounds 16 and 20 were chosen as representatives of the tellurium-containing 
compounds. The caspase-3 assay was also performed for cells treated with the test 
compounds in the presence of H2O2. These investigations should verify, whether or 
not the compounds are able to exploit the presence of ROS to induce cell death via 
apoptosis. 
The activation of a certain kind of cysteine-proteases, the caspases, plays an 
important role in the controlled cell death via apoptosis [98]. This complex mode of 
cell death is characterised morphologically by cell shrinkage and blebbing of the 
plasma membrane and can be triggered by various stimuli. Initiator caspases pass 
the apoptotic signal on to other (pro)-caspases, including the cleavage and activation 
of these effector caspases, and finally resulting in cell death. 
The caspase-3-assay is used to measure the enzymatic activity of caspase-3, which 
is activated after induction of apoptosis. Caspase-3 is able to cleave the substrate 
DEVD-AFC (Asp-Glu-Val-Asp-AFC) after the aspartate residue, under the release of 
2. Results and Discussion 
   
 - 69 - 
the fluorescent dye 7-amino-4-trifluoromethylcoumarin (AFC) [99]. Therefore, the 
substrate DEVD-AFC was added to lysed compound-treated cells and the cleaved 
fluorogenic AFC was quantified by spectrofluorometry. Briefly, cells were stimulated 
with the different compounds in the absence or presence of 10 µM H2O2 in the two 
most interesting concentrations chosen for each compound (i.g. which showed the 
highest difference in the MTT assay between the cell viabilities in the absence or 
presence of H2O2). As determined by the MTT assay, treatment with 10 µM H2O2 did 
not influence cell viability significantly, a cell viability of 97 % was observed. Hence, 
the effect of H2O2 on caspase-3 activation should be considerably low (as a 
comparison see [89]). The caspase-3 activity was evaluated after 3 h, 6 h, 9 h and  
24 h and actinomycin D (a transcription inhibitor [100]) was used as positive control. 
Therefore the amount of AFC released in compound-treated cells was determined 
spectrofluorometrically and caspase-3 activity was calculated relative to the 
appropriate solvent-treated control. In a preliminary experiment, cell lysates of 
actinomycin D-treated cells were treated with 10 µM of test compounds and the 
caspase-3 assay was performed as described. This negative control indicated that 
the test compounds did not interact with caspase-3 or any of its substrates. 
Among the compounds investigated, compound 20 exhibited the highest caspase-3 
activity (Figure 2.13). Treatment with 2 µM of compound 20 for 6 h caused a 4-fold 
activation of caspase-3, which resulted in a maximum of nearly 11-fold activation 
after 9 h. After 24 h of treatment, a rather low activity was observed. It appears that 
the apoptotic pathways induced resulted in cell death (maybe later on secondary 
effects of apoptosis and/or necrosis were induced). In the MTT assay a concentration 
of 3.125 µM of compound 20 reduced cell viability to around 28 % after 24 h. This 
result supports the idea that cell death was induced rather quickly and thus 
afterwards the activity of caspase-3 disappeared. 
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Figure 2.13: Caspase-3-assay for compound 20 after treatment with 2 µM of compound 20 for 3, 
6, 9 and 24 h in the absence (white bars) or in the presence of 10 µM H2O2 (grey bars). 
Significances are expressed relative to the appropriate control. Data show means of four 
independent experiments and error bars represent SE. 
In the presence of compound 20 and 10 µM H2O2 a maximum 4-fold activation of 
caspase-3 after 24 h treatment (Figure 2.13) was observed. Up to 9 h, compound 20 
did not induce caspase-3 to the same extent in the absence or presence of H2O2, but 
after 24 h, caspase-3 activity in H2O2-treated cells was by trend slightly higher  
(P = 0.07). These findings were similar to the results obtained in CLL-cells. There, 
the activation of caspase-3/7 activity caused by 0.5 µM of compound 20 was higher 
in CLL cells (which suffered from elevated ROS levels compared to PBMC) than in 
healthy PBMC as determined by colourimetric caspase-3/7 activity measurements 
after 36 h [47]. Even if a different concentration was used (and thus the activation of 
caspase-3/7 was lower in CLL cells: approximately 2.4-fold after 36 h), both findings 
point towards apoptosis induced in the presence of ROS. It seems that different 
biochemical processes may be involved, depending of the intracellular amount of 
ROS. 
The ability to induce apoptosis depending on the absence or presence of ROS in 
RAW 264.7 cells might have several reasons. On the one hand, compound 20 could 
have reacted with ROS such as H2O2 to a species which exerted only a minor 
influence on caspase-3. The effect on other caspases was not evaluated and 
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therefore can not be excluded. On the other hand, a species, which induced late 
apoptosis, could have been formed, and thus caspase-3 activity was presumably still 
increasing after 24 h. This idea is supported by the observations in the MTT assay, 
where cells treated with 2 µM of compound 20 and H2O2, showed a slightly higher 
cell viability of 33 % compared to the absence of H2O2 (28 %). Thus, cell death (not 
necessarily via apoptosis) was induced more ‘gently’. This delay in the onset of 
apoptosis offers the possibility for a clean ablation of abnormal tissue and makes 
compound 20 even more interesting with regard to possible therapeutic use. 
The 1,4-benzoquinone-containing compound 2 exhibited a caspase-3-activity 
maximum with approximately 4-fold activation at a concentration of 10 µM after  
24 h treatment (Figure 2.14). It has to be emphasised, that a concentration of  
10 µM of compound 2 is not very toxic to the cells, thus the effects on apoptosis are 
expectedly low. A higher concentration of compound 2, such as 25 µM, would 
presumably have caused a higher effect on caspase-3, but according to the results of 
the MTT assay, no significant difference between the absence and presence of H2O2 
could have been observed. Compared to the tellurium-containing compound 20, 
however, the selenium-containing compound 2 exhibited a lower effect on caspase-
3-activity, which is in agreement with the findings of the MTT assay, i.e. that the 
tellurium-containing compounds in general exhibit a higher activity at this 
concentration. After 6 h treatment with 10 µM of compound 2, cells started to die and 
thus increased levels of caspase-3 were found. In the presence of 10 µM H2O2, cells 
treated with compound 2 and 10 µM H2O2 showed a lower activation of caspase-3 
compared to the caspase-3-activity in the absence of H2O2. In the MTT assay, the 
presence of H2O2 slightly decreased cell viability. Thus the caspase-3 activity for cells 
treated with compound 2 and H2O2 was expected to be higher than the caspase-3 
activity for the cells treated with compound 2 alone. Once again, these findings may 
point towards a late, gently induced apoptosis in the presence of H2O2. But these 
findings also may lead to the conclusion that cell death in the presence of H2O2 might 
be induced via other pathways, e.g. via the involvement of other caspases such as 
caspase-6 or 7. Another possibility could be the induction of caspase-independent 
pathways, including necrosis. 
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Figure 2.14: Caspase-3-assay for compound 2 after treatment with 10 µM of compound 2 for 3, 
6, 9 and 24 h in the absence (white bars) or in the presence of 10 µM H2O2 (grey bars). 
Significancies are expressed relative to the appropriate control. Data show means of three 
independent experiments and error bars represent SE. 
Compounds 1, 3, 5, and 16 resulted in minor activation of caspase-3 after 24 h 
(compare to Table 2.3, chapter 2.2.6). These compounds activated caspase-3 
approximately 1.5-fold, and compound 3 even up to 2.7-fold (10 µM) (see appendix). 
In general, in the MTT assay, these compounds caused similar or lower cell viabilities 
for cells co-treated with compound and H2O2 compared to the cell viability of cells 
treated with compound alone. Yet for all compounds, no significant difference in the 
activation of caspase-3 was observed in the absence or presence of H2O2. Even if 
caspase-3 activity in the presence of H2O2 was in trend slightly elevated after 24 h, 
calculated P-values were not found to be statistically significant. 
The different caspase-3 activities in the absence or presence of H2O2 proved that 
compounds 2 and 20 were able to interfere with the intracellular aspects of OS at the 
concentrations investigated. In particular after 24 h, the compounds influenced the 
H2O2-induced intracellular signalling pathways, probably via the formation of other 
species derived from the compounds and ROS, which consequently led to a late 
induction of apoptosis (as indicated by compounds 2 and 20). Since only caspase-3 
was evaluated, the involvement of other caspases can not be excluded. 
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The effect of redox-modulators, such as 1,4-naphthoquinones, on apoptosis and its 
related pathways remain an interesting research field. Brüne and co-workers have 
shown, that preincubation with 5 µM of 2,3-dimethoxy-1,4-naphthoquinone for 15 h in 
RAW 264.7 cells attenuated S-nitrosoglutathione-initiated apoptotic cell death via 
blocking the •NO-initiated caspase activation [101]. Thus, further investigations 
concerning these effects might reveal more interesting properties of the  
1,4-naphthoquinones. 
2.2.6 Staining of cell nuclei 
For the assessment of mitochondrial and nuclear features of apoptosis, cells treated 
with compounds 1-3, 5, 16 and 20 were cultured on a coverslip and incubated for 9 h. 
Afterwards, cells were fixed with paraformaldehyde, exposed to the fluorescent stain 
4,6-diamidino-2-phenylindole (DAPI) and examinated under a fluorescence 
microscope. Apoptotic cell death is usually characterised by morphological changes 
such as chromatin condensation, cell shrinkage, and blebbing of the plasma 
membrane, which finally results in the fragmentation of the cell into multiple small 
membrane-bound bodies [92, 98, 102]. Viable cells display diffuse fluorescence in 
the nuclei, whereas apoptotic cells show shrunken nuclei and concentrated, 
condensed chromatin (as actinomycin D-treated cells, which were used as a 
reference, do). 
For each sample, at least 150 cells were counted and the ratio of apoptotic cells to 
the total number of cells was expressed as percentage. DMSO-treated cells, which 
served as control, showed on average a nearly round appearance of approximately  
8 to 10 µM diameter and roughly the same size (Figure 2.15 A). Their nuclei 
displayed consistent fluorescence (Figure 2.15 B). In the control just 2 % of cells 
were found to be apoptotic. 
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Figure 2.15: Representative fluorescence images of RAW 264.7 cells, treated with 0.05 % DMSO 
(serving as control) using DAPI staining. A: brightfield image, B: DAPI-channel image. 
The treatment with the test compounds caused the loss of the round appearance of 
the cells and resulted in shrunken nuclei. After 6 h, cells started to blebb some 
membrane-bound bodies, causing a sunflower-like appearance. Fluorescence 
images of cells treated with 2 µM of compound 20 for 9 h are shown in Figure 2.16. 
Cells tended to change their round appearance to shrunken, smaller agglomerates 
(whites arrows in Figure 2.16 A). Chromatin assembled at the edge of the nucleus 
(white arrows in Figure 2.16 B), indicating apoptotic processes induced. 
On average 15 % of the cells treated with compound 20 were found to suffer from 
apoptosis. As a comparison, treatment with 200 ng/ml actinomycin D for 9 h caused 
nearly 26 % apoptotic cells. These findings were in agreement with the results of the 
caspase-3 assay, where treatment with 2 µM of compound 20 caused a 11-fold 
increased activity of caspase-3 after an incubation time of 9 h. 
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Figure 2.16: Representative fluorescence images of RAW 264.7 cells treated with 2 µM of 
compound 20 for 9 h using DAPI staining. A: brightfield image, B: DAPI-channel image. 
Incubation with 10 µM of compound 2 for 9 h resulted in nearly 8 % apoptotic cells. 
Similar to compound 20, compound 2 caused the assembling of chromatin in the 
nucleus. As already found in the caspase-3 assay, apoptotic pathways were induced 
after a few hours of treatment. Treatment with 10 µM of compounds 1, 3, 5 or 0.2 µM 
of compound 16 did not show any significant alterations compared to the control. The 
number of apoptotic cells was in each case less than 5 %, which was in accordance 
with the results obtained in the caspase-3 assay, where these compounds induced 
caspase-3 only slightly (Table 2.3). 
Table 2.3: Calculated caspase-3 activity (in the absence and presence of H2O2) and percentages 
of apoptotic cells counted as determined by DAPI staining. 
compound caspase-3 activity 
after 24 h 
caspase-3 activity in the 
presence of H2O2 after 24 h 
apoptotic 
cells [%] 
1 (10 µM) 2.1 1.9 4 
2 (10 µM) 3.7 2.1 8 
3 (10 µM) 2.7 2.1 5 
5 (10 µM) 1.2 1.5 2 
16 (0.2 µM) 1.4 1.7 5 
20 (2 µM) 2.5 3.8 15 
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2.2.7 Griess assay 
During inflammatory processes macrophages trigger the generation of ROS, •NO and 
cytokines. The resulting oxidising environment is on the one hand highly damaging 
towards invading microorganisms, but on the other hand also damaging towards the 
surrounding tissue, whilst macrophages themselves remain unaffected by the 
reactive species they produce. Although •NO executes important regulatory 
processes like signal transduction, antimicrobial activities or prevention of 
propagation of bacteria, the augmented production of •NO may lead to severe 
damage due to the formation of RNOS (e.g. ONOO-)[103] or the initiation of 
processes such as S-nitrosation of proteins and nucleic acids [22, 93]. Increased 
levels of •NO are associated with OS and chronic inflammatory diseases like arthritis, 
nephritis or also diabetes type I [8, 9, 93]. The biological diverse actions of •NO are 
often related to its reactive nitrogen intermediates, such as NO+, NO-, NO2- or NO3- 
[21, 22, 104]. Thus, the effect of the compounds on LPS-induced •NO-release was 
determined to investigate the anti-inflammatory properties of the test compounds. 
The Griess assay is a spectrophotometric assay to measure the stable breakdown 
product of nitric oxide •NO, nitrite NO2-. In order to stimulate the generation of •NO, 
RAW 264.7 cells were treated with lipopolysaccharide LPS. That major component of 
the outer membrane of Gram-negative bacteria stimulates the augmented release of 
•NO in macrophages via the activation of inducible nitric oxide synthase (iNOS) [105, 
106]. Whilst the other two isoforms of NOS, the endothelial NOS (eNOS) and the 
neuronal NOS (nNOS) play a subordinated role in macrophages [33], iNOS produces 
•NO from L-arginine and molecular oxygen [8, 9, 28, 107]. The induction of iNOS is 
mainly triggered and regulated by a series of signalling pathways including NF-κB 
transcription factor, IL-1β [108] and mitogen-activated protein (MAP) kinases [109]. 
NO2- reacts under acidic conditions with sulfanilamide to a diazoniumion. That 
species can react with N-(1-naphthyl)-ethylene-diamine (NED) to form the pink 
azodye 4-((4-((2-aminoethyl)amino)naphthalen-1-yl)diazenyl)benzenesulfonamide 
(Figure 2.17), whose absorbance was measured photometrically at a wavelength of 
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550 nm. Sodium nitrite was used for the standard curve to quantify the amount of 
released NO2- [110], which is used as a measure of the amount of •NO released. 
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Figure 2.17: The chemistry behind the Griess assay: sulfanilamide reacts with NED to a pink 
azodye, whose absorbance can be quantified photometrically. 
Briefly, cells were incubated with the different test compounds in the absence or 
presence of 100 ng/ml LPS for 20 h and the amount of •NO released was determined 
by the Griess assay (the amount of •NO released by LPS-treated cells was set at  
100 %). Moreover, the MTT assay for the determination of cell viability was 
performed with the remaining cells. Only samples with a cell viability of 80 % and 
more were included in the calculation of •NO released. It should be noted that the test 
compounds used at that concentrations relevant in this assay, did not exert a strong 
toxicity. 
In order to preclude a chemical interaction of the compounds with some of the 
ingredients of the Griess assay, the assay was performed in the absence of cells 
using the •NO-donors diethylamine nonoate diethylammonium salt (DEA) and  
S-nitroso-N-acetyl-D,L-penicillamine (SNAP). 
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Figure 2.18: Amount of •NO released in the presence of 100 µM of test compounds and released 
from 100 µM DEA. The amount of •NO released was quantified after 15 min incubation time via 
the Griess assay and the amount of •NO released by 100 µM DEA was set at 100 %. Determined 
•NO levels of test compounds are expressed relative to that of the control. Data show means of 
three experiments, error bars represent SE. 
2. Results and Discussion 
   
 - 78 - 
DEA belongs to the group of short-living •NO-donors, its half-time is only 16 min, 
whereas SNAP with a half time of 6 h breaks down slowly under the release of •NO. 
As determined by Griess assay, neither the levels of •NO released for 100 µM DEA 
(Figure 2.18) nor for 100 µM SNAP (data not shown) changed statistically 
significantly when the •NO-donors were co-incubated with the different test 
compounds (100 µM). This observation led to the conclusion, that the observations in 
the cell-based Griess assays surrounding the release or inhibition of •NO were 
dependent of the presence of cells and thus related to biochemical events (and not to 
simple chemical interactions). 
The treatment of RAW 264.7 cells with compounds 1-5, 12 and 14-20 alone did not 
have any notable effects on the amount of •NO released. All investigated test 
compounds resulted in a •NO level comparable to the control. Thus, the compounds 
themselves neither induced the release of •NO nor activated iNOS. Furthermore, a 
contamination of the compounds with endotoxins liberated by bacteria (in this case 
LPS) could be excluded. This kind of negative control is important: Due to the ability 
of bacteria to grow in nutrient poor media like buffer, saline and water, endotoxins 
can be found almost everywhere, as bacteria continuously release LPS not only 
during cell death, but also during growth and cell division [111]. 
Among the compounds tested, the 1,4-benzoquinone-containing selenium-
compounds 1-4 caused a strong decrease in LPS-induced •NO release, with 
compound 3 exhibiting the strongest •NO-reducing effect in a dose-dependent 
manner (Figure 2.19 A). Co-treatment of LPS-treated cells with 2.5 µM, 5 µM and  
10 µM of compound 3 resulted in a reduced •NO-release of 20 %, 15 % and 7 %, 
respectively. As confirmed by MTT assay, the cell viability was not affected by  
2.5 µM, 5 µM or 10 µM of compound 3 (Figure 2.19 B) and exhibited cells viabilities 
about 100 %. Interestingly, upon treatment with LPS, cell viability in general was 
increased up to 120-130 %. This phenomenon, which was already observed by other 
groups [112], was found in all MTT assays performed with LPS-treated cells and 
might, for example, originate from an increased metabolic activity. In any case, these 
results suggest that the observed •NO-reducing effects are not a result of the toxicity 
of the compounds. 
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The selenium-free analogue bq did not exhibit any significant •NO-reducing effect 
(Figure 2.20 A). Even when applied at a concentration of 5 µM, bq did not reduce 
LPS-induced release of •NO. Instead, •NO-release was even slightly elevated 
compared to LPS, maybe pointing towards an additional induction of •NO. 
Furthermore, bq was not toxic to the cells at the concentration applied, as 
determined by the MTT assay (Figure 2.20 B). It therefore seemed that the presence 
of a selenium atom was pivotal for the reduction of LPS-induced •NO-release. 
The effect of different quinones in RAW 264.7 cells on LPS-induced •NO-release 
such as hydroquinone, nq or 1,4-benzoquinone was already studied by Pinho et al. 
[113]. In these studies, all quinones investigated exhibited a dose-dependent 
reducing effect in NO-release, but only hydroquinone exhibited an effect comparable 
to the selenium-containing 1,4-benzoquinones investigated here, the other quinones 
applied at a concentration of 5 µM reduced LPS-induced •NO-release to around  
60 %, i.e. to less extent than the selenium-containing 1,4-benzoquinones. 
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Figure 2.19: Griess assay for compound 3 in RAW 264.7 cells. Panel A shows the amount of 
•NO released by cells treated with 2.5 µM, 5 µM and 10 µM of compound 3 in the absence (white 
bars) or presence (grey bars) of 100 ng/ml LPS. Panel B shows the cell viabilities of cells 
treated with 2.5 µM, 5 µM and 10 µM of compound 3 in the absence (white bars) or presence 
(grey bars) of LPS as determined by MTT assay. Data show means of three experiments, error 
bars represent SE. 
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Figure 2.20: Griess assay for compound bq in RAW 264.7 cells. Panel A shows the amount of 
•NO released by cells treated with 1.25 µM, 2.5 µM and 5 µM of compound bq in the absence 
(white bars) or presence (grey bars) of 100 ng/ml LPS. Panel B shows the cell viabilities of cells 
treated with 1.25 µM, 2.5 µM and 5 µM of compound bq in the absence (white bars) or presence 
(grey bars) of LPS as determined by MTT assay. Data show means of three experiments, error 
bars represent SE. 
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In order to support the hypothesis for the need of the presence of selenium, 
menadione (nq) was used as a chalcogen-free reference substance for the 1,4-
naphthoquinones. In fact, nq exerted little effect on the release of •NO either: 
concentrations of 1.25 µM, 2.5 µM and 5 µM of compound nq caused a reduction of 
the LPS-induced •NO-release to 92 %, 73 % and to 45 % (see appendix) 
respectively, whilst cell viability was not affected. These findings are in good 
agreement with data obtained by other groups [113]. In contrast, the presence of a 
chalcogen led to a dramatic impact on the LPS-induced •NO-release. The sulfur-
containing compounds 18 and 12 were not particularly active. Exhibiting very similar 
results as compound 12, the presence of 1.25 µM, 2.5 µM and 5 µM of compound 18 
caused a reduction of LPS-induced •NO-release to 70 %, 52 % and 23 % (Figure 
2.21 A), whilst cell viability remained largely unaffected (see appendix). 
The selenium-containing compounds, such as compounds 19 or 17 also did not differ 
significantly in their •NO-reducing activity from each other, but exhibited a stronger 
effect on the •NO-release compared to their sulfur analoga. Treatment with 
compound 17 at non-toxic concentrations reduced the LPS-induced •NO-release to 
50 % (1.25 µM), 30 % (2.5 µM) and 24 % (5 µM) (Figure 2.21 B). Again, cell viability 
was not affected significantly by compound 17 at the concentrations employed (data 
not shown). 
Due to their distinct toxicity in macrophages, the tellurium-containing compounds 14-
16 and 20 had to be applied at rather low concentrations, i.e. in the nanomolar range. 
At these concentrations the LPS-induced •NO-release was only slightly affected. The 
presence of 100 nM or 250 nM of compound 20 caused a reduction of LPS-induced 
•NO-release to 90 % and 80 %, respectively, but from 250 nM onwards, toxicity 
became noticable, thus the slightly reduced •NO-release observed might be due to 
compound-induced cell death. 
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Figure 2.21: Griess assay for compounds 18 and 17 in RAW 264.7 cells. Panel A shows the 
amount of •NO released by cells treated with 1.25 µM, 2.5 µM and 5 µM of compound 18 in the 
absence (white bars) or presence (grey bars) of 100 ng/ml LPS. Panel B shows the amount of 
•NO released by cells treated with 1.25 µM, 2.5 µM and 5 µM of compound 17 in the absence 
(white bars) or presence (grey bars) of 100 ng/ml LPS. Data show means of three experiments, 
error bars represent SE. 
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In order to investigate the effects of the substituents in para-position of the phenyl 
ring, the tellurium-containing compounds 14-16 and 20 were tested at a non-toxic 
concentration of 50 nM. Compounds 15 and 16 had only little impact on the release 
of •NO (decrease to 87 % for both compounds), whereas compounds 14 and 20 had 
no impact on •NO-release at that concentration at all (96 % and 105 %). Due to these 
barely noticable effects, conclusions regarding a possible structure-activity 
relationship could not be drawn. 
The extensive studies concerning the inflammatory properties of the compounds 
showed that the selenium-containing 1,4-benzoquinones had a much stronger 
reducing effect on the LPS-induced •NO-release when compared to the  
1,4-naphthoquinone-containing compounds. Structural differences, such as the 
monosubstitution or the disubstitution of 1,4-naphthoquinones did not affect the LPS-
induced •NO-release, both groups of compounds exhibited similar results. In general, 
selenium-containing compounds were more active in non-toxic concentrations 
compared to their sulfur-analoga, and of course, their tellurium-analoga, which 
exerted a strong toxicity. That might lead to the conclusion that selenium plays an 
essential role in the inhibition of LPS-induced •NO-release. Since the augmented 
release of •NO induces complicated biochemical actions, which may also result in cell 
death, the inhibition of the •NO-release by low concentrations of selenium-containing 
compounds, such as compounds 1-3 or 17, might be a promising therapeutical 
approach for the treatment of inflammatory diseases. 
The Griess assay did not provide any information on how the reduction of LPS-
induced •NO-release was achieved. Considering that the iNOS is the sole •NO-
generating synthase in macrophages, the inhibition of •NO-release was probably 
related to an inhibition of the signalling pathways leading to the activation of iNOS by 
the test compounds or even to a disturbed biosynthesis of •NO itself. The diminished 
ability of macrophages to generate •NO might also influence their pro-inflammatory 
actions. The augmented production of •NO during inflammatory processes could be 
diminished by compounds such as compound 3 and thus might prevent severe cell 
damage. 
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2.2.8 ROS assay 
Healthy cells possess a balanced equilibrium of oxidants and antioxidants, whereas 
abnormal cells mostly exhibit high intracellular concentrations of ROS. In turn, the 
cellular presence of these reactive species may harm vital cellular activities by the 
oxidation of proteins, lipids or also DNA [1, 7]. In the case of cancer cells, the 
stimulated altered functions in cellular proliferation, cell differentiation and in 
sensitivity towards anticancer agents might lead to the formation of a tumour [17]. 
The disturbed redox balance can also be exploited for therapeutic approaches which 
are based on ROS-mediated mechanisms. Furthermore, the intracellular redox status 
might also help to distinguish between abnormal cells (which are usually rich in ROS) 
and healthy cells [7]. 
In order to investigate whether compounds 1-3, 14, 16 and 17-20 were able to 
influence intracellular ROS levels, the DCF-DA (2′,7′-dichlorodihydrofluorescein 
diacetate) assay was performed. In the presence of ROS, cells incubated with the 
dye emitted fluorescence which was directly proportional to the concentration of 
reactive species [110, 114]. Therefore, cells were incubated with the different test 
compounds at various concentrations for 25 min. After incubation with the dye, cells 
were stimulated with either 1 µM phorbol-12-myristate-13-acetate (PMA) or 50 µM 
H2O2. Both stimuli are commonly used to induce the intracellular generation of ROS. 
H2O2 diffuses easily between intra- and extracellular compartiments and initiates the 
production of other ROS [97]. Similarly, the tumour promoter PMA induces the 
internal production of superoxide radicals [115]. The ROS formed interacted with the 
dye and the resulting fluorescence was followed spectrophotometrically for 40 min. 
Alternatively, the ROS formed could also interact intracellularly with the absorbed 
chalcogen compounds. The fluorescence of the cells only treated with PMA or H2O2 
was therefore set at 1.00-fold and all other fluorescent readings were expressed 
relative to these controls. In a preliminary experiment, different concentrations of 
PMA and H2O2 were tested and the fluorescence of cells treated with 1 µM PMA or 
50 µM H2O2 was found to differ statistically significantly from the fluorescence of cells 
only treated with the dye. 
2. Results and Discussion 
   
 - 86 - 
Quinones are known to tilt the intracellular redox balance towards more oxidising 
species, and thus enhance the levels of intracellular ROS [116-118]. The chalcogen-
free reference compound bq at a concentration of 10 µM raised the intracellular ROS 
levels in RAW 264.7 cells induced by PMA or H2O2 up to 1.17-fold and to 1.11-fold 
(Figure 2.22). Although the elevation of ROS levels was only exerted in a small 
extent, it confirmed the redox-modulating properties of such quinones. It has to be 
emphasised, however, that only changes in the ROS levels were determined by the 
ROS assay, and not absolute levels. Furthermore, this particular ROS assay is not 
specific for a certain reactive species, instead various different ROS were detected. 
Some ROS, such as O2•-, belong to the short-lived species, since they are rapidly 
scavenged [119], and thus might not have been detected. 
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Figure 2.22: ROS assay for compound bq in RAW 264.7 cells. Data show relative fluorescence 
in cells incubated for 40 min with compound bq in the presence of H2O2 (___) or PMA (….) 
compared to H2O2 or PMA treatment alone. Data show means of four experiments, error bars 
represent SE. 
In the ROS assay remarkable differences between the selenium- and tellurium-
containing compounds were observed. The selenium-containing 1,4-benzoquinones, 
such as compound 2, reduced the ROS levels induced by PMA or H2O2 in a 
concentration-dependent manner (Figure 2.23). Even at low concentrations (e.g.  
10 µM) ROS levels were decreased significantly, and at higher concentrations this 
effect was even more pronounced. In contrast to the selenium-free reference bq, 
ROS levels were not elevated at any concentration of test compound. In fact, 
compared to bq, the ROS levels were reduced by compound 2 to a much higher 
O
O
 
ns *  * ns 
ns
***
ns
ns ns 
** * 
** 
** 
ns 
2. Results and Discussion 
   
 - 87 - 
extent. Whilst the presence of 50 µM bq elevated the ROS levels to 1.07-fold (PMA) 
and 1.05-fold (H2O2), the presence of 50 µM of compound 2 reduced the ROS levels 
to 0.69-fold (PMA) and 0.66-fold (H2O2). These findings point towards a certain 
activity of selenium in order to achieve that particular ROS-reducing effect. 
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Figure 2.23: ROS assay for compound 2 in RAW 264.7 cells. Data show relative fluorescence in 
cells incubated for 40 min with compound 2 in the presence of H2O2 (___) or PMA (…) 
compared to H2O2 or PMA treatment alone. Data show means of four experiments, error bars 
represent SE. 
The presumably antioxidant activity of the selenium-containing 1,4-benzoquinones 
may have several causes, such as the inhibition of pro-oxidant enzymes or the 
intracellular chemical ‘neutralisation’ of various ROS via the formation of an oxidised 
chalcogenic species. Although the assay was performed for only 40 min, it may be 
possible that macrophages were also affected as a whole by the treatment (in 
particular at higher concentrations) and thus the relative fluorescence decreased. 
Nonetheless, cytotoxicity usually becomes notable after a few hours only and 
therefore should not have been the main cause of the effects observed in the ROS 
assay. 
To date, only little is known about the effects of compound nq on RAW 264.7 cells. 
Menadione, as a quinone, is usually able to enhance intracellular ROS levels [120]. 
In RAW 264.7 cells, the chalcogen-free reference compound nq did not show that 
effect: At concentrations of 5 µM up to 150 µM no increase in ROS levels was 
observed. In fact, decreases of ROS levels to 0.53-fold and 0.52-fold were observed 
for nq (50 µM) in the presence of H2O2 or PMA. Compounds 18 and 19 exhibited 
similar results like nq, whereas the monosubstituted selenium-containing compound 
O
O
SePh
PhSe
*** 
ns 
*** 
******
***
***
*** 
*** 
* 
* ns 
** 
*** 
2. Results and Discussion 
   
 - 88 - 
17 showed ROS-decreasing properties to an extent comparable to the selenium-
containing benzoquinones (see appendix). 
In contrast, tellurium-containing compounds such as 14 increased ROS levels 
significantly up to 1.40-fold (i.e. higher than the reference compound bq) when 
applied at low concentrations in RAW 264.7 cells (Figure 2.24). Yet, due to toxic 
effects (which were observed in the MTT assay), the tellurium-containing compounds 
had to be applied at lower concentrations. At higher concentrations, such as 15 µM of 
compound 14, ROS levels were decreased probably due to toxic effects. Similar 
results were obtained for compound 20, which increased ROS levels to 1.26-fold 
(H2O2) and to 1.40-fold (PMA) at a concentration of 5 µM and decreased ROS levels 
at higher concentrations. Concerning the lower concentration range, it seemed as if 
the tellurium moiety itself is responsible for increased ROS levels (and not the 
quinone part) and thus may be pivotal for the generation of reactive species. When 
exceeding a critical threshold of ROS levels, cells were no longer able to deal with 
such a highly oxidising environment and induced complex processes which might 
have resulted in apoptosis, as observed for compound 20, which induced caspase-3 
after 9 h. 
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Figure 2.24: ROS assay for compound 14 in RAW 264.7 cells. Data show relative fluorescence 
in cells incubated for 40 min with compound 14 in the presence of H2O2 (___) or PMA (…) 
compared to H2O2 or PMA treatment alone. Data show means of four experiments, error bars 
represent SE. 
In summary, the selenium-containing 1,4-benzoquinones 1-4 and also compound 17 
exhibited strong antioxidant effects against PMA or H2O2-induced ROS. In contrast, 
the tellurium-containing 1,4-naphthoquinones 14-16 and 20 increased ROS levels. 
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2.2.9 Proliferation assay 
As macrophages play a key role in inflammatory diseases, the inhibition of their 
proliferation could be a promising therapeutic approach to avoid the progression of 
severe tissue damage. The effects observed in the MTT assay could not only be 
effects originating from the toxicity of the compounds, they could also be an early 
detectable inhibition of cell proliferation. Therefore a proliferation assay assisted by 
electric cell-substrate impedance sensing (ECIS®) and accompanied by a MTT assay 
as control, was performed. 
ECIS was firstly developed by Giaever and Keese in 1984 [121] and records changes 
in the cellular behaviour such as adhesion, spreading and proliferation [122, 123]. A 
microarray containing small gold film electrodes is used to measure cell-based 
impedance, which increases by the attachment and spreading of the cells on these 
electrodes since cells restrict the flow of electrical current. It has to be mentioned that 
the change in the impedance is caused only by cells which cover the surface of these 
electrodes and not by all cells cultured in that well. Based on this biosensoric 
technique, many methods to observe cell attachment, cell micromotion, cell migration 
and also cell toxicology have been developed [122]. Even effects on the cytoskeleton 
or membrane-permeability can be observed [124]. The advantages of that technique 
range from comparably little lab work to a detailed insight of cellular processes via 
continuous monitoring of the cellular behaviour. 
A common ECIS diagram shows the cell-based impedance versus time (Figure 2.25). 
In the first phase, cells attach to the surface and thus impedance increases. The 
higher the number of cells, the higher is the increase in impedance. Later on, 
depending on the cell cycle behaviour, cells start to devide causing an increased 
area of occupation on the surface of electrodes and thus increasing the impedance 
further. As soon as the bottom of the wells is completely covered by the cell-
monolayer, due to density-dependent inhibition, impedance caused by such cells 
reaches a plateau. The impedance does not change anymore for a certain period of 
time and as soon as cells start to die (and thus detach from the occupied electrodes), 
impedance decreases again (orange line in Figure 2.25). 
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Figure 2.25: ECIS diagram for different cell numbers/well (7000, 10000, 13000 cells/well) 
recorded at a frequency of 16000 Hz. Data show normalised impedance versus time (h) for a 
mean of three wells/sample. After allowing the cells to adhere for 24 h, cells were treated with 
0.05 % DMSO (black arrow) and impedance recording was continued. 
The comparison between non-treated and compound-treated cells reveals effects of 
the compounds such as toxicity or anti-proliferative effects. Since ECIS-assisted 
assays are very sensitive, even small interferences and disturbances (for example 
small movements caused by opening of the incubator door) may also be detected, 
and show up as outliers or even as artifacts in the diagram. 
In order to determine the effects of compounds 1, 2 and 20 on cell proliferation, cells 
were seeded at low density, treated with the test compounds and impedance was 
recorded for 72 h using the multi-frequency option at an ECIS apparatus. A low initial 
cell number/well and a relatively long experimental time were used to monitore the 
cell-based impedance. At the end of the ECIS-assisted assay, cell viability of a 
control plate treated simultaneously was checked using MTT assay and compared 
(as described in section 2.2.4). 
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A concentration of 2.5 µM of compounds 2 and 1 did not affect significantly cell 
viability (105 % and 89 % respectively) as determined by MTT assay after 24 h, thus 
this low concentration was chosen to observe effects on cell proliferation (toxic 
effects should be low). In case of treatment with 0.1 µM of compound 20 a stronger 
effect compared to compounds 1 and 2 was expected to be observed: cell viability 
was only 69 % for compound 20 and thus effects due to the toxicity of this compound 
should also be investigated and co-determined. 
In Figure 2.26 the ECIS diagram of cells treated with 2.5 µM of compounds 1 and 2,  
0.1 µM of compound 20 and 0.05 % DMSO (control) is shown. As expected, DMSO-
treated cells continued to devide, but treatment with the test compounds inhibited the 
cell-devision to a certain extent. 
 
Figure 2.26: ECIS diagram for 10000 cells/well (RAW 264.7) recorded at a frequency of 16000 
Hz. Data show normalised impedance versus time (h) for a mean of three wells/sample. After 
allowing the cells to adhere for 6 h, cells were treated (black arrow) with 0.05 % DMSO (green 
line), 2.5 µM of compound 2 (yellow line), 0.1 µM of compound 20 (orange line) and 2.5 µM of 
compound 1 (red line) and impedance recording was continued. Data are representative as one 
of three experiments performed under identical conditions. 
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Whilst the impedance of cells treated with 2.5 µM of compound 1 and 0.1 µM of 
compound 20 slightly decreased, it was rather surprising to record that the treatment 
with 2.5 µM of compound 2 caused significantly decreased impedance. Since 
compound 20 was found to be one of the most toxic compounds in the MTT assay 
and found to strongly induce caspase-3-activity, the observed decrease in cell-based 
impedance was rather surprising. A change of cell-based impedance roughly 
comparable to 2.5 µM of compound 2 would have been expected instead. 
Considering the previous results in the apoptotic studies, the observations 
concerning the cell-based impedance clearly supported the notion that compound 2 
had a strong negative effect on the cell proliferation. 
In order to investigate these effects in more detail, higher concentrations of 
compounds were also applied in the ECIS-assisted experiments. In expectation to 
observe stronger decreased cell-based impedances, the concentrations of 10 µM 
and 25 µM for compounds 1 and 2 were chosen as stronger decreased cell-based 
impedances may be expected at these concentrations (based on cell viabilities 
determined by the MTT assay after 24 h)(Table 2.4). Extrapolating from the results 
obtained by the MTT assay, the impedance of cells treated with 10 µM and 25 µM of 
compound 2 should be nearly the same for both compounds but lower than the 
impedance of the cells treated with 2.5 µM of compound 2. Surprisingly, impedance 
decreased at all concentrations to the same extent (Figure 2.27). 
Considering the results of the caspase-3 assay, where compound 2 caused an 
increased caspase-3-activity at a concentration of just 10 µM, the strongly decreased 
impedance at a concentration of 2.5 µM could be partly explained by the induction of 
apoptosis. Yet such a strong effect on impedance could not simply be explained by a 
minor apoptotic effect. In fact, compound 2 seemed to have a strong effect on the cell 
proliferation itself. One may argue that toxicity also played an important role, since 
cell viability in MTT assay was reduced to 74 % by treatment with 25 µM of 
compound 2. Nonetheless, if toxicity (alone) played the major role, the same results 
would have been expected for the treatment with compound 1. 
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Figure 2.27: ECIS diagram for 10000 cells/well (RAW 264.7) recorded at a frequency of 16000 
Hz. Data show normalised impedance versus time (h) for a mean of three wells/sample. After 
allowing the cells to adhere for 6 h, cells were treated (black arrow) with 0.05 % DMSO (dark 
blue line), 2.5 µM of compound 2 (light blue line), 10 µM of compound 2 (green line) and 25 µM 
of compound 2 (yellow line) and impedance recording was continued. Data are representative 
as one of three experiments performed under identical conditions. 
In particular, the treatment with compound 1 at a concentration of 10 µM or 25 µM 
caused comparably lower cell viabilities as determined by the MTT assay after 24 h. 
But as shown in Figure 2.26, treatment with 2.5 µM of compound 1 caused higher 
cell-based impedance compared to the cell-based impedance caused by treatment 
with 2.5 µM of compound 2. Furthermore, treatment with 2.5 µM of compound 1 still 
facilitated cell proliferation, whereas the concentrations of 10 µM or 25 µM caused 
decreased cell-based impedance (Figure 2.28). 
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Figure 2.28: ECIS diagram for 10000 cells/well (RAW 264.7) recorded at a frequency of 16000 
Hz. Data show normalised impedance versus time (h) for a mean of three wells/sample. After 
allowing the cells to adhere for 6 h, cells were treated (black arrow) with 0.05 % DMSO (blue 
line), 2.5 µM of compound 1 (light blue line), 10 µM of compound 1 (orange line) and 25 µM of 
compound 1 (green line) and impedance recording was continued. Data are representative as 
one of three experiments performed under identical conditions. 
Besides these findings, the differences in cell viability for compound 1 (used at 10 µM 
and 25 µM) should have also been observed in the cell proliferation assay. Thus, 
toxicity alone cannot explain the results of the proliferation assay. Nevertheless, 
toxicity should not be ignored. Surely, toxicity is also co-captured in the ECIS assay. 
But to derive at a reliable statement concerning toxicity, additional ECIS 
measurement for 24 h with higher cell numbers/well would have to be performed. 
As already explained, ECIS-assisted assays were accompanied by MTT assays in 
order to compare/ evalidate both assays. The results of these MTT assays and the 
results of the MTT assays after 24 h are summarised in Table 2.4. 
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Table 2.4: Cell viabilities of RAW 264.7 cells (10000 cells/well) treated with compounds as 
determined by MTT assay after 24 h and 72 h. 
compound 
(concentration) 
cell viability after 
24 h [%] 
cell viability after 
72 h [%] 
normalised impedance 
after 72 h 
2 (2.5 µM) 105 54 1.0185 
2 (10 µM) 110 27 1.0170 
2 (25 µM) 74 9 1.0145 
1 (2.5 µM) 89 68 1.1030 
1 (10 µM) 65 18 1.0160 
1 (25 µM) 32 7 1.0145 
20 (0.1 µM) 69 66 1.0575 
20 (0.25 µM) ~ 50 47 1.0260 
The results of the MTT assay after 72 h for compound 2 are shown in Figure 2.29. 
After three days of incubation with compound 2, cell viability was decreased in a 
dose-dependent manner.  
 
0
20
40
60
80
100
120
control 2.5 µM 10 µM 25 µM
ce
ll 
vi
ab
ili
ty
 [%
]
7000 cells/well 10000 cells/well
 
Figure 2.29: Cell viability of RAW 264.7 cells incubated with compound 2 for 72 h as measured 
by the MTT assay. Cells treated with 0.05 % DMSO served as control and were set as  
100 % viable. Data show means of three independent experiments and error bars represent SE. 
Significances are expressed relative to the appropriate control. 
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The viability of cells treated with 2.5 µM of compound 2 was decreased to 34 % for 
the initial cell number of 7000 cells per well and to 54 % for the initial cell number of 
10000 cells per well. Treatment with 10 µM or 25 µM of compound 2 reduced cell 
viability even more dramatically. 
Treatment with compound 1 caused similar changes to cell viability. With an initial 
cell number of 7000 cells/well, cell viability was reduced to 68 % (2.5 µM), 18 %  
(10 µM) and 7 % (25 µM) respectively. Even if it is difficult to compare these assays 
with each other, both compounds resulted in much lower cell viabilities than found in 
the MTT assay after 24 h. Yet due to different durations of the experiments and 
different cell numbers, some differences were expected. In contrast, the results of the 
different MTT assays for compound 20 were very similar to each other. 
In the proliferation assays reduced cell viabilities could be explained by toxicity as 
well as by inhibition of cell proliferation. Either the compounds exerted a toxic effect 
resulting in decreased cell viabilities or the compounds inhibited the cell proliferation, 
ultimately also resulting in lower cell numbers, which are expressed as ‘lower’ cell 
viabilities. Considering the results of the ECIS-assisted studies, it is more likely that 
the effects observed were a combination of both processes. After treatment with the 
test compounds, the surviving cells may have devided and thus increased the cell 
number to a little extent. Likewise, some cells could have been affected in their ability 
to proliferate and thus were no longer able to devide. Since the ECIS diagrams 
persistently showed an increasing slope, toxicity presumably was not the only 
predominant effect causing a reduced cell-based impedance. 
In summary, the ECIS-assisted cell proliferation assay raised the suspicion that the 
compounds, compound 2 in particular, exerted inhibitory effects on the proliferation. 
Even if toxic effects of the compounds were surely co-captured, toxicity alone could 
not explain all effects observed. The MTT assays allowed the observation of the end 
point of the experiment. In contrast, measuring the cell-based impedance via ECIS 
did not just give a ‘snapshot’, it actually continuously provided information over a long 
time period. In any case, the apparent anti-proliferative effect of compound 2 on 
macrophages could be used for therapeutic benefits of inflammatory diseases. 
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Another very interesting approach would be the investigation of the anti-proliferative 
effects of such compounds on cancer cells. These cells tend to devide continously 
and thus facilitate the formation of a tumour and metastasis. If compound 2 were to 
exhibit its anti-proliferative effect in the cancer cells as well, then these compounds 
and its growth-arresting properties may be used for therapeutic benefits in the future. 
2.2.10 Results in cancer cell lines 
A redox modulator as potential drug candidate for diseases related to OS should 
combine efficiency with selectivity by recognising the pre-existing disturbed redox 
balance and exploiting such an oxidising environment to ablate abnormal tissue. 
Permanently increased intracellular ROS levels may lead to the stimulation of cellular 
proliferation, cell differentiation, alterations in sensitivity to anticancer agents and the 
promotion of mutations and genetic instability. These circumstances contribute to 
carcinogenesis [17]. Therefore the ideal redox modulator should be applicable in low 
concentrations and effectively remove such cancerous tissue preferentially via 
induction of apoptotic pathways whilst leaving the ‘healthy’ cells largely unaffected. 
The ability to exploit increased ROS levels in cancer cells or in cells suffering from 
inflammatory diseases ultimately might lead to a new therapeutic approach, which 
uses such redox modulators as candidates for selective drugs. 
Thus the compounds 12-15 and 18-21 were chosen to be investigated in cancer cell 
lines for activity and to explore any potential structure-activity relationships. These 
compounds were tested in different cancer cell lines (K562, HT29, A549 and MCF7) 
as well as in healthy control cell lines (human umbilical vein endothelial cells 
(HUVEC), NIH 3T3 (mouse fibroblast)). 
An initial screen in a cancer cell line was performed using K562 myeloid leukaemia 
cells (studies were performed by the group of Dr. M. Diederich, Hospital Kirchberg, 
Luxembourg). These cells are derived from chronic myelogenous leukaemia in blast 
crisis. To estimate cell viability, the quantification of ATP as an indicator of metabolic 
activity was performed using a specific assay kit. Among the compounds tested, the 
three tellurium-containing naphthoquinones 14, 15 and 20 showed the highest 
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toxicity against K562 cells. Cell viability was reduced to 4 %, 15 % and to 30 % upon 
addition of 10 µM of compounds 14, 20 and 15 respectively. The selenium-containing 
analoga 13 and 19 did not alter the cell viability significantly. These findings support 
the previously held notion that tellurium-containing agents are considerably more 
active (i.e. cytotoxic) compared to their selenium-containing analogues. These 
findings also pointed towards a certain selectivity of the tellurium agents towards 
cancer cells over normal cells. 
Compounds 14 and 20 were applied at concentrations from 156 nM up to 5 µM in 
HT29 colon carcinoma cells, A549 lung carcinoma cells and MCF7 breast carcinoma 
cells with HUVEC and NIH 3T3 fibroblasts serving as controls. Cell viability was 
determined by Crystal Violet method (Figure 2.30). 
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Figure 2.30: Cytotoxicity assay of compounds 20 and 14 in HT29 (A, F), A549 (B, G), MCF7 (C, 
H), HUVEC (D, I) and NIH 3T3 (E, J) cells as assayed by Crystal Violet method, adopted from 
[47]. Error bars represent SE. 
In order to reduce cell viability of the cancer cell lines to less than 50 %, a 
concentration of 312 nM to 625 nM of compound 20 was required. In contrast, a 
concentration of 1.25 µM of compound 20 had to be used to observe the same effect 
in HUVEC or NIH 3T3 control cells. Compound 14 exhibited a similar activity in A549, 
MCF7, HUVEC and NIH 3T3 cells, but was considerably less active in HT29 cells, 
which seemed to be more resistant (a concentration of 2.5 µM of compound 14 had 
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to be used to decrease cell viability of HT29 cells to less than 50 %). These findings 
again point towards a certain selectivity of the tellurium-containing compounds: 
Whilst normal cells are less affected, the cancer cells are affected rather strongly and 
at low concentrations of compounds used. 
Based on these findings, compound 20 was investigated further in drug synergy 
studies using irinotecan and 5-fluorouracil (5-FU) (Figure 2.31). 
 
Figure 2.31: Cell proliferation of HT29 (A, C) and NIH 3T3 (B, D) cells incubated with 2 µM of 
compound 20 for 24 h in the absence or presence of irinotecan or 5-FU as measured by 
thymidine incorporation, adopted from [47]. Error bars represent SE. 
HT29 cells were incubated for 24 h with 2 µM of compound 20 in the absence or 
presence of 15 µM of irinotecan or 200 µM of 5-FU. As a control, NIH 3T3 cells were 
incubated for 24 h with 2 µM of compound 20 in the absence or presence of 2.5 µM 
of irinotecan or 20 µM of 5-FU. In order to determine the cell proliferation, cells were 
pulsed with [3H]thymidine during the last 16 h of incubation and cell viability was 
determined using the Crystal Violet method. The treatment with irinotecan caused a 
decreased cell viability of approximately 50 % and the treatment with 5-FU 
decreased cell viability to approximately 60 % to 70 % for HT29 cells and NIH 3T3 
cells. The treatment with 2 µM of compound 20 caused a decrease in cell viability to 
approximately 40 % in HT29 and to approximately 35 % in NIH 3T3 cells. 
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Interestingly the co-incubation with 2 µM of compound 20 and one of the 
chemotherapeutic drugs caused an additional decrease in cell viability to 
approximately 25 % in HT29 cells, whereas the cell viability in NIH 3T3 cells was not 
affected significantly when compared to the single compound treatments. 
In order to explain this effect, the ability of compound 20 to raise the ROS levels in 
HT29 and NIH 3T3 cells was investigated. Results showed that upon addition of 
compound 20, H2O2 levels were significantly increased in both cell lines. When 
different concentrations of compound 20 were co-incubated with irinotecan or 5-FU, 
an additional increase in H2O2 production was observed only in HT29 cells, whereas 
in NIH 3T3 cells ROS levels were not altered further significantly. These different 
responses may originate in pre-existing differences in the redox environment of the 
cell types themselves. Such differences may have caused the selectivity of the 
tellurium-containing compounds in particular. 
This apparent selectivity of the tellurium agents towards cancer cells was 
investigated further as part of detailed studies using CLL cells (studies were 
performed by the group of Dr. M. Herling, University of Cologne). As part of these 
studies cell viability of CLL cells (isolated from the peripheral blood of three different 
leukaemia patients) was compared to cell viability of healthy peripheral blood 
mononuclear cells (PBMC) (isolated from healthy blood donors). Both sets of cells 
were treated with compounds 14, 15 and 18-21 and cell viability was determined by 
measurement of the intracellular ATP levels. Treatment of PBMC with 0.5 µM of 
compounds 14, 15 and 18-20 affected cell viability to a small extent only, whereas 
treatment with compound 21 reduced cell viability dramatically. In contrast, treatment 
with 0.5 µM of compounds 19 and 20 reduced CLL cell viability severely and 
compound 14 reduced cell viability to a small extent. Compounds 15, 18 and 21 did 
not show a significant ‘selectivity’ between CLL cells and PBMC. Hence the more 
interesting compounds 14 and 20 were investigated further by flow cytometry 
(annexin V-based staining assays) to determine the number of dying or dead cells 
after 36 h treatment with the test compounds. In general, the percentage of dying or 
dead cells was significantly higher in CLL cells than in PBMC, particularly at 
concentrations of 500 nM and 1 µM of compounds 14 and 20. Determination of 
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caspase-3 activity showed that cell death in CLL cells was mostly induced via 
apoptosis. In contrast, and in line with the results obtained in the cell viability assays, 
caspase-3-activity was not increased significantly in PBMC. 
In order to investigate the apparent selectivity of the compounds for the CLL cells 
further, the intracellular ROS levels in CLL cells and PBMC were measured by flow 
cytometry using V/7AAD staining. As expected, CLL cells showed higher pre-existing 
intracellular ROS levels compared to PBMC, as well as lower levels of reduced 
glutathione. These studies were conducted with cells derived from patients and 
healthy volunteers. 
For the first time, however, it was also possible to isolate remaining normal B-cells in 
the peripheral blood of a CLL patient. Figure 2.32 shows ROS levels in CLL cells 
from a patient in the early stage of the disease (patient 1) and from a patient in the 
advanced stage of the disease (patient 2). 
 
Figure 2.32: Flow cytometry based determination of ROS levels in CLL cells (CD19+5+ profile) 
compared to normal B-cells (CD19+5- profile). In both cases, cells were derived from the same 
patient. Patient 1 is an early stage case, patient 2 an advanced stage case, adopted from [47]. 
In all five cases investigated, the CLL cells as marked by a CD19+5+ flow cytometry 
profile showed significantly higher ROS levels compared to the healthy B-cells 
(CD19+5- profile), which were isolated from the same patient. Furthermore, the ROS 
levels increased with elevated CD5 expression [25]. 
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Treatment of such cells with compounds 14 or 20 for 12 h caused an increase in the 
pre-existing ROS levels in the CLL cells, but not in PBMC. This effect pointed 
towards a certain selectivity which might have several reasons: The generation of 
additional ROS, the oxidation of redox-sensitive proteins and enzymes; or the 
conversion of the already pre-existing ROS into more aggressive species; insufficient 
reduction of aggressive species in CLL cells; whatever cause(s) are ultimately 
responsible, they result in the induction of apoptotic pathways in CLL cells, whereas 
PBMC seem to be resistant to these processes. 
In order to obtain additional information regarding the biochemical mode(s) of action 
of the most active compounds 14 and 20, impedance of compound-treated A-431 
cells was measured and compared to references (studies were performed in the 
group of Prof. F. Sasse group, Department of Chemical Biology, Helmholtz Centre for 
Infection Research, Braunschweig). In these studies, compound 14 exhibited a 
similar behaviour as compounds known to bind to tubulin. A Chemical Genetic 
Interaction (CGI) approach revealed that mutants of Saccharomyces cerevisiae, 
related to events associated with OS, were more sensitive to exposure to compounds 
14 and 20, with compound 14 being more active than compound 20. Using 
microtubule-related mutants, it was also possible to postulate the microtubule 
network as potential target of compound 14. In vitro polymerisation assays as well as 
fluorescence images of PtK2 cells confirmed that compound 14 induced a depletion 
of microtubules and actin filaments after incubation for 18 h, whereas compound 20 
caused a disappearance of microfilaments only. These findings were confirmed 
further with Western blots. In addition, a ROS assay performed in A-431 and in 
HUVEC showed that the increase in ROS levels was more prominent with the cancer 
cell line when compared to healthy cells emphasising once more the selectivity of the 
compounds for cells suffering from (pre-existing) elevated ROS levels [120]. 
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2.2.11 Results in in vivo models 
Systemic sclerosis (SSc) is an autoimmune disease characterised by deposition of 
collagen in the skin and in internal organs, vascular dysfunction and dysimmunity. 
Although the aetiology of this disease is currently still unknown, there is evidence for 
an involvement of ROS in the pathogenesis of SSc, since skin fibroblasts from SSc 
patients spontaneously produce large amounts of ROS which in turn trigger collagen 
synthesis [125]. As in cancer cells intracellular ROS can not only stimulate cell growth 
but also induce cell death beyond a certain threshold (discussed in detail in section 
2.2.10). Therefore compound 20 was investigated as potential new cytotoxic agent 
for the treatment of SSc (these studies were perfomed by Wioleta Marut in the group 
of Prof. Dr. F. Batteux, Paris University). The results obtained were published 2012 
[125] and are summarised shortly in the following section. 
Firstly, cytotoxic effects using a concentration of 4 µM of compound 20 on fibroblasts 
from normal mice and from HOCl-mice were investigated. Results revealed a higher 
cytotoxic effect on ‘such’ fibroblasts (decreased cell viability of 30 %) when compared 
to normal fibroblasts (decreased cell viability of 68 %), leading to the suggestion that 
the induction of an oxidative burst caused by compound 20 can also be exploited for 
the selective treatment of SSc. Compound 20 also increased H2O2 and •NO 
production, as expected in SSc fibroblasts, and, once more, to a higher extent in SSc 
fibroblasts compared to normal fibroblasts. Furthermore, a decreased basal level of 
GSH was observed in SSc fibroblasts compared to normal fibroblasts. Modulations of 
H2O2 related events may explain the selectivity of compound 20 for SSc fibroblasts 
and may point towards a glutathione-controlled pathway for the H2O2-mediated 
toxicity of compound 20. Interestingly, the analysis of cell death for cells treated with 
4 µM of compound 20 for between 12 and 48 h indicated that compound 20 induced 
necrotic processes (and not apoptotic cell death as observed in cancer cell lines). 
Histopathological analysis of skin and lung biopsies revealed that weekly injection 
with 10 mg/kg of compound 20 reduced the increased dermal thickness in HOCl-
induced SSc in mice after two weeks. All results obtained show so far that compound 
20 induces a lethal oxidative burst selectively in cells with pre-existing increased 
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levels of intracellular ROS and thus may open up a new therapeutic strategy in the 
treatment of SSc. 
The metabolic behaviour of compound 16 was also investigated in a preliminary 
screen in male Wistar rats (studies were performed in the group of Prof. Dr. Dr. h. c. 
H. Maurer, Saarland Medical School). An amount of 20 mg/kg of test compound was 
administered by gavage into the stomach of the rats and urine was collected during 
24 h. The combined fractions were extracted and analysed using GC/MS. Mass 
spectra showed a peak at 172 g/mol, which belongs to 2-methyl-1,4-naphthoquinone. 
Yet neither the original compound nor any breakdown products bearing the tellurium-
containing part were identified in the urine. Either the compound or its metabolic 
products were excreted with the faeces or the substances were retained in the 
animal. 
2.2.12 Results in yeast-based assays 
The internal ROS levels in RAW 264.7 macrophages as well as in CLL cells were 
changed by the presence of test compounds. This raised the question which 
enzymatic system(s) were involved in these changes. In order to identify the 
responsible redox system(s), a chemogenetic approach using yeast mutants was 
employed (studies were performed in the group of Prof. Dr. A. Slusarenko, RWTH 
Aachen). A certain sensitivity of yeast mutants which lack either SOD1, SOD2, GR or 
cytosolic catalase (CTT1) towards compounds 1-4 and 13-16 may point towards a 
disturbed antioxidant enzyme system. Therefore, yeast colonies were treated with 
the test compounds at a concentration of 10 µM or 100 µM and cell survival was 
determined by counting the colonies formed. 
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Figure 2.33: Cell survival assay of wild-type BY4742 and mutants (SOD1, SOD2, CTT1). Data 
represent cell survival rates of mutants expressed relative to the appropriate control, each 
strain was incubated with 100 µM of test compound. 
The initial screen confirmed a higher toxicity of most test compounds against the 
mutants deficient in antioxidant defence enzymes than against the wild-type BY4742 
(Figure 2.33). The cell viability for the wild-type was in the moderate range of  
55-85 %, whereas cell viability of the mutant lacking SOD1 was in general a bit lower 
(with the exception of compound 15, where the resulting cell viability was 
approximately 30 % lower). In contrast, mutants which lack SOD2 were much more 
affected; their viability was much lower, in general less than 40 %. In sharp contrast, 
viability of the CTT-mutant was only affected to a small extent. 
The selectivity of the test compounds towards SOD2-mutants pointed towards an 
involvement of SOD2-related enzymes. The removal of O2•- seemed to play a more 
important role than the removal of H2O2, since the CTT mutant was less affected. 
Hence, a lucigenin-based assay for the generation of ROS in the absence or 
presence of cells was performed (Figure 2.34). The increases in ROS levels could 
appear due to either chemical reactions (in the absence of cells) or biochemical 
events (in the presence of cells), triggered by the compounds. 
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Figure 2.34: Lucigenin-based ROS assay. Data represent relative luminescence induced by  
100 µM of test compounds in the absence (white bars) or presence of yeast cells (grey bars). 
Error bars represent SE and statistical differences refer to the respective DMSO-containing control. 
With the exception of compound 16, the compounds did not generate any significant 
amounts of ROS in the absence of cells. Menadione (nq) as well as compounds 13, 
14 and 16 caused an increase in relative luminescence in the presence of cells at a 
concentration of 100 µM. Interestingly, the benzoquinones 1-4 were notably less 
active than the naphthoquinones in this assay. The basic structure of the 2-methyl-
1,4-naphthoquinone seemed to play an important role in the generation of oxygen-
containing reactive species in yeast. The results are in agreement with the data 
obtained in macrophages, where the tellurium-containing compounds 14 and 16, in 
particular also dramatically increased ROS levels. 
2.2.13 DNA-damage and DNA-repair 
A selection of menadione-based compounds is currently still under investigation 
regarding their DNA-damaging properties (these studies were performed in the group 
of Prof. Dr. A. Hartwig, KIT Karlsruhe). The compounds could directly interact with 
the DNA, and cause oxidative damage. Likewise, the compounds could inhibit 
various DNA-repair enzymes, also resulting in a disturbed system. During the 
process of apoptosis, caspase-3 is activated. This step leads to the activation of 
DNA-fragmenting enzymes, and also to the cleavage of PARP-1, a DNA-repair 
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enzyme [27]. In order to investigate the effect of the test compounds, assays 
regarding the oxidative DNA-damage and DNA-fragmentions were performed. 
Preliminary data concerning the induction of oxidative DNA-damage caused by 
treatment with 0.5 µM or 5 µM of the selenium- or tellurium-containing derivatives of 
nq showed that tellurium-containing 1,4-naphthoquinones are more damaging to the 
DNA than nq itself, whereas the selenium-containing 1,4-naphthoquinones are 
notably less damaging than nq. 
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Figure 2.35: Oxidative DNA damage after incubation with 0.5 µM (white bars) or 5 µM (grey 
bars) of compounds 13, 14, 16 or 17 for 60 min in HaCat cells. Data represent means of three 
independent triplicate determinations. DNA-strand breaks are expressed as lesions per base 
pairs as induced by alkaline unwinding and error bars represent SD. 
Treatment of HaCat cells with 5 µM of the selenium-containing compounds 13 and 17 
caused 0.15 and 0.05 lesion per 106 base pairs, respectively, whereas the tellurium-
containing compounds 14 and 16 caused 5.37 and 5.40 lesion per 106 base pairs 
(Figure 2.35), respectively. 
These findings yet again pointed towards a different and in some respect also certain 
beneficial activity of the selenium-based 1,4-naphthoquinones compared to the 
tellurium-based 1,4-naphthoquinones. On the one hand the toxicity of the tellurium-
containing compounds observed in the toxicity assays might be a result of their DNA-
damaging properties, which were also expressed at the lower concentration of 5 µM. 
On the other hand, DNA-fragmentation could be a result (rather than a course) of the 
ROS-generating and apoptosis-inducing activity of the tellurium-compounds 
beforehand induced cell death and thus is observed as a secondary effect. 
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Therefore, yeast based toxicity assays for compounds 13, 16, 17 and 19 using wild 
type BY4741 cells and rad52 cells (which have a defect in homologous 
recombination repair) were performed (studies were performed in the group of M. 
Chovanec, Cancer Research Institute, Slovak Academy of Sciences, Bratislava, 
Slovak Republic). No significant differences in the survival rates of the different yeast 
strains were observed. Furthermore there was no increased DNA-fragmentation as 
illustrated by pulsed-field gel electrophoresis (PFGE), which showed significant DNA-
damages in terms of induction of DNA double-strand breaks (solely in the case of 
sodium selenite (SeL), which was used as a positive control (Figure 2.36). 
 
Figure 2.36: Representative image of pulsed-field gel electrophoresis for compounds 17, 19, 13 
and sodium selenite (SeL). 
Presumably, DNA-damage and DNA-repair did not play a mayor role in the activity of 
the test compounds, at least in yeast. The compounds did not seem to interact 
preferentially with DNA itself. Oher biochemical events, such as the elevation of ROS 
levels, were probably the main cause(s) of activity and induced and secondary 
processes resulting in the observed fragmentation of the DNA were a consequence 
of these primary processes. As already mentioned the data presented have to be 
understood as preliminary data and further, more detailed investigations are required 
in the future. 
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2.3 Porphyrins 
2.3.1 Synthesis 
The second part of this thesis deals with the development of selenium-containing 
porphyrins as potential redox modulators. In order to synthesise a selenium-
containing porphyrin, different methods such as the modification of 
monofunctionalised tetraarylporphyrins, the synthesis of quinone-containing 
selenoporphyrins and nucleophilic substitution reactions with suitable porphyrins 
were developed. 
For the coupling of monofunctionalised tetraphenylporphyrins, the appropriate 
starting materials, such as 5-(4-carboxy)phenyl-10,15,20-triphenylporphyrin,  
5-(4-hydroxy)phenyl-10,15,20-triphenylporphyrin and 5-(4-amino)phenyl-10,15,20-tri-
phenylporphyrin were successfully synthesised via Lindsey condensation reaction 
according to slightly modified literature procedures. Subsequent coupling of the 
monosubstituted tetraphenylporphyrins then provided the desired porphyrins 22-24. 
Selenoporphyrins 22 and 23 were synthesised successfully via amide coupling in 
yields of 10 % and 38 %, respectively, and chemically characterised using 1H NMR 
and 13C NMR spectroscopy as well as mass spectrometry. Amide coupling was 
performed under mild reaction conditions on the basis of a literature procedure [126]. 
In brief: to an ice cold solution of 5-(4-carboxy)phenyl-10,15,20-triphenylporphyrin in 
chloroform N-methyl morpholine (NMM) and ethylchloroformiate were added. The 
subsequently formed mixed anhydride was spiked with 3-(phenylselanyl)propane 
amine generating amidoporphyrin 22 (Figure 2.37). Work-up of the reaction and 
subsequent column chromatography provided porphyrin 22. Similarly, porphyrin 23 
was synthesised by reacting 4-phenylselanyl-butanoic acid with 5-(4-amino)phenyl-
10,15,20-triphenylporphyrin. 
2. Results and Discussion 
   
 - 110 - 
N
NH N
HN
C6H5
C6H5
C6H5
C6H4R
N
NH N
HN
C6H5
C6H5
C6H5
C6H4R
1.) NMM
2.) ClCOOEt
3.) PhSe(CH2)3R2
22: R = COOH 22: R2 = NH2 22: R = CONH(CH2)3SePh
23: R = NH2 23: R2 = COOH 23: R = NHCO(CH2)3SePh
CHCl3, 0°C
 
Figure 2.37: Reaction scheme for the synthesis of porphyrins 22 and 23 via amide coupling. 
Upon addition of NMM and ethylchloroformiate to the carboxylic acid a mixed anhydride is 
formed, which is subsequently reacted with the appropriate amine generating amido 
porphyrins 22 or 23, respectively. 
For the synthesis of porphyrin 24, 5-(4-hydroxy)phenyl-10,15,20-triphenylporphyrin 
was reacted with 3-(phenylselanyl)-propane bromide in analogy to Williamson-ether-
synthesis using K2CO3 as base (Figure 2.38). Briefly, the starting materials were 
dissolved in a 98:2 mixture of THF/water as solvent and heated under reflux for 24 h. 
After removal of the solvent, column chromatography of the violet fraction using a 
mixture of n-hexane/dichloromethane provided porphyrin 24 in a yield of 18 %. The 
structure of porphyrin 24 was confirmed with 1H NMR, 13C NMR and 77Se 
spectroscopy as well as by mass spectrometry. 
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Figure 2.38: Reaction scheme for the synthesis of porphyrin 24 via ether synthesis.  
5-(4-hydroxy)phenyl-10,15,20-triphenylporphyrin was reacted with 3-(phenylselanyl)-propane 
bromide in the presence of K2CO3 and heated under reflux. Work-up of the reaction provided 
porphyrin 24. 
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In order to compare the properties of a porphyrin to a similar chlorin, the appropriate 
chlorin bearing a hydroxyl group in β-position was used in a Williamson-ether 
synthesis (Figure 2.39). Chlorin was dissolved in THF and spiked with freshly 
washed sodium hydride. The green reaction mixture was heated gently for 3 days, 
until TLC analysis indicated the appearance of a new fraction. The reaction was 
cooled to room temperature, the solvent removed and the residue chromatographed 
on a preparative plate using dichloromethane as solvent. The structure of chlorin 43 
was confirmed with 1H NMR and mass spectrometry. 
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Figure 2.39: Reaction scheme for the synthesis of chlorin 43 via Williamson-ether synthesis. 
Chlorin was reacted with 3-(phenylselanyl)-propane bromide in the presence of NaH and 
heated slightly. After work-up of the reaction, subsequently performed preparative TLC 
provided chlorine 43. 
Metal-containing tetrapyridylporphyrin derivatives often behave as SOD mimics and 
hence are of special interest: These compounds also exhibit good solubility in water, 
and the ability to generate ROS [127-129].  
Porphyrin 25 should have been synthesised via the reaction of 5,10,15,20-
tetrapyridylporphyrin with 0.25 eq. of 3-(phenylselanyl)propane bromide in DMF 
(Figure 2.40). Therefore the starting materials were heated under reflux for 18 h. The 
solvent was removed and different work-up methods were tried with the slightly 
purple residue obtained during the reaction. Salting out with NH4Cl did not cause the 
anticipated precipitation of the product. Neither column chromatography using a 
mixture of acetic acid, methanol and dichloromethane (1:1:98) provided the pure 
product. The presence of porphyrin 25 was confirmed in the reaction mixture by  
mass spectrometry, yet due to solubility problems no NMR spectroscopy data could 
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be obtained. The mixture presumably contained mono-, di-, tri- as well as  
N-tetraalkylated porphyrins, which could not be separated from each other with 
different methods available. 
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Figure 2.40: Reaction scheme for the synthesis of porphyrin 25. Tetrapyridylporphyrin was 
heated under reflux in the presence of 0.25 eq. of 3-(phenylselanyl)propane bromide in DMF. 
Different work-up procedures of the reaction mixture included column chromatography or 
salting out with aqueous NH4Cl. Porphyrin 25 was identified in the reaction mixture by mass 
spectrometry, but could not be isolated in a pure form. 
Quinone-containing porphyrins were selected as second synthetic target. These 
rather interesting molecules enabled to interact with OS-related events, could also 
find potential applications as photosensitizers. The within these molecules quinone 
contained is expected to generate ROS. 
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Figure 2.41: Reaction scheme for the synthesis of porphyrins 26 and 27 via amide coupling. 
Addition of NMM and ethylchloroformiate to the carboxylic acid results in a mixed anhydride, 
which is subsequently reacted with the appropriate amine generating amido porphyrins 26 and 
27, respectively. 
Porphyrins 26 and 27 were synthesised in a yield of 55 % and 71 %, respectively 
using the same mild amide coupling conditions as described above (Figure 2.41). 
The structures of porphyrins 26 and 27 were confirmed using 1H NMR, 13C NMR and 
LC-MS. 
In order to modify a porphyrin with a quinone as meso-substituent, porphyrin 28 was 
synthesised according to a literature procedure [130] starting from benzaldehyde, 
2,5-dimethoxybenzaldehyde and pyrrol, and forming 5,10,15-triphenyl-20-(2,5-
dimethoxyphenyl)porphyrin via Lindsey condensation. The dimethoxy porphyrin was 
transformed into 5,10,15-triphenyl-20-(2,5-dihydroxyphenyl)porphyrin by adding BBr3 
at -78°C followed by stirring overnight at room temperature. Chemical oxidation with 
DDQ provided the desired 5,10,15-triphenyl-20-(3,6-dioxocyclohexa-1,4-
denyl)porphyrin (28). The poor yield of 34 %, however, somewhat hindered 
subsequent modifications. 
2. Results and Discussion 
   
 - 114 - 
N
NH N
HN
C6H5
C6H5
C6H5
O
O
N
NH N
HN
C6H5
C6H5
C6H5
O
OBr
PhSe(CH2)3COOH
N
NH N
HN
C6H5
C6H5
C6H5
O
O
N
NH N
HN
C6H5
C6H5
C6H5
O
O
NH(CH2)3SePh
(CH2)3SePh
PhSe(CH2)3NH2,
28
NaOAc, Br2
29
31
32
N
NH N
HN
C6H5
C6H5
C6H5
O
O
NH(CH2)3SePh
32a
PhSe(H2C)3HN
CH3COOH
ACN
CH2Cl2, rt, 3 days
 
Figure 2.42: Reaction scheme for the synthesis of porphyrins 29-32. Neither bromination of 
porphyrin 28 to porphyrin 29 in glacial acetic acid nor the oxidative decarboxylation to 
porphyrin 31, where unexpected solubility problems appeared, were successful. The 
aminoalkylation of porphyrin 28 with 3-(phenylselanyl)propane amine resulted in the formation 
of porphyrins 32 and 32a. 
The intended nucleophilic substitution reaction of the brominated porphyrin 29 with 
diphenyldiselenide (which should result in the formation of seleno-porphyrin 30) failed 
already at the bromination step. Since porphyrins are known to decompose during 
radicalic brominations [131], such as brominations using NBS, bromine was used 
instead. The bromination of the 1,4-benzoquinones was performed in glacial sodium 
acetate using an excess of bromine and the reaction mixture was stirred in the dark 
for 3 days (Figure 2.42). Analogously, the bromination of porphyrin 28 was 
performed. But TLC monitoring did not show any changes, even not after 5 days, 
indicating that the quinone did no longer react. NMR analysis of the partially purified 
reaction mixture showed solely unreacted starting material. Due to the failure of the 
synthesis of porphyrin 29, the nucleophilic substitution reaction forming porphyrin 30 
could not be performed. 
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Instead, aminoalkylation leading to porphyrin 32 was performed. As part of this 
synthesis, porphyrin 28 was stirred with 3-(phenylselanyl)propane amine in 
dichloromethane as solvent until the quinone spot on TLC disappeared (after 3 days). 
After evaporation of the solvent, preparative TLC in dichloromethane provided two 
fractions, the first one containing the monosubstituted porphyrin 32 and the second 
fraction containing the disubstituted porphyrin 32a (Figure 2.42). Each porphyrin was 
obtained in a yield of less than 10 %. 
In order to synthesise porphyrin 31, the oxidative decarboxylation using porphyrin 28 
and glutaric acid in the presence of ammoniumperoxodisulfate and silvernitrate was 
performed (Figure 2.42). During the performance of this reaction, however, 
unexpected solubility problems were faced. Porpyhrin 28 was not soluble in 
acetonitrile. Addition of a few drops of dichloromethane did not dissolve porphyrin 28 
completely either, thus a higher amount of apolar solvent was required. Yet addition 
of more dichloromethane caused the immediate precipitation of the porphyrin. The 
preticipated porphyrin did not re-dissolve anymore, neither in dichloromethane nor in 
ethanol. In the face of the minute availability of porphyrin 28 in its ‘preferred’ solvent 
systems, the search for other, more exotic solvent systems was not considered as 
particularly promising either and not followed further. 
Finally, nucleophilic substitution reaction of PFPP with selenium-containing 
precursors was investigated. The fluorine in para-position of PFPP is known to be 
substituted easily against nucleophilic reaction partners, such as hydroxyls, amines 
and also thiols. Therefore, PFPP was dissolved in DMF, 3-(phenylselanyl)propane 
amine was added and the reaction mixture was heated under reflux overnight (Figure 
2.43). TLC monitoring indicated the formation of four new spots, probably belonging 
to the mono-, di-, tri- and tetrasubstituted porphyrins 33-36. Although an excess of  
3-(phenylselanyl)propane amine was used, four different substitution products were 
formed. The formation of the mono- and the disubstituted products 33 and 34 was 
confirmed by mass spectrometry. Thus, it was assumed, that the other two spots 
found on TLC belonged to the tri- and tetrasubstituted products 35 and 36, even if the 
isolated amount was too little to obtain any conclusive analytical data. 
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Figure 2.43: Reaction scheme for the synthesis of porphyrins 33-36 via nucleophilic 
substitution reaction. PFPP and 3-(phenylselanyl)propane amine were dissolved in DMF and 
heated under reflux overnight. After work-up and preparative TLC, different substitution 
products (33-36) were identified. 
Due to the more or less amphiphilic behaviour of the products, the product mixture 
could not be separated easily. Repeated preparative TLC provided only a few 
milligram of each fraction (yields < 5 %). Nevertheless, the structures of the products 
were confirmed with 1H NMR, 19F NMR spectroscopy, mass spectrometry and 
UV/VIS spectroscopy. 
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Figure 2.44: Reaction scheme for the synthesis of porphyrins 37-40 via nucleophilic 
substitution reaction. PPFF was added to a solution of Ph2Se2 in aqueous NaBH4 at a 
temperature of 0°C and progress of the reaction was followed by TLC. After work-up of the 
reaction and preparative TLC, four different substitution products (37-40) were identified. 
Finally, phenylselenolate itself was used as nucleophile. Therefore, 
diphenyldiselenide (dissolved in THF) was reduced with aqueous sodiumborohydride 
to phenylselenolate and PFPP, dissolved in THF, was added (Figure 2.44). The 
reaction was heated under reflux and progress of the reaction was followed by TLC. 
As soon as the PFPP spot had almost completely disappeared, the reaction was 
quenched via addition of aqueous NH4Cl and extracted with dichloromethane. After 
almost complete evaporation of the solvent, preparative TLC was performed with the 
purple residue and provided four different fractions. Unexpectedly, these fractions did 
not contain the mono-, di-, tri- and tetrasubstituted products 37-40, but rather one (or 
more) yet unknown species. Hence, the reaction conditions were changed, including 
varying the solvents. Using a 4:1 mixture of THF/water was found to be a suitable 
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solvent for the reaction. Finally, performing the nucleophilic substitution reaction at a 
temperature of 0°C for only 30 min resulted in the formation of the desired products, 
as confirmed by mass spectrometry. The different substituted products with small 
different Rf values were separated from each other via preparative TLC using a 
mixture of n-hexane and dichloromethane. 
In contrast, the reaction of the appropriate diphenylditelluride, even after further 
modifications of the reaction conditions, did not yield the desired tellurium-species 41 
(Figure 2.45). The nucleophilic substitution reaction of PFPP with diphenylditelluride 
resulted in an interesting mixture of diverse side products. 
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Figure 2.45: Reaction scheme for the synthesis of porphyrin 41 via nucleophilic substitution 
reaction. The reaction of PFPP with Ph2Te2 did not result in the formation of porphyrin 41. 
Instead porphyrin 42 and other complex porphyrin species were formed, as identified by mass 
spectrometry and NMR spectroscopy. 
19F NMR and 1H NMR measurements of the reaction mixtures allowed the 
identification of these species. During the reaction, a fluorine atom is apparently 
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removed and exchanged against an hydrogen yielding 5,10,15,20-tetra(2,2’,3,3’-
tetrafluorophenyl)-porphyrin 42. With the identification of that particular species, the 
explanation for the nucleophilic substitution reaction of PFPP with diphenyldiselenide 
in DMF under refluxing conditions was found: The reaction led to the formation of 
intermediates, which contained hydrogen as well as some PhSe-groups in para-
position. These intermediates were not formed at lower reaction temperatures. But in 
case of tellurium, the phenyltellurate seems to be too active and thus immediately 
leads to the generation of these mixed species. 
In summary, different methods to synthesise seleno-porphyrins were developed and 
some were employed successfully. The desired target porphyrins 22-24, 26, 27 and 
32 (and also the unexpected porphyrin 32a) were synthesised in moderate yields. 
Additionally, a method to insert a selenium-containing part into a porphyrin via 
‘simple’ nucleophilic substitution reaction provided the target porphyrins 33, 34 and 
37-40. Porphyrin chemistry in general is usually associated with rather low yields and 
high expenses. The straight-forward coupling methods developed resulted in 
comparably higher yields. Regarding these yields, the purification of the porphyrins 
with preparative TLC was mostly favoured against column chromatography. Amphilic 
porphyrins such as porphyrin 25 in particular caused insuperable difficulties. 
Nevertheless, most of the porphyrins were extensively characterised analytically 
using methods such as 1H NMR, 13C NMR, 19F NMR, 77Se NMR, mass spectrometry 
and UV/VIS spectroscopy. The following chapters will deal in detail with the analytical 
characteristics of the target porphyins. 
2.3.2 UV/VIS spectroscopy of porphyrins 
The intensively red to purple coloured metal-free or metal-containing porphyrins can 
be characterised by UV/VIS spectroscopy. In general, in the range of 390 to 425 nm 
an intensive band, the so-called Soret-band, and in the range of 450 to 700 nm two 
to four smaller bands, the so-called Q-bands, can be found. 
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Figure 2.46: Typical UV/VIS spectra of Q-bands spectra of porphyrins. a) phyllo-type, b) etio-
type, c) rhodo-type and d) oxorhodo-type, adopted from [132]. 
Based on the number and the appearance of these Q-bands (with I being the band 
with the longest wavelength), the UV/VIS spectra can be classified into phyllo-type  
(I < III < II < IV), etio-type (I < II < III < IV), rhodo-type (I < II < IV < III) and oxorhodo-
type (I < IV < II < III) (Figure 2.46). Thus conclusions concerning the substitution of 
the porphyrins can be made. For example, mono-meso-substituted porphyrins belong 
to the phyllo-type, whereas porphyrins with six or more substituents without  
π-electrons in the β-positions belong to the etio-type. Porphyrins bearing substituents 
with π-electrons in β-positions belong to the rhodo-type or oxorhodo-type [133]. The 
porphyrins synthesised for this work belong to the etio-type (I < II < III < IV), their 
characteristics will be discussed in detail below. 
Pentafluoroporphyrin exhibited an intensive Soret-band at 411 nm and smaller  
Q-bands at 506 nm, 584 nm and 638 nm. As expected, the substitution of the para-
fluorine of PFPP by selenium under formation of porphyrin 40 caused no shift of the 
Soret-band, which was found at 413 nm (Figure 2.47). In contrast, the formation of 
porphyrin 36 caused a bathochromic shift of the Soret-band of approximately 8 nm 
(Figure 2.47). This shift from 411 nm to 419 nm was caused by the mesomeric effect 
of the amino group in para-position, which increased the electron density at the 
centre of the porphyrin. The Q-bands remained unaffected. 
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Figure 2.47: UV/VIS spectra for PFPP, porphyrin 40 and porphyrin 36. The replacement of 
fluorine against a phenylseleno group did not have any influence on the UV/VIS-spectrum 
(compare PFPP and porphyrin 40). In contrast, the +M-effect of the amino group caused an 
increased electron density of the porphyrin core (compared to PFPP) and thus a bathochromic 
shift of the Soret-band (porphyrin 36). 
As expected, the introduction of a selenium-containing moiety did not influence the 
electronic and thus spectroscopic behaviour, hence the selenium-containing 
porphyrins 24, 25, 32, 32a, 33, 34 and 37-42 did not show any alteration of their 
UV/VIS spectra compared to their selenium-free precursors (Table 2.5). 
Table 2.5: Absorption data for the porphyrins synthesised and chlorin 43 
porphyrin/ chlorin absorption bands [nm] 
24 417, 514, 548, 591, 645 
25 416, 512, 545, 587, 641 
32, 32a 415, 511, 543, 590, 648 
33, 34 419, 509, 545, 586, 646 
37-40 412, 507, 542, 586, 646 
42 411, 505, 545, 586 
43 415, 516, 543, 643 
470 520 570 620 670
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Since chlorins have lost the aromatic character, the UV/VIS spectra of chlorins differ 
considerably from the UV/VIS spectra of porphyrins, showing a different absorption 
pattern for the Q-bands. The UV/VIS spectrum of chlorin 43 is shown in Figure 2.48. 
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
350 400 450 500 550 600 650 700
wavelength [nm]
ab
so
rb
an
ce
 [-
]
chlorin 43
 
Figure 2.48: UV/VIS spectrum for chlorin 43. 
The Q-band IV at 643 nm was more intense compared to Q-band IV of the 
porphyrins and also more intense than the three Q-bands at lower wavelengths. Like 
porphyrins, chlorines can be characterised by their UV/VIS spectra. 
2.3.3 NMR spectroscopy of porphyrins 
Porphyrins show a characteristic signal pattern in their 1H NMR spectra. The NMR 
spectra for non-symmetrical porphyrins usually look rather complex, whereas the 
spectra of symmetrical porphyrins appear comparably simple. Considering the 
porphyrin core structure as an [18]-annulen-derivative, the ‘Ringstrom’-model can be 
exerted. As a consequence of this effect, the inner NH-protons are strongly shielded, 
thus appearring in the range of -2 to -4 ppm. Due to the NH-tautomery, the inner NH 
groups usually appear as just one signal [134]. In contrast, the outer protons are 
deshielded and appear at a higher part of the spectrum (8 to 9 ppm for β-H, 
approximately 10 ppm for meso-H).  
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Representative for a typical monosubstituted tetraphenylporphyrin, the 1H NMR 
spectrum of porpyhrin 24 is shown in Figure 2.49. As expected, the β-H appeared as 
merged singuletts at 8.87 to 8.91 ppm, and the appearance of the signal revealed the 
kind of substitution. The inner NH appeared as singulett at -2.73 ppm. The phenyl 
groups in positions 10, 15 and 20 appear as multiplets with chemical shifts of 8.26 to 
8.23 ppm and 7.80 to 7.71 ppm. Presumably, due to the appearance of the 
multiplets, the signals in the downfield at 7.65 to 7.63 ppm and 7.33 to 7.28 ppm 
were caused by the selenophenyl group, whereas the signals more upfield at a 
chemical shift of 8.14 to 8.12 ppm and 7.26 to 7.23 ppm belonged to the phenyl 
group bearing the ether functionality. The three signals at 4.37 ppm, 3.30 ppm and 
2.40 ppm originated from the methylen groups of the alkyl chain. 
       
Figure 2.49: 1H NMR spectrum for porphyrin 24. Details are discussed in the text. 
Compared to the 1H NMR spectra of the coupling products, the 1H NMR spectra of 
the four isolated products of the nucleophilic substitution reaction of PFPP looked 
rather simple. The β-hydrogens were found at 8.94 ppm and the inner NH were found 
at -2.91 ppm. Depending on the substitution, the integration of the multiplets at 
around 7.88 ppm and 7.46 ppm caused by the phenylseleno group differed in their 
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integration due to the kind of substitution (Figure 2.50). By means of the appearance 
of the β-pyrrol signal, the kind of substitution can be deducted. The symmetrical 
tetrasubstituted porphyrin 40 exerted a singulett for the β-hydrogen, the disubstituted 
porphyrin 38 exerted an almost symmetrically split dublett. In contrast, the mono- and 
trisubstituted porphyrins 37 and 39 exerted a non-symmetrical split signal. 
 
Figure 2.50: Cut-outs of stacked 1H NMR spectra for porphyrins 37-40. Details are provided and 
discussed in the text. 
In order to confirm the proposed structure of porphyrins 37-40, 19F NMR spectra were 
recorded. Fluorine is an atom of certain interest, since fluorine is the smallest 
substituent to replace hydrogen. Additionally, fluorine enhances the lipophilicity of a 
compound, compared to other substituents. 19F has a relative abundance of 100 % 
and a nuclear spin of ½, and thus fluorine couples to proximate hydrogen [135]. Spin-
spin coupling between fluorine and hydrogen causes multiplicities which follow the 
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n+1 rule. The resulting complex signal pattern in the 19F NMR spectrum will be 
discussed in detail here. 
           
Figure 2.51: 1H NMR and 19F NMR spectrum for porphyrin 42. Details are discussed in the text. 
In Figure 2.51 cut-outs of the 1H and 19F NMR spectra of the isolated product of the 
nucleophilic substitution reaction of PFPP with diphenylditelluride, which was later on 
identified as the symmetrical porphyrin 42, are shown. In the 1H NMR spectrum, the 
signal for the β-H was found at 8.92 ppm and the signal for the inner NH was found 
at -2.87 ppm. The signal for the hydrogen in para-position of the tetrafluorophenyl 
group was split up by the neighbouring fluorines into a multiplet at 7.68 to 7.60 ppm. 
In the 19F NMR spectrum, two multiplets at -137.19 to -137.30 ppm and at -138.52 to 
-138.64 ppm were found. The signal pattern was caused by the coupling with the 
neighbouring fluorine or hydrogen, respectively. The identification of that hydrogen-
containing species allowed a further improvement of the synthesis in order to 
selectively generate porphyrins 37-40. Modifying the reaction conditions resulted in 
the formation of the desired porphyrins, whilst avoiding the generation of the 
hydrogen-containing species. 
The recording and interpretation of 2D-NMR spectra allows identification of the exact 
position of an atom in a molecule. The coupling of an atom with its neighbours results 
in a typical signal pattern, unique for this specific atom in the appropriate molecule. 
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HHCOSY techniques are therefore commonly used, but not only protons are able to 
correlate, fluorine does this as well, and thus FFCOSY spectra were recorded for the 
fluorine-containing porphyrins. In Figure 2.52, the FFCOSY NMR spectrum of 
porphyrin 39 is shown. The signals at -127.4 and -136.1 ppm coupled to each other 
exclusively; hence these signals belong to the fluorines located at the tetraflourinated 
phenyl groups in meso-positions. The signals at -136.4 ppm, -151.4 ppm and -161.4 
ppm were caused by the ortho-, para- and meta-fluorines of the pentafluorophenyl 
groups. Depending on the substitution, the 19F NMR spectra for porphyrins 37-39 
looked very similar, only differing in the integration of the fluorines. 
 
Figure 2.52: FFCOSY NMR spectrum of porphyrin 39. Details are provided and discussed in the 
text. The structure of porphyrin 39 also provides the assignment of the signals.   
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The selenium isotope 77Se has a natural abundance of 7.58 % [136] and a nuclear 
spin of ½, thus selenium can be used for NMR spectroscopy. Although 77Se NMR 
spectroscopy is currently considered as exotic, it was used to proof the presence of 
selenium in the selenium-containing porphyrins. Diphenyldiselenide with a chemical 
shift of δ = 463 ppm was used as a reference [137]. The reduction of diphenyl-
diselenide with sodiumborohydride provided a nucleophilic selenolate. Subsequent 
attachment of this phenylselenium part to another carbon caused an upfield-shift of 
the selenium peak from 463 ppm to 289 ppm (Figure 2.53). As comparison, the 
chemical shift of (pentafluorophenyl)(phenyl)selenide is found at δ = 265 ppm [137], 
thus in the same range as the selenium peak found. Hence it could be concluded, 
that the new species formed also belonged to the type of (pentafluorophenyl) 
(phenyl)selenide-derivatives. As expected, the shifts of the different substituted 
porphyrins 37-40 did not differ too extensively. 
 
Figure 2.53: Stacked 77Se NMR spectra of Ph2Se2 and porphyrin 40. During the nucleophilic 
substitution reaction of PFPP with Ph2Se2, the selenium peak was shifted from 463 ppm to  
289 ppm, indicating the presence of a new selenium-containing species. 
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2.3.4 Mass spectrometry of porphyrins 
In general, porphyrins can be identified easily by mass spectrometry (MS), mostly 
appearing as molecular peak as [M]+ or [M+H]+. The differently substituted porphyrins 
37-40, which were isolated from the same reaction mixture via preparative TLC, all 
showed their corresponding M+-peaks and some additional fragments. A 
representative mass spectrum of porphyrin 40 in acetonitril is shown in Figure 2.54. 
 
Figure 2.54: Mass spectrum of porphyrin 40. Details are provided and discussed in the text. 
The intense peak at m/z = 1523.64, which showed the typical isotopic pattern for 
74Se, 76Se, 77Se, 78Se, 80Se and 82Se, belonged to the tetrasubstituted porphyrin 40. 
As expected, these porphyrins formed fragments which differed in the parts formed 
by the phenyl groups. Whilst the peak at m/z = 1444.74 was caused by a species 
consisting of [M-Ph+]-, the peak at m/z = 1598.69 was caused by the species 
consisting of [M+Ph+]+. The identification of the remaining fragments facilitated the 
modification of the reaction conditions, resulting in the preferred generation of the 
desired species.  
As the isotopic pattern of the signals revealed, these species contained a selenium 
atom. In the species with different phenylseleno group substitutions a fluorine atom 
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was replaced against a hydrogen atom. For example, the intense signal at m/z = 
1367.72 was caused by a species consisting of [M-SePh-F]+H+, a derivative of 
porphyrin 39. The fragments at higher m/z such as the peaks at m/z = 2425.77 or  
m/z = 2889.54 were representative of dimeric structures of these derivatives with 
exchanged atoms. For all reactions, in which PFPP was reacted with 
diphenylditelluride, a peak at m/z = 901.94 was found. This peak was identified as 
belonging to a derivative of PFPP, whose para-fluorine atoms (as confirmed by 
intensive 2D-NMR studies) were replaced by hydrogen, e.g. porphyrin 42. Varying 
the reaction conditions including reaction time or temperature, did not succeed in the 
formation of the desired porphyrin 41. 
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3. Summary and Outlook 
The present work deals with the development of new redox catalysts able to interfere 
with different cellular aspects occurring during OS. The first part deals with the 
detailed biological evaluation of synthesised quinone-based redox modulators, 
whereas the second part focuses on the development of new selenium-containing 
porphyrins as potential redox modulators. 
The 1,4-benzoquinone- or 1,4-naphthoquinone-containing compounds 1-21 were 
synthesised successfully via a nucleophilic substitution reactions. The structures and 
purities of these organochalcogenic compounds were confirmed using different NMR 
spectroscopy techniques as well as LC-MS or HPLC. Their catalytic activity was 
determined with the thiophenol assay (chapter 2.2.3). The compounds were 
expected to modulate redox signalling of cells suffering from OS. Therefore, 14 
compounds were investigated in detail in cell culture assays towards their toxic, 
antioxidative and anti-inflammatory properties using macrophages (RAW 264.7) and 
CLL cells. 
Firstly, a MTT assay was employed to confirm the compound’s toxicity and 
investigate first structure-activity relationships. That cell viability assay revealed a 
stronger toxicity of the tellurium-containing compounds 14-16 and 20 compared to 
the selenium- or sulfur-containing compounds, which were in general less toxic. All 
compounds reduced the cell viability in a dose-dependent manner. In the presence of 
H2O2 (to simulate OS), different effects on cell viability compared to the absence of 
H2O2 were observed. Compound 1 exhibited a certain ROS-dependend toxic effect at 
low concentrations, whereas compound 13 exerted a protective effect against ROS 
(chapter 2.2.4). 
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Figure 3.1: Chemical structures of compounds 1, 13 and 20, which were found to be 
particularly active in the MTT assay. Compound 1 exhibited a toxic effect in the presence of 
ROS, compound 13 exhibited a protecting effect against ROS and compound 20 was generally 
toxic, already in the submicromolar range. 
In order to investigate the mode of cell death, a caspase-3 assay for determining cell 
death via apoptosis was performed with the most interesting compounds 1-3, 5, 16 
and 20 (chapter 2.2.5). Compounds 1-3 and 5 caused significant differences in cell 
viabilities in the absence or presence of H2O2, and compounds 16 and 20 were 
chosen as representatives of the tellurium-containing compounds. Compounds 2 and 
20 both induced elevated levels of caspase-3, indicating that apoptosis played an 
important role during cell death. These findings were also confirmed in a microscope-
assisted dying technique, using DAPI for staining of cell nuclei (chapter 2.2.6). 
Treatment with these compounds led to approximately 15 % (compound 20) and 8 % 
(compound 2) apoptotic cells, characterised by shrunken nuclei containing 
condensed chromatin. The data obtained in the caspase-3 assay and in the staining 
assay pointed towards an involvement of compound-induced cell death via 
apoptosis. During this process, which is characterised by the activation of caspases 
and plasma membrane blebbing, affected cells are removed and homeostasis is 
regained [138]. 
Since caspase-3 leads to the activation of DNA-fragmenting enzymes, preliminary 
studies concerning DNA-damage and DNA-repair were performed with the selenium-
containing compounds 13 and 17 and the tellurium-analoga 14 and 16 (studies 
performed by the group of Prof. Dr. Andrea Hartwig, KIT Karlsruhe, chapter 2.2.13). 
Interestingly, the compounds did not exhibit a huge DNA-damaging effect as 
confirmed by the estimation of DNA-strand breaks induced by alkaline unwinding. 
Furthermore, yeast-based assays with mutants, which lack certain DNA-repair 
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systems, also did not reveal any major effect of the compounds (studies performed 
by group of Prof. A. Slusarenko, RWTH Aachen). 
In order to verify whether the compounds were able to interfere with different reactive 
species, such as RNS and ROS, the Griess assay (chapter 2.2.7) and ROS assay 
using DCF-DA (chapter 2.2.8) were performed. Data obtained in the Griess assay 
revealed a reduction of LPS-induced •NO-release caused by treatment with the 
selenium-containing compounds, whereas the tellurium-containing compounds did 
not exhibit this anti-inflammatory effect. Similarly, in the ROS assay, the tellurium-
containing compounds, such as compound 20, slightly enhanced internal ROS levels 
induced by treatment with H2O2 or PMA, whereas selenium-containing compounds, 
such as compounds 2 or 3, strongly reduced ROS levels in a concentration 
dependent manner. 
In order to examine the effects on the cell proliferation, an ECIS-based proliferation 
assay was performed (chapter 2.2.9). The cell-based impedance, which was 
recorded for 72 h, generally decreased to a certain extent when cells were treated 
with the test compounds. Even if toxic effects were also determined, it seemed as the 
compounds, 2.5 µM of compound 2 in particular, inhibited cell proliferation. These 
findings were confirmed by an MTT assay after 72 h of cells treated in an analogous 
manner. 
Cancer is also related to the occurrence of OS. Abnormal cells vigorously divide 
without control, invade adjacent tissues and spread through the body via 
bloodstreams or lymphatic vessels [123]. Therefore, some of the compounds were 
also investigated using cancer cells such as CLL cells or K562 cells in studies 
performed by collaborative partners (chapter 2.2.10). Among the compounds tested, 
the tellurium-containing 1,4-naphthoquinones 14, 15 and 20 exhibited the highest 
toxicity against K562 cells. Furthermore, compounds 14 and 20 were applied at low 
concentrations in other cancer cell lines (HT29, A549, MCF7), with HUVEC and  
NIH 3T3 fibroblasts serving as controls (studies were performed in the group of Prof. 
Dr. F. Batteux, Paris University). In these assays, a certain selectivity of the tellurium-
containing compounds against cancer cells was observed, whereas the normal cells 
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were generally less affected. More in depth drug synergy studies using irinotecan or 
5-fluorouracil in combination with compound 20 revealed that co-incubation of 2 µM 
of compound 20 with one of the chemotherapeutic drugs caused an additional 
decrease in cell viability in HT29 cells, whereas the cell viability in NIH 3T3 cells was 
not affected significantly. This effect was likely caused by the elevation of the pre-
existing ROS levels, as confirmed by a ROS assay. 
After a pre-screening in CLL cells and healthy PBMC, compounds 14 and 20 were 
investigated further in detailed studies (performed in the group of Dr. M. Herling, 
Cologne University). A reduced cell viability of CLL cells compared to the cell viability 
of PBMC was observed. As confirmed by the determination of caspase-3 activity, 
CLL-selective cell death was mostly induced via apoptosis, whereas the caspase-3-
activity was not increased significantly in PBMC. Measurement of the intracellular 
ROS levels by flow cytometry in CLL cells and PBMC obtained from the same patient 
showed higher pre-existing intracellular ROS levels in CLL cells compared to PBMC, 
as well as lowered levels of reduced glutathione. The treatment with compounds 14 
or 20 for 12 h caused an increase in the pre-existing ROS levels in CLL cells, but not 
in PBMC, once again pointing towards a certain selectivity of the tellurium-
compounds towards cancer cell lines (chapter 2.2.10). Additional studies indicated, 
that compound 14 was able to bind to tubulin and actin, whereas compound 20 only 
bond to actin. 
The results obtained in cell culture assays were also confirmed for compound 20 in a 
mouse model, where compound 20 reduced the increased dermal thickness in HOCl-
induced systemic sclerosis in mice possibly offering a new therapeutic strategy in its 
treatment (chapter 2.2.11). 
Additional investigations were performed with yeast mutants in order to identify the 
enzymatic system which might be responsible for the ROS-modulating properties 
(studies performed in the group of Prof. A. Slusarenko, RWTH Aachen University). 
BY4742-mutants, which either lack SOD1, SOD2, GR or cytosolic catalase (CTT1), 
revealed a certain selectivity of the compounds towards SOD2-mutants, and thus 
pointed towards an involvement of SOD2 or a related enzyme. A lucigenin-based 
3. Summary and Outlook 
   
 - 134 - 
assay for the generation of ROS in the absence or presence of cells once again 
confirmed that compounds 13, 14 and 16 increased pre-existing ROS levels (chapter 
2.2.12). 
The ability to exploit the pre-existing increased ROS levels in cancer cells or in cells 
suffering from inflammatory diseases might promote the new therapeutic approach 
which uses redox modulators as selective drug-candidates, whilst leaving healthy 
cells largely unaffected. Summarising the biological data obtained so far, compounds 
such as the 1,4-benzoquinones 1-3 and also the tellurium-containing compound 20 
seem to be promising multifunctional compounds which exploit the intracellular 
‘signature’ for a beneficial approach. The benzoquinones 1-3, in particular, exhibited 
very interesting properties: When applied at low concentrations, they reduced cell 
viability in the presence of H2O2 significantly, decreased LPS-induced •NO-release in 
a dose-dependent manner and also showed a ROS-reducing effect. Furthermore, 
compounds 1 and 2 were shown to inhibit cell proliferation. If these findings were 
confirmed in cancer cells, the augmented cell division leading to the formation of a 
tumour or metastasis may be prevented, and thus compounds 1-3 could be used as 
potential anti-tumour agents. As shown for compound 2, cell death was (at least in 
part) induced via apoptosis. In summary, the data obtained pointed towards 
compounds 1-3 being promising agents for therapeutic use in the context of 
inflammatory diseases. The augmented •NO-release as well as the induction of ROS 
during inflammation could be reduced and the persistence of macrophages in the 
inflammed tissue could be restricted due to anti-proliferative effects. 
The modes of intracellular actions, however, still remain unclear. Additional studies 
concerning the mode of cell death (involvement of other caspases, such as caspase-
1 or caspase-7 and also involvement of caspase-independent pathways) have to be 
conducted in the future. Furthermore, the anti-inflammatory properties surrounding 
inhibition of •NO-release (as seen in the case of the 1,4-benzoquinones 1-3) have to 
be investigated in more detail. 
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The second part of the present work deals with the development of new redox 
catalysts based on porphyrins. Hence 12 hitherto unknown selenium-containing 
porphyrins were synthesised using different synthetic approaches (chapter 2.3.1). 
Amide coupling and ether synthesis of appropriate porphyrins provided porphyrins 
22-24, 26 and 27 in adequate purity and acceptable yields. The approach of 
modifying the quinone-containing porphyrin 28 only succeeded in the synthesis of 
porphyrin 32. After a few modifications, the nucleophilic substitution reaction of PFPP 
with diphenyldiselenide or 3-(phenylselanyl)propane amine resulted in a mixture of 
differently substituted porphyrins (33-40), from which some porpyhrins could be 
separated by preparative thin layer chromatography. The resulting porphyrins were 
characterised intensively including different NMR techniques (1H, 13C, 19F and 77Se), 
UV/VIS spectroscopy and mass spectrometry (chapters 2.3.2 to 2.3.4). The isolation 
of the interesting side-product porphyrin 42 opened up a new way for further 
reactions, such as the selective nucleophilic substitution reaction in meta-position. 
Future research will focus on the biological behaviour of the new porphyrins. Due to 
their similarity to heme, the compounds should be easily applicable and uptaken in 
the human body. Solubility problems can be avoided easily by the attachment of 
hydrophilic groups such as ethylenglycole. Porphyrins can also be used as 
photosensitizers in PDT. The insertion of different metals could provide a new kind of 
photosensitizers. Via this kind of modification, a SOD-like activity could also be 
‘inserted’ [129] and thus should be investigated further in the future, together with its 
possible applications in intracellular redox modulation. 
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4. Experimental Part 
4.1 Materials and methods 
4.1.1 Materials 
Diphenyldiselenide, diphenylditelluride, 4,4’-dimethoxyphenylditelluride, bis(2-amino-
phenyl)diselenide and diphenyldisulfide were purchased from Sigma-Aldrich 
(Germany) and used without further purification. For chemical synthesis, reactions 
were carried out in distilled water or in laboratory grade solvents at room temperature 
and under nitrogen atmosphere. Purification was carried out by column 
chromatography using silica gel throughout (Macherey-Nagel, 50-200 μm diameter) 
under nitrogen pressure. Used columns had 2.5 to 3.0 diameter and column was 
filled to  
30 cm with dissolved silica gel. TLC (thin layer chromatography) was performed on 
silica-coated aluminia plates (Merck, silica gel 60 F254). 
4.1.2 Melting points 
Melting points were recorded using a digital melting point apparatus (IA9000 series, 
ThermoFischer Scientific, Rochford, U.K.) and are given without correction. 
4.1.3 NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded at the Institute of 
Pharmaceutical Chemistry. 1H NMR spectra were recorded at 500 MHz, and  
13C NMR spectra were recorded at 125 MHz on a Bruker Avance 500 spectrometer. 
77Se spectra and 19F spectra were recorded at 400 MHz on a Bruker Avance 500 
spectrometer at the University of Connecticut. All spectra were recorded in CDCl3 
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and chemical shifts are reported in δ (ppm), expressed relative to the solvent signal 
at 7.26 ppm (1H NMR) and at 77.16 ppm (13C NMR) [139]. 
4.1.4 HPLC 
High-performance liquid chromatography (HPLC) separations were performed on a 
Bischoff Lambda 1000 UV/VIS at 275 nm using a YMCC 18 Pro column and 
methanol/water (85:15) as mobile phase at a flow rate of 1.0 ml/min. 
4.1.5 IR spectroscopy 
IR data were measured on a Bruker Tensor 27 using a golden gate. 
4.1.6 HRMS 
HRMS were recorded on a Finnigan MAT 95 spectrometer using the Ci positive 
technique. 
4.1.7 UV/VIS spectroscopy 
UV/VIS spectra were recorded on a CARY 50 spectrophotometer (Varian Inc.) and 
quartz cells (1000 µl) were used throughout. 
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4.2 Synthesis of organochalcogen-containing compounds 
4.2.1 Starting materials 
The chalcogen-containing precursors, p-hydroxyphenyltellurium(IV)trichloride,  
3-(phenylseleno)propane amine, 4,4’-dimethoxydiphenyldiselenide and 4-(phenyl-
selanyl)butanoic acid were synthesised according to literature procedures [140-145]. 
The bromides 2-bromo-3-methyl-1,4-naphtho-quinone, 2,5-dibromo-3,6-dimethyl-1,4-
benzoquinone, 2-bromo-5,6-dimethoxy-3-methyl-1,4-benzoquinone, 2,6-dibromo-3,5-
dimethyl-1,4-benzoquinone, 2-bromo-5-methyl-1,4-benzoquinone were prepared 
analogously to a literature procedure [146]. 
4.2.2 General procedure for nucleophilic substitution reaction (A) 
Under argon-atmosphere, disulfide (or diselenide or ditelluride) (1 eq.) was dissolved 
in a mixture of 100 ml THF and 25 ml water. NaBH4 (~4 eq.) was added to the yellow 
or orange solution and the mixture was stirred vigorously until it became colourless. 
The appropriate haloquinone (1 eq. for dihaloquinone or 2 eq. for monohaloquinone) 
in THF (5 mL) was added and the formation of the desired product was monitored via 
TLC. Afterwards the solution was stirred for further 15 min on air. The violet, dark red 
or orange coloured reaction mixture (depending upon the Te, Se or S counterpart of 
the product) was diluted with saturated NH4Cl (aq) and extracted with ethyl acetate 
(EtOAc). The combined organic extracts were dried over Na2SO4 and the solvent 
was evaporated under reduced pressure. The crude product was purified by 
chromatography using mixtures (v/v) of petrol ether (40-65°C, PE) and EtOAc as 
specified for each compound below. Since the compounds might be sensitive to 
oxidation and light, they were stored in the dark under argon atmosphere. 
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4.2.3 2,6-Bis(phenylselanyl)-3,5-dimethyl-1,4-benzoquinone (1) 
Compound 1 was synthesised from diphenyldiselenide (376 mg, 1.2 mmol) and 2,6-
dibromo-3,5-dimethyl-1,4-benzoquinone (354 mg, 1.2 mmol) according to general 
procedure A. Compound 1 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent, yielding 11 % of a red solid. 
C20H16O2Se2 (M = 446.26 g/mol). 
TLC: Rf = 0.51 (PE/EtOAc, 95:5). Mp: 112°C. 1H NMR: δ = 
7.25-7.24 (m, 4H, H-a), 7.04-7.01 (m, 6H, H-b and H-c), 1.90 
(s, 6H, CH3) ppm. 13C NMR: δ = 182.5, 180.0, 147.8 (2C), 
144.1 (2C), 133.6 (4C), 129.6 (2C), 129.5 (4C) 128.0 (2C), 17.5 (2C) ppm. 77Se 
NMR: δ = 371.25 ppm. HRMS (m/z): calc.: 477.95 (100 %), 445.95 (92.2 %), 443.95 
(51.8 %); found 447.9486 (100 %), 445.9583 (93.10 %), 443.9655 (55.60 %). 
4.2.4 2,5-Bis(phenylselanyl)-3,6-dimethyl-1,4-benzoquinone (2) 
Compound 2 was synthesised from diphenyldiselenide (978 mg, 3.0 mmol) and  
2,5-dibromo-3,6-dimethyl-1,4-benzoquinone (949 mg, 3.2 mmol) following general 
procedure A. Compound 2 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 23 % of an intense red solid. 
C20H16O2Se2 (M = 446.26 g/mol). 
TLC: Rf = 0.50 (PE/EtOAc, 95:5). Mp: 112°C. 1H NMR: δ = 
7.45-7.44 (m, 4H, H-a), 7.24-7.22 (m, 6H, H-b and H-c), 1.99 
(s, 6H, CH3) ppm. 13C NMR: δ = 181.5 (2C), 148.1 (2C), 143.9 (2C), 133.7 (4C), 
129.6 (2C), 129.5 (4C), 128.1 (2C), 17.8 (2C) ppm. 77Se NMR: δ = 364.90 ppm. 
HRMS for C20H16O2Se2 (m/z): calc.: 477.95 (100 %), 445.95 (92.2 %), 443.95 (51.8 
%); found 447.9483 (100 %), 445.9556 (96.37 %), 443.9646 (55.23 %). 
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4.2.5 2,6-Bis(phenylselanyl)-3,5-dimethoxy-1,4-benzoquinone (3) 
Compound 3 was synthesised from diphenyldiselenide (470 mg, 1.5 mmol) and  
2,6-dibromo-3,5-dimethoxy-1,4-benzoquinone (441 mg, 1.3 mmol) following general 
procedure A. Compound 3 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 34 % of a black solid. 
C20H16O4Se2 (M = 478.26 g/mol). 
TLC: Rf = 0.32 (PE/EtOAc, 95:5). Mp: 81°C. 1H NMR: δ = 
7.54-7.53 (m, 4H, H-a), 7.26-7.21 (m, 6H, H-b and H-c), 3.57 
(s, 6H, CH3) ppm. 13C NMR: δ = 182.6, 174.9, 156.9 (2C), 134.7 (4C), 129.3 (2C), 
129.1 (4C), 128.7 (2C), 128.3 (2C), 60.7 (2C) ppm. 77Se NMR: δ = 355.35 ppm. 
HRMS for C20H16O4Se2 (m/z): calc.: 479.94 (100 %), 477.94 (92.3 %), 475.94 (51.6 
%); found 479.9597 (100 %), 477.9580 (97.56 %), 475.9626 (53.00 %). 
4.2.6 2-(Phenylselanyl)-5-methyl-1,4-benzoquinone (4) 
Compound 4 was synthesised from diphenyldiselenide (492 mg, 1.5 mmol) and  
2-bromo-5-methyl-1,4-benzoquinone (158 mg, 0.8 mmol) according to general 
procedure A. Compound 4 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 21 % of a orange solid. 
C13H10O2Se (M = 277.18 g/mol). 
TLC: Rf = 0.51 (PE/EtOAc, 95:5). Mp: 112°C. 1H NMR: δ = 7.82-7.80 
(m, 2H, H-a), 7.74-7.66 (m, 3H, H-b and H-c), 7.50 (s, 1H, H-3 or H-
6), 6.45 (s, 1H, H-3 or H-6), 1.80 (s, 3H, CH3) ppm. 13C NMR: δ = 185.2, 184.7, 154.6 
(2C), 147.3, 137.1 (2C), 132.7, 130.6, 130.4 (2C), 130.3, 16.1 ppm. 77Se NMR: δ = 
414.08 ppm. HRMS for C13H10O2Se (m/z): calc.: 277.98 (100 %), 275.99 (50.4 %), 
273.99 (18.9 %); found 277.9823 (100 %), 275.9825 (49.87 %), 273.9939 (18.49 %).  
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4.2.7 2,6-Bis(phenylselanyl)-1,4-benzoquinone (5) 
Compound 5 was synthesised from diphenyldiselenide (161 mg, 0.5 mmol) and  
2,6 dichloro-1,4-benzoquinone (96 mg, 0.5 mmol) following general procedure A. 
Compound 5 was purified by column chromatography using PE/EtOAc (95:5) as 
solvent yielding 18 % of a red solid. 
C18H12O2Se2 (M = 418.21 g/mol). 
TLC: Rf = 0.38 (PE/EtOAc, 95:5). 1H NMR: δ = 7.60-7.58 (m, 
4H, H-a), 7.49-7.41 (m, 6H, H-b and H-c), 6.05 (s, 2H, H-3 and 
H-5) ppm. 13C NMR: δ = 182.8, 181.8, 153.1 (2C), 137.2 (4C), 131.5 (2C), 130.5 
(4C), 130.3 (2C), 124.3 (2C) ppm. 
4.2.8 2,5-Bis((2-aminophenyl)selanyl)-3,6-dimethyl-1,4-benzoquinone 
(6) 
Compound 6 was synthesised from bis(2-amino-phenyl)diselenide (195 mg,  
0.6 mmol) and 2,5-dibromo-3,6-dimethyl-1,4-benzoquinone (168 mg, 0.6 mmol) 
following general procedure A. Compound 6 was purified by column chromatography 
using PE/EtOAc (95:5) as solvent yielding 7 % of a intensively red solid. 
C20H18N2O2Se2 (M = 476.29 g/mol). 
TLC: Rf = 0.45 (PE/EtOAc, 95:5). Mp: 146°C. 1H NMR: δ = 
8.01-7.99 (dd, 2H, H-d, J = 9.8 Hz), 7.60-7.58 (dd, 2H, H-a, J = 
9.8 Hz), 7.48-7.44, 7.38-7.34 (each dt, each 2H, H-b and H-c), 
2.02 (s, 6H, CH3) ppm. 13C NMR: δ = 178.9 (2C), 143.8 (2C), 139.7 (2C), 135.7 (2C), 
130.6 (2C), 129.9 (2C), 128.2 (2C), 127.1 (2C), 124.5 (2C), 18.5 (2C) ppm. 77Se 
NMR: δ = 367.14 ppm. 
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4.2.9 5,6-Dimethoxy-3-methyl-2-(phenylselanyl)-1,4-benzoquinone 
(7) 
Compound 7 was synthesised from diphenyldiselenide (302 mg, 1.0 mmol) and  
2-bromo-5,6-dimethoxy-3-methyl-1,4-benzoquinone (142 mg, 0.5 mmol) following 
general procedure A. Compound 7 was purified by column chromatography using 
PE/EtOAc (95:5) as solvent yielding 73 % of a yellow solid. 
C15H14O4Se (M = 337.23 g/mol). 
TLC: Rf = 0.27 (PE/EtOAc, 95:5). 1H NMR: δ = 7.42-7.40 (m, 2H, 
H-a), 7.20-7.19 (m, 3H, H-b and H-c), 3.94 (s, 3H, OCH3), 3.88 (s, 
3H, OCH3), 1.99 (s, 3H, CH3) ppm. 13C NMR: δ = 182.0, 180.9, 145.9, 145.2, 144.9, 
141.5, 133.5 (2C), 129.5 (2C), 129.5, 128.1, 61.5, 61.3, 17.0 ppm. 
4.2.10 2,5-Bis(phenylselanyl)-1,4-benzoquinone (8) 
Compound 8 was synthesised from diphenyldiselenide (426 mg, 1.4 mmol) and  
2,5-dichloro-1,4-benzoquinone (242 mg, 1.4 mmol) according to general procedure 
A. Compound 8 was purified by column chromatography using PE/EtOAc (95:5) as 
solvent yielding 9 % of a orange solid. 
C18H12O2Se2 (M = 418.21 g/mol). 
TLC: Rf = 0.20 (PE/EtOAc, 95:5). 1H NMR: δ = 7.83-7.81 (m, 
4H, H-a), 7.75-7.67 (m, 6H, H-b and H-c), 6.45 (s, 2H, H-3 and 
H-6) ppm. 13C NMR: δ = 181.6 (2C), 157.3 (2C), 137.1 (4C), 130.5 (4C), 130.4 (2C), 
129.5 (2C), 124.3 (2C) ppm. 
4.2.11 2,6-Bis(phenyltellanyl)-3,5-dimethyl-1,4-benzoquinone (9) 
Compound 9 was synthesised from diphenylditelluride (558 mg, 1.4 mmol) and  
2,6-dibromo-3,5-dimethyl-1,4-benzoquinone (401 mg, 1.4 mmol) following general 
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procedure A. Compound 9 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 11 % of a purple solid. 
C20H16O2Te2 (M = 543.54 g/mol). 
TLC: Rf = 0.32 (PE/EtOAc, 95:5). 1H NMR: δ = 7.81-7.78 (m, 
4H, H-a), 7.36-7.31 (m, 2H, H-c), 7.25-7.21 (m, 4H, H-b), 2.26 
(s, 6H, CH3) ppm. 13C NMR: δ = 181.8, 172.3, 146.3 (2C), 139.9 (2C), 139.7 (4C), 
134.3 (4C), 129.8 (2C), 129.7 (2C), 17.5 (2C) ppm. 
4.2.12 2,5-Bis(phenyltellanyl)-3,6-dimethyl-1,4-benzoquinone (10) 
Compound 10 was synthesised from diphenylditelluride (814 mg, 2.0 mmol) and  
2,5-dibromo-3,6-dimethyl-1,4-benzoquinone (585 mg, 2.0 mmol) following general 
procedure A. Compound 10 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 38 % of a purple solid. 
C20H16O2Te2 (M = 543.54 g/mol). 
TLC: Rf = 0.55 (PE/EtOAc, 95:5). 1H NMR: δ = 7.79-7.75 (m, 
4H, H-a), 7.34-7.28 (m, 2H, H-c), 7.24-7.18 (m, 4H, H-b), 1.82 
(s, 6H, CH3) ppm. 13C NMR: δ = 181.3 (2C), 146.0 (2C), 139.8 (2C), 139.4 (4C), 
134.1 (2C), 129.5 (4C), 129.4 (2C), 17.3 (2C) ppm. 
4.2.13 2,6-Bis(phenyltellanyl)-3,5-dimethoxy-1,4-benzoquinone (11) 
Compound 11 was synthesised from diphenylditelluride (570 mg, 2.0 mmol) and  
2,6-dibromo-3,5-dimethoxy-1,4-benzoquinone (652 mg, 2.0 mmol) following general 
procedure A. Compound 11 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 9 % of a purple solid. 
C20H16O4Te2 (M = 575.54 g/mol). 
TLC: Rf = 0.35 (PE/EtOAc, 95:5). 1H NMR: δ = 7.84-7.82 (m, 
4H, H-a), 7.28-7.24 (m, 2H, H-c), 7.18-7.15 (m, 4H, H-b), 3.36 
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(s, 6H, CH3) ppm. 13C NMR: δ = 187.1, 172.3, 160.8 (2C), 140.7 (2C), 138.2 (4C), 
129.5 (4C), 129.2 (2C), 128.7 (2C), 60.3 (2C) ppm. 
4.2.14 2-(Phenylsulfuryl)-3-methylnaphthoquinone (12) 
Compound 12 was synthesised from diphenyldisulfide (985 mg, 4.5 mmol) and  
2-bromo-3-methyl-1,4-naphthoquinone (566 mg, 2.3 mmol) according to general 
procedure A. Compound 12 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 22 % of a orange solid. 
C17H12O2S (M = 280.34 g/mol). 
TLC: Rf = 0.29 (PE/EtOAc, 95:5). 1H NMR: δ = 8.08-8.06 (m, 1H), 
7.99-7.97 (m, 1H), 7.69-7.63 (m, 2H), 7.36-7.33 (m, 2H, H-a), 
7.27-7.19 (m, 3H, H-b and H-c), 2.32 (s, 3H, CH3) ppm. 13C NMR: δ = 183.1, 180.6, 
149.3, 145.6, 134.2, 133.8, 133.7, 132.7, 132.2, 130.7 (2C), 129.3 (2C), 127.4, 
127.2, 126.7, 16.0 ppm. 
4.2.15 2-(Phenylselanyl)-3-methylnaphthoquinone (13) 
Compound 13 was synthesised from diphenyldiselenide (502 mg, 1.5 mmol) and  
2-bromo-3-methyl-1,4-naphthoquinone (191 mg, 0.8 mmol) following general 
procedure A. Compound 13 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 80 % of a orange solid. 
C17H12O2S (M = 280.34 g/mol). 
TLC: Rf = 0.72 (PE/EtOAc, 80:20). 1H NMR: δ = 8.04-7.99 (m, 
2H), 7.67-7.61 (m, 2H), 7.52-7.50 (m, 2H, H-a), 7.27-7.24 (m, 3H, 
H-b and H-c), 2.17 (s, 3H, CH3) ppm. 13C NMR: δ = 182.3, 181.4, 149.7, 146.7, 
133.6, 133.4 (2C), 133.3, 132.1, 132.0, 129.7, 129.4 (2C), 127.8, 127.0, 126.3, 17.8 
ppm. 77Se NMR: δ = 367.34 ppm. 
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4.2.16 2-(Phenyltellanyl)-3-methylnaphthoquinone (14) 
Compound 14 was synthesised from diphenylditelluride (50 mg, 0.1 mmol) and  
2-bromo-3-methyl-1,4-naphthoquinone (46 mg, 0.2 mmol) following general 
procedure A. Compound 14 was purified by column chromatography using PE/EtOAc 
(95:5) as solvent yielding 98 % of a purple solid. 
C17H12O2Te (M = 375.88 g/mol). 
TLC: Rf = 0.45 (PE/EtOAc, 90:10). Mp: 89°C. 1H NMR: δ = 8.07-
8.05 (m, 2H), 7.83-7.81 (m, 2H), 7.71-7.64 (m, 2H, H-a), 7.35-7.32 
(m, 1H, H-c), 7.25-7.22 (m, 2H, H-b), 1.95 (s, 3H, CH3) ppm. 13C NMR: δ = 184.2, 
181.2, 153.5, 142.0, 139.6 (2C), 133.8, 133.3, 132.0, 131.6, 129.5 (2C), 128.6, 
127.1, 126.9, 114.2, 20.2 ppm. HPLC: tR 6.571 min, purity 98.8 %. HRMS (m/z): [M]+ 
calculated for C17H12O2Te 377.9899; found 377.9855; [M+H]+ calculated 378.9977; 
found 378.9935. Isotope pattern of Te: m/z (relative abundance %) 368.9602 (1.91), 
369.9776 (7.01), 370.9761 (5.18), 372.9816 (23.12), 375.9858 (90.11), 376.9880 
(20.71), 377.9855 (100), 378.9935 (24.28), 379.9995 (2.90). 
4.2.17 2-(4-Hydroxyphenyltellanyl)-3-methylnaphthoquinone (15) 
Compound 15 was synthesised from 4-hydroxyphenyltelluriumtrichloride (598 mg, 
1.8 mmol) and 2-bromo-3-methyl-1,4-naphthoquinone (458 mg, 1.8 mmol) following 
general procedure A. Compound 15 was purified by column chromatography using 
PE/EtOAc (95:5) as solvent yielding 18 % of a purple solid. 
C17H12O3Te (M = 391.88 g/mol). 
TLC: Rf: = 0.33 (PE/EtOAc, 80:20). Mp: 161°C, 1H NMR: δ = 
8.06-8.03 (m, 2H), 7.74-7.63 (m, 4H), 6.74-6.71 (m, 2H), 5.03 
(br s, OH) 1.92 (s, 3H, CH3) ppm. 13C NMR: δ = 184.8, 181.6, 179.8, 156.7, 153.4, 
142.5 (2C), 134.1, 133.5, 132.2, 131.8, 127.2, 127.1, 117.1 (2C), 103.4, 19.6 ppm. 
IR: ν = 1655, 1568, 1256, 1116, 781, 731, 654 cm-1. HPLC: tR 4.692 min, purity 97.3 
%. HRMS (m/z): [M]+ calculated for C17H12O3Te 393.9848; found 393.9677. Isotope 
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pattern of Te: m/z (relative abundance %) 385.9653 (7.08), 386.9681 (4.92), 
387.9660 (14.12), 388.9688 (23.79), 389.9700 (58.90), 391.2749 (0.09), 391.9746 
(91.89), 393.1926 (0.19), 393.9677 (100), 394.9754 (30.57), 395.9840 (4.62). 
4.2.18 2-(4-Methoxyphenyltellanyl)-3-methylnaphthoquinone (16) 
Compound 16 was synthesised from 4,4’-dimethoxyphenylditelluride (100 mg,  
0.2 mmol) and 2-bromo-3-methyl-1,4-naphthoquinone (154 mg, 0.6 mmol) following 
general procedure A. Compound 16 was purified by column chromatography using 
PE/EtOAc (95:5) as solvent yielding 50 % of a purple solid. 
C18H14O3Te (M = 405.90 g/mol). 
TLC: Rf: = 0.50 (PE/EtOAc, 85:15). 1H NMR: δ = 8.02-7.99 (m, 
2H), 7.76-7.74 (m, 2H), 7.67-7.60 (m, 2H), 6.77-6.75 (m, 2H), 
3.78 (s, 3H, OCH3), 1.89 (s, 3H, CH3) ppm. 13C NMR: δ = 184.5, 181.3, 160.4, 153.2, 
142.2, 142.0 (2C), 133.8 (2C), 133.2, 132.1, 131.7, 127.1, 127.0, 115.6, 103.5, 
55.25, 19.44 ppm.  
4.2.19 2-(4-Methoxyphenylselanyl)-3-methylnaphthoquinone (17) 
Compound 17 was synthesised from 4,4’-dimethoxyphenyldiselenide (550 mg,  
1.5 mmol) and 2-bromo-3-methyl-1,4-naphthoquinone (256 mg, 0.7 mmol) following 
general procedure A. Compound 17 was purified by column chromatography using 
PE/EtOAc (95:5) as solvent yielding 60 % of a orange solid. 
C18H14O3Se (M = 357.26 g/mol). 
TLC: Rf: = 0.51 (PE/EtOAc, 80:20). 1H NMR: δ = 8.06-8.01 (m, 
2H), 7.72-7.62 (m, 2H), 7.50-7.47 (m, 2H, H-a), 6.83-6.77 (m, 
2H, H-b), 3.79 (s, 3H, OCH3), 2.15 (s, 3H, CH3) ppm. 13C NMR: δ = 182.6, 182.0, 
160.2, 159.9, 148.8, 147.6, 136.1 (2C), 135.5, 133.7, 132.4, 127.1, 119.6, 115.4, 
115.2 (2C), 55.4, 17.5 ppm.  
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4.2.20 2,3-Bis(phenylsulfuryl)naphthoquinone (18) 
Compound 18 was synthesised from diphenyldisulfide (754 mg, 3.5 mmol) and  
2,3-dibromo-1,4-naphthoquinone (1203 mg, 3.8 mmol) following general procedure 
A. Compound 18 was purified by column chromatography using PE/EtOAc (90:10) as 
solvent, yielding 52 % of a orange solid. 
C22H14O2S2 (M = 374.48 g/mol). 
TLC: Rf: = 0.24 (PE/EtOAc, 95:5). 1H NMR: δ = 7.99-7.96 (m, 2H), 
7.69-7.65 (m, 2H), 7.39-7.36 (m, 4H, H-a), 7.32-7.27 (m, 6H, H-b 
and H-c) ppm. 13C NMR: δ = 178.9 (2C), 148.5 (2C), 133.9 (2C), 133.8 (2C), 132.0 
(2C), 131.4 (4C), 129.3 (4C), 128.0 (2C), 127.4 (2C) ppm. 
4.2.21 2,3-Bis(phenylselanyl)naphthoquinone (19) 
Compound 19 was synthesised from diphenyldiselenide (205 mg, 0.7 mmol) and  
2,3-dibromo-1,4-naphthoquinone (235 mg, 0.7 mmol) following general procedure A. 
Compound 19 was purified by column chromatography using PE/EtOAc (85:15) as 
solvent yielding 28 % of a orange solid. 
C22H14O2Se2 (M = 468.27 g/mol). 
TLC: Rf: = 0.54 (PE/EtOAc, 85:15). 1H NMR: δ = 7.99-7.96 (m, 
2H), 7.66-7.64 (m, 2H), 7.54-7.52 (m, 4H, H-a), 7.33-7.27 (m, 6H, 
H-b and H-c) ppm. 13C NMR: δ = 179.0 (2C), 152.3 (2C), 133.8 (4C), 133.7 (2C), 
132.7 (2C), 130.9 (2C), 129.6 (4C), 128.3 (2C), 127.5 (2C) ppm. 
4.2.22 2,3-Bis(phenyltellanyl)naphthoquinone (20) 
Compound 20 was synthesised from diphenylditelluride (302 mg, 0.7 mmol) and  
2,3-dichloro-1,4-naphthoquinone (84 mg, 0.4 mmol) following general procedure A. 
Compound 20 was purified by column chromatography using PE/EtOAc (95:5) as 
solvent yielding 25 % of a purple solid. 
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C22H14O2Te2 (M = 565.55 g/mol). 
TLC: Rf: = 0.24 (PE/EtOAc, 95:5). Mp: 163°C. 1H NMR: δ = 7.96-
7.94 (m, 2H); 7.80-7.78 (m, 4H, H-a); 7.61-7.59 (m, 2H); 7.34-7.31 
(m, 2H); 7.25-7.22 (m, 4H, H-b) ppm. 13C NMR: δ = 179.7 (2C), 154.2 (2C), 139.1 
(4C), 133.3 (2C), 132.0 (2C), 129.6 (4C), 128.5 (2C), 127.7 (2C), 118.4 (2C) ppm. IR: 
ν = 1655, 1568, 1256, 1116, 781, 731, 654 cm-1. HPLC: tR 12.53 min, purity 99.1 %. 
HRMS (m/z): [M]+ calculated for C22H14O2Te2 569.9118; found 569.9187; [M+H]+ 
calculated 570.9196; found 570.9188. Calculated isotope pattern of Te: m/z (relative 
abundance %) 559.9069 (7.7), 560.9071 (12.6), 561.9060 (16.8), 562.9082 (21.1), 
563.9071 (56.1), 564.9100 (22.5), 565.9089 (59.8), 566.9122 (14.2), 567.9100 (100), 
568.9134 (23.8), 569.9118 (53.3), 570.9152 (12.7), 571.9185 (1.4); found isotope 
pattern of Te: m/z (relative abundance %) 559.9163 (17.09), 560.9181 (17.28), 
561.9150 (37.09), 562.9155 (29.45), 563.9117 (67.96), 564.9149 (34.77), 565.9121 
(100), 566.9224 (24.76), 567.9161 (90.34), 568.9227 (21.59), 569.9187 (50.01), 
570.9188 (11.65), 571.9195 (1.51). 
4.2.23 2,3-Bis(phenylselanyl)-5,8-dihydroxynaphthoquinone (21) 
Compound 21 was synthesised from diphenyldiselenide (57.3 mg, 0.2 mmol) and 
2,3-dichloro-5,8-dihydroxy-1,4-napthoquinone (74.8 mg, 0.3 mmol) following general 
procedure A. Compound 21 was purified by column chromatography using PE/EtOAc 
(90:10) as solvent yielding 27 % of a purple solid. 
C22H14O4Se2 (M = 500.26 g/mol). 
TLC: Rf = 0.45 (PE/EtOAc, 90:10). Mp: 166°C. 1H NMR: δ = 12.30 
(s, 2H, H-6, H-7), 7.55-7.53 (m, 4H, H-a), 7.36-7.31 (m, 6H, H-b 
and H-c) ppm. 13C NMR: δ = 181.3 (2C), 159.0 (2C), 152.0 (2C), 133.4 (4C), 130.7 
(2C), 129.4 (4C), 129.3 (2C), 128.1 (2C), 111.7 (2C) ppm. HPLC: tR = 16.748 min, 
purity 99.8%. IR: ν = 2918, 2849, 1648, 1588, 1559, 1398, 1177, 1123, 736 cm-1. 
Calculated isotope pattern of Se: m/z (relative abundance %) 494.9283 (5.6), 
495.9257 (17.2), 496.9264 (14.5), 497.9249 (36.3), 498.9256 (30.6), 499.9230 
(94.8), 500.9264 (22.5), 501.9222 (100), 502.9256 (23.8), 503.9224 (37.9), 505.9226 
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(3.6); found isotope pattern of Se: m/z (relative abundance %) 494.9563 (6.86), 
495.9487 (20.55), 496.9485 (19.72), 497.9478 (54.57), 498.9545 (45.83), 499.9536 
(94.80), 500.9564 (39.93), 501.9472 (100.00), 502.9539 (39.12), 503.9546 (35.47), 
505.9578 (5.13). 
4.3 Synthesis of porphyrins 
The starting materials used for the couplings were synthesised according to literature 
procedures, Table 4.1 provides an overview over the according references. 
Table 4.1: Starting materials were synthesised according to literature procedures. 
porphyrin reference 
5-(4-Carboxyphenyl)-10,15,20-triphenylporphyrin [147], [148] 
5,10,15-Triphenyl-20-(3,6-dioxocyclohexa-1,4-denyl)-porphyrin [130] 
5-(4-Aminophenyl)-10,15,20-triphenylporphyrin [149], [150] 
5-(4-Hydroxyphenyl)-10,15,20-triphenylporphyrin [151] 
5,10,15,20-Tetrapyridylporphyrin [152] 
4-(3-Methyl-1,4-naphthoquinone-2-yl)butanoic acid [68] 
6-(1,4-Naphthoquinone-2-ylamino)hexane acid [68] 
4.3.1 General procedure for amide coupling (B) 
The amide coupling was performed according to a literature procedure [145]. A 
solution of 1 eq. carboxylic acid in 5 ml CHCl3 was cooled to 0°C and 1 eq. N-methyl-
morpholin was added dropwise The mixture was stirred for 15 min, 1 eq. ethyl 
chloroformiat was added and the mixture was stirred at 0°C for additional 30 min.  
1 Eq. of amine was added, the mixture was stirred for 1 h at 0°C and stirred at room 
temperature overnight. The solvent was removed and afterwards individual work-up 
as indicated for each compound was performed. 
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4.3.2 Porphyrin 22 
Porphyrin 22 was synthesised from 5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin 
(107 mg, 0.16 mmol) and 3-(phenylselanyl)propane-amine (35 mg, 0.16 mmol) 
following general procedure B. Porphyrin 22 was purified by column chromatography 
using CH2Cl2/MeOH (95:5) as solvent, yielding 10 % of a purple solid. 
C54H41N5OSe (M = 854.90 g/mol). 
TLC: Rf = 0.46 (CH2Cl2/MeOH, 95:5). 1H NMR: δ = 8.78-8.73 
(m, 8H), 8.13-8.10 (m, 6H), 7.73-7.66 (m, 9H), 7.49-7.47 (m, 
4H), 7.39-7.37 (m, 2H), 7.23-7.12 (m, 3H), 6.04 (br s, NH), 
3.04 (t, 2H, J = 7.8 Hz), 2.83 (t, 2H, J = 7.8 Hz), 1.78 (m, 
2H), -2.91 (s, 2H) ppm. 
4.3.3 Porphyrin 23 
Porphyrin 23 was synthesised from 4-(phenylselanyl)butanoid acid (161 mg,  
0.66 mmol) and 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (110 mg, 0.18 mmol) 
following general procedure B. Porphyrin 23 was purified by column chromatography 
using CH2Cl2 as solvent, yielding 37 % of a purple solid. 
C54H41N5OSe (M = 854.90 g/mol). 
TLC: Rf = 0.61 (CH2Cl2). 1H NMR: δ = 8.91-8.89 (m, 8H), 
8.27-8.24 (m, 6H), 8.15-8.13 (m, 2H), 7.79-7.74 (m, 11H), 
7.59-7.57 (m, 2H), 7.30-7.27 (m, 3H), 3.07 (t, 2H), 2.51 (t, 
2H), 2.21 (m, 2H), -2.67 (s, 2H) ppm. 
4.3.4 Porphyrin 24 
For the synthesis of porphyrin 24, 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin 
(75 mg, 0.12 mmol), 3-(phenylselanyl)propane-bromide (165 mg, 0.60 mmol) and 
K2CO3 (165 mg, 1.20 mmol) as well as 2 ml water were dissolved in THF and heated 
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to reflux overnight. After cooling to rt the solvent was evaporated and the residue was 
purified by column chromatography using CH2Cl2/n-hexane (50:50) as solvent, 
yielding 27 % of a purple solid. 
C53H40N4OSe (M = 827.87 g/mol). 
TLC: Rf = 0.87 (CH2Cl2). 1H NMR: δ = 8.91-8.87 (m, 8H), 
8.26-8.23 (m, 6H), 8.14-8.12 (m, 2H), 7.79-7.74 (m, 9H), 
7.65-7.63 (m, 2H), 7.33-7.26 (m, 5H), 4.37 (t, 2H, J = 7.8 Hz), 
3.30 (t, 2H, J = 7.8 Hz), 2.40 (m, 2H), -2.73 (s, 2H) ppm. 13C 
NMR: δ = 158.9, 142.5, 142.3, 135.7, 134.8, 132.9, 130.3, 
129.4, 128.0 127.2, 126.9, 120.2, 120.1, 113.2, 112.9, 77.4, 67.3, 30.2, 29.8, 24.5 
ppm. 77Se NMR: δ = 279.75 ppm. UV/VIS: λ = 417, 514, 550, 590, 646 nm. MS: m/z= 
829.1 [M+H]+. 
4.3.5 Porphyrin 25 
Porphyrin 25 was synthesised by the reaction of 5,10,15,20-tetrapyridylporphyrin  
(20 mg, 0.03 mmol) with 3-(phenylselanyl)propane-bromide (91 mg, 0.33 mmol) in 
the presence of K2CO3 (165 mg, 1.20 mmol). The reagents, dissolved in DMF, were 
heated to reflux overnight. After cooling to rt, the solvent was evaporated and the 
residue was purified by column chromatography using CH2Cl2/MeOH (99:1) as 
solvent yielding a purple solid. Due to solubility problems, no NMR data could be 
obtained. 
C49H37N8Se (M = 816.83 g/mol). 
UV/VIS: λ = 434, 520, 562, 592, 651 nm. MS: m/z = 816.8 
[M]+. 
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4.3.6 Porphyrin 26 
Porphyrin 26 was synthesised from 4-(3-methyl-1,4-naphthoquinone-2-yl)butanoic 
acid (94 mg, 0.36 mmol) and 5-(4-aminophenyl)-10,15,20-triphenylporphyrin  
(226 mg, 0.36 mmol) following general procedure B. Porphyrin 26 was purified by 
column chromatography using CH2Cl2 as solvent, yielding 71 % of a purple solid. 
C59H43N5O3 (M = 870.00 g/mol). 
TLC: Rf = 0.20 (CH2Cl2). 1H NMR: δ = 8.93-8.90 (m, 8H), 
8.29-8.26 (m, 6H), 8.22-8.20 (m, 2H), 8.12 (s, NH), 7.96-
7.92 (m, 4H), 7.79-7.76 (m, 9H), 7.55-7.53 (m, 2H), 2.59 
(t, 2H, J = 7.8 Hz), 2.47 (t, 2H, J = 7.8 Hz), 2.12 (s, 3H), 
1.92 (m, 2H), -2.73 (s, 2H) ppm. 13C NMR: δ = 185.2, 
184.8, 171.0, 145.9, 144.2, 142.2, 138.0, 137.9, 135.2, 
134.7, 133.4, 133.3, 133.2, 131.9, 131.8, 127.8, 126.8, 
126.2, 126.1, 120.3, 120.2, 119.8, 118.2, 37.1, 26.2, 24.2, 12.7 ppm. LC-MS: tR = 
15.5 min, m/z = 870.54 [M]+. 
4.3.7 Porphyrin 27 
Porphyrin 27 was synthesised from 6-(1,4-naphthoquinone-2-ylamino)hexane acid 
(58 mg, 0.20 mmol) and 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (126 mg, 
0.20 mmol) following general procedure B. Porphyrin 27 was purified by column 
chromatography using CH2Cl2 as solvent yielding 55 % of a purple solid. 
C60H46N6O3 (M = 899.05 g/mol). 
TLC: Rf = 0.80 (CH2Cl2). 1H NMR: δ = 8.86-8.84 (m, 
8H), 8.22-8.20 (m, 6H), 8.16-8.14 (m, 2H), 8.10-
8.09 (m, 1H), 8.03 - 8.02 (m, 1H), 7.90-7.88 (m, 
2H), 7.79-7.76 (m, 9H), 7.60-7.55 (m, 2H), 5.93 (s, 
1H, NH), 5.78 (s, 1H), 3.27 (q, 2H), 2.53 (t, 2H, J = 
7.8 Hz), 1.93 (quint, 2H), 1.81 (quint, 2H), 1.58 (m, 
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2H), -2.76 (s, 2H) ppm. 13C NMR: δ = 183.3, 171.2, 148.2, 142.3, 135.3, 134.9, 
134.7, 133.8, 132.1, 130.7, 127.9, 126.8, 126.4, 126.3, 120.3, 118.9, 118.1, 100.9, 
42.5, 37.7, 28.23, 26.85, 25.3 ppm. LC-MS: tR = 14.9 min, m/z = 899.58 [M]+. 
4.3.8 Porphyrin 32 and 32a 
3-(Phenylseleno)propane-1-amine (5 mg, 0.02 mmol), dissolved in CH2Cl2, was 
added dropwise to a solution of porphyrin 28 (14 mg, 0.02 mmol), dissolved in 
CH2Cl2. The reaction mixture was stirred in the dark at rt for 4 days. After removal of 
the solvent, the residue was purified by column chromatography using CH2Cl2 as 
solvent. The fraction containing the product was concentrated and loaded onto a 
preparative TLC plate using CH2Cl2 as solvent. Scratching, re-dissolving in CH2Cl2 
and evaporation of the solvent provided porphyrins 32 and 32a in 5 % and 5 % yield 
as purple solids. The upper fraction contained the monosubstituted porphyrin 32 and 
the lower fraction contained the disubstituted porphyrin 32a.  
32: C53H39N5O2Se (M = 856.87 g/mol). 
TLC: Rf = 0.83 (CH2Cl2). 1H NMR: δ = 9.18-8.82 (m, 8H), 8.26-
8.15 (m, 6H), 7.78-7.72 (m, 9H), 7.15 (m, 1H), 6.86-6.81 (m, 
2H), 6.66-6.55 (m, 4H), 5.81 (s, 1H), 3.46 (t, 2H, J = 7.8 Hz), 
2.97 (t, 2H, J = 7.8 Hz), 2.09 (quint, 2H), -2.70 (s, 2H) ppm. 
MS: m/z = 857.7 [M+H]+. UV/VIS: λ = 415, 512, 591, 651 
nm. 
32a: C62H50N6O2Se2 (M = 1069.02 g/mol). 
TLC: Rf = 0.17 (CH2Cl2). 1H NMR: the resulting amount was 
too little to get clear signals. MS: m/z = 1070.7 [M+H]+. 
UV/VIS: λ = 416, 514, 548, 588 nm. 
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4.3.9 Porphyrins 33-36 
3-(Phenylseleno)propane-amine (44 mg, 0.20 mmol) in 2 ml DMF was added 
dropwise to a solution of PFFF (50 mg, 0.05 mmol) in 5 ml DMF. The reaction 
mixture was heated to reflux overnight. After cooling to rt, the solvent was removed 
and the residue was loaded onto a preparative TLC plate using CH2Cl2: n-hexane 
(70:30) as solvent. Scratching, re-dissolving in CH2Cl2 and evaporation of the solvent 
provided porphyrins 33, 34, 35 and 36 in 5 % and 5 % yield as purple solids. 
33: C53H22F19N5Se (M = 1168.70 g/mol). 
TLC: Rf = 0.76 (CH2Cl2). 1H NMR: δ = 9.01-8.89 (m, 8H), 7.64-
7.62 (m, 2H), 7.35-7.32 (m, 3H), 3.71 (t, 2H, J = 8.0 Hz), 3.19 (t, 
2H, J = 8.0 Hz), 2.24 (quint, 2H), -2.90 (s, 2H) ppm. 19F NMR: δ 
= -136.48 (dd, 6F, F-c), -140.46 (dd, 2F, F-b), -151.51 (dt, 3F, 
F-e), -160.60 (dd, 2F, F-a), -161.61 (dt, 6F, F-d) ppm. (MS: m/z 
= 1168.6 [M+H]+. UV/VIS: λ = 419, 509, 545, 586, 646. 
34: C62H34F18N6Se2 (M = 1362.86 g/mol). 
TLC: Rf = 0.43 (CH2Cl2/n-hexane, 50:50). 1H NMR: the resulting 
amount was too little to get clear signals. MS: m/z =1364.0 
[M+H]+. UV/VIS: λ = 419, 509, 545, 586, 646. 
 
 
4.3.10 Porphyrins 37-40 
A solution of diphenyldiselenide (15 mg, 0.05 mmol) in 5 ml THF was cooled to 0°C 
under N2-atmosphere. Sodiumborohydride (6 mg, dissolved in 1 ml H2O) was added 
dropwise, until the solution turned colourless. Then, the mixture was poured into an 
icecold solution of PFPP (24 mg, 0.025 mmol) in THF. As soon as TLC-monitoring 
did not show any starting material (after 40 min), the reaction was quenched with 
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NH4Cl-solution and extracted with CH2Cl2. The solvent was evaporated and the 
residue loaded onto a preparative TLC plate using CH2Cl2/n-hexane (50:50). 
Scratching, re-dissolving in CH2Cl2 and evaporation of the solvent provided the 
desired porphyrins 37, 38, 39 and 40 in 13 %, 23 %, 24 % and 20 % yield as reddish 
purple solids. 
37: C50H15F19N4Se (M = 1111.61 g/mol). 
TLC: Rf = 0.46 (CH2Cl2/n-hexane, 50:50). 1H NMR: δ = 8.94 (s, 
8H), 7.89-7.87 (m, 2H), 7.45-7.43 (m, 3H), -2.91 (s, 2H) ppm. 
19F NMR: δ = -127.37 (dd, 2F, F-a or F-b), -136.11 (dd, 2F, F-a 
or F-b), -136.48 (dd, 6F, F-c), -151.28 (t, 3F, F-e), -161.35 (dt, 
6F, F-d) ppm. 77Se NMR: δ = 289.33 ppm. MS: m/z =1112.1 
[M]+. UV/VIS: λ = 412, 507, 542, 586, 646. 
38: C56H20F18N4Se2 (M = 1248.68 g/mol). 
TLC: Rf = 0.48 (CH2Cl2/n-hexane, 50:50). 1H NMR: δ = 8.94-
8.89 (m, 8H), 7.88-7.86 (m, 4H), 7.47-7.45 (m, 6H), -2.91 (s, 
2H) ppm. 19F NMR: δ = -127.42 (dd, 4F, F-a or F-b), -136.09 
(dd, 4F, F-a or F-b), -136.48 (dd, 4F, F-c), -151.36 (t, 2F, F-e), -
161.41 (dt, 4F, F-d) ppm. 77Se NMR: δ = 289.33 ppm. MS: m/z 
= 1249.3 [M]+. UV/VIS: λ = 412, 507, 542, 586, 646. 
39: C62H25F17N4Se3 (M = 1385.74 g/mol). 
TLC: Rf = 0.56 (CH2Cl2./n-hexane, 50:50). 1H NMR: δ = 
8.89-8.88 (m, 8H), 7.87-7.86 (m, 6H), 7.47-7.45 (m, 9H), 
-2.90 (s, 2H) ppm. 19F NMR: δ = -127.44 (dd, 6F, F-a or 
F-b), -136.07 (dd, 6F, F-a or F-b), -136.47 (dd, 2F, F-c), -
151.38 (dt, 1F, F-e), -161.45 (dt, 2F, F-d) ppm. 77Se 
NMR: δ = 288.69 ppm. MS: m/z = 1386.3 [M]+. UV/VIS: λ 
= 412, 507, 542, 586, 646. 
N
NH N
HN
C6F5
C6F5
C6F5
SePh
F
F F
F
37
N
NH N
HN
C6F5 C6F5
SePh
SePh
F
F
F
F
F
F F
F
38
N
NH N
HN
C6F5
SePh
SePh
SePh
F
F
F
F
F
F F
F
F F
FF
39
4. Experimental Part 
   
 - 156 - 
40: C68H30F16N4Se4 (M = 1522.81 g/mol). 
TLC: Rf = 0.60 (CH2Cl2/n-hexane, 50:50). 1H NMR: 
δ = 8.90 (s, 8H), 7.87-7.85 (m, 8H), 7.47-7.45 (m, 
12H), -2.90 (s, 2H) ppm. 19F NMR: δ = -127.48 
(dd, 8F, F-a or F-b), -136.05 (dd, 8F, F-a or F-b) 
ppm. 77Se NMR: δ = 288.45 ppm. MS: m/z = 
1523.0 [M]+. UV/VIS: λ = 412, 507, 542, 586, 646. 
4.3.11 Porphyrin 42 
Under N2-atmosphere sodiumborohydride (100 mg, dissolved in 5 ml of H2O) was 
added dropwise to diphenylditelluride (32 mg, 0.08 mmol), dissolved in 5 ml THF until 
the solution turned colourless. Then, the mixture was poured into an icecold solution 
of PFPP (10 mg, 0.01 mmol) in THF. As soon as TLC-monitoring did not show any 
starting material (after 40 min), the reaction was quenched with NH4Cl-solution and 
extracted with CH2Cl2. The solvent was evaporated and the residue loaded onto a 
preparative TLC plate using CH2Cl2/n-hexane (50:50). Scratching, re-dissolving in 
CH2Cl2 and evaporation of the solvent provided porphyrin 42 in 8 % yield as reddish 
purple solid. 
C44H14F16N4 (M = 902.58 g/mol). 
TLC: Rf = 0.52 (CH2Cl2/n-hexane, 50:50). 1H NMR: δ = 8.92 
(s, 8H), 7.68-7.60 (m, 4H), -2.81 (s, 2H) ppm. 19F NMR: δ = 
-137.25 (m, 8F, F-a or F-b), -138.57 (m, 8F, F-a or F-b) 
ppm. MS: m/z = 901.9 [M]+. UV/VIS: λ = 411, 505, 545, 586. 
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4.3.12 Chlorin 43 
Under N2 atmosphere, tetraphenyl-2-hydroxychlorin (16 mg, 0.025 mmol), dissolved 
in 5 ml THF, was spiked with freshly washed sodiumhydride (100 mg) and the purple 
solution turned green. Then 3-(phenylselanyl)propane-bromide (13 mg, 0.05 mmol), 
dissolved in THF, was added dropwise and the reaction mixture was gently heated 
for 3 days. After cooling to rt, the solvent was evaporated and the residue was 
purified by column chromatography using CH2Cl2 as solvent. Evaporation of the 
solvent provided chlorine 43 in less than 5 % yield as purple solid. 
C53H42N4OSe (M = 829.89 g/mol). 
TLC: Rf = 0.80 (CH2Cl2). MS: m/z = 831.3 [M+H]+. UV/VIS: λ 
= 415, 516, 543, 643. 
 
4.3.13 Thiophenol assay 
In order to measure the catalytic GPx-like properties of the compounds, the 
thiophenol assay was performed. In a cuvette containing 890 µl of a methanolic 
solution of thiophenol (1 mM) and NEt3 (0.05 mM) 10 µl of the test compound in 
DMSO (100 µM) were added and mixed carefully by pipetting up and down. 100 µl 
H2O2 (2 mM) were added to the mixture, mixed and the reaction was followed 
spectrophotometrically on a Cary Varian at 305 nm for 25 min at room temperature. 
The initial rate of disulfide formation of the first 5 min of the reaction of 1 mM 
thiophenol and 2 mM H2O2 was set at 1.00-fold and all other initial rates of disulfide 
formation were related to that control. Table 2.1 summarises the calculated 
normalised reaction rates (the experimental error was set at 5 %). In a preliminary 
experiment, DMSO showed no influence on disulfide formation.  
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4.4 Cell culture 
4.4.1 Materials and methods 
All cell culture assays were performed under sterile conditions at the institute for 
pharmaceutical biology of Prof. Dr. A. K. Kiemer at Saarland University under the 
instructions of Dr. Britta Diesel. RAW 264.7 cells were kindly provided by the institute 
for pharmaceutical biology of Prof. Dr. A. K. Kiemer at Saarland University. 
All used plastic- or glass-materials were sterilised prior to use. All solutions were 
sterilised by steam autoclaving. Experiments were performed in 96-well or in 24-well-
plates from Greiner bio-one. All solutions were warmed gently prior to use in a 
waterbath (37°C). While treatment of cells, cells were additionally warmed by an 
underlying warmed base. All experiments were also followed visually via microscope. 
Used chemicals were purchased either from Sigma Aldrich or Roth. Other 
commercial sources of used chemicals and solutions are provided in Table 4.2. 
PBS, HBSS, buffer B and the lysis buffer were prepared as following and stored at a 
temperature of 4°C. For PBS 8 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g KH2PO4 
were dissolved in 950 ml bi-destilled water. The pH-value was adjusted to 7.4 and 
the volume was adjusted to 1000 ml with additional H2O. For HBSS 8.18 g NaCl,  
0.4 g KCl, 50 mg Na2HPO4, 50 mg KH2PO4, 180 mg CaCl2, 200 mg MgSO4, 1.0 g 
glucose and 4.76 g HEPES were filled with bi-destilled water to a volume of 1l. For 
the buffer B 5.96 g HEPES, 5.0 g sucrose and 0.5 g CHAPS were dissolved in  
500 ml bidestilled water and pH was adjusted to 7.5. For the lysis-buffer 406.8 mg 
MgCl2, 152 mg EGTA, 400 µl Triton X and 200 ml of 50 mM HEPES were filled with 
bi-destilled water to a volume of 400 ml. 
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Table 4.2: commercial sources of used chemicals. 
chemical commercial source 
Bradford-reagent Biorad 
DEVD-AFC Enzo Life Sciences 
DMSO Acros Organics 
FCS PAA Pasching, Austria 
Glu PAA Pasching, Austria 
LPS, ultrapure from E.coli, K12 strain-TLR 4 ligand Invivogen 
NaNO2 Fluka 
P/S PAA Pasching, Austria 
PMA Calbiochem, USA 
RPMI 1640 PAA Pasching, Austria 
trypsin-EDTA PAA Pasching, Austria 
4.4.2 Culturing of cells 
RAW 264.7 are murine, macrophage-like cells which grow adherently. Cells were 
cultured in 250 ml cell culture flasks in RPMI 1640 medium at a temperature of 37°C 
and an atmosphere of 5 % CO2 and 95 % air humidity. The medium was supplied 
with 10 % FCS (3.0-4.5 g/dl), an antibiotic mixture of 1 % penicilline/ streptomycine 
(Penicellin: 10000 Units/ml, streptomycine: 10 mg/ml) and 1 % glutamine (200 mM). 
Cells were grown to approximately 70 % confluence before they were used for the 
experiments. Cells of passages between 4 to maximum 16 were used for the 
experiments cells. 
4.4.3 Thawing of cells 
Cells frozen in cryo-vials at a temperature of -80°C were softly heated in a water bath 
at a temperature of 37°C. In order to minimize the toxic effect of DMSO, cells were 
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quickly poured into 10 ml of warmed medium. The suspension was centrifuged at 
200 g for 10 min and the upper medium was removed. The cell pellet was re-
suspended in 10 ml fresh medium and poured into a 40 ml cell culture flask. Cells 
were allowed to grow for at least three days before they were used for the following 
experiments. 
4.4.4 Freezing of cells 
For freezing, cells were washed twice with PBS, detached with trypsin-EDTA, 
centrifuged at 200 g for 10 min and the cell pellet was re-suspended in 10 ml of ice 
cold medium containing 70 % RPMI 1640 medium, 20 % FCS and 10 % DMSO. 
Cells-suspensions were aliquoted and transferred into cryo-vials. Cells were stored at 
a temperature of -80°C for three days and afterwards stored in liquid nitrogen at a 
temperature of -198°C. 
4.4.5 Splitting of cells 
Every three to four days cells were split. Therefore, the upper medium was removed 
and cells were washed twice with 5 ml PBS. Afterwards cells were incubated for 5 
min with 1 ml trypsin-EDTA. For complete detachment of the cells, the flask was 
softly knocked. Cells were diluted with fresh medium, which stops the reaction of 
trypsin. Cells which were used for subsequent experiments, were transferred into a 
50 ml falcon tube, diluted with medium and seeded in a 96-well plate. The remaining 
cells were diluted with fresh medium and placed into a 250 ml cell culture flask. 
4.4.6 Counting of cells 
Cells were detached with Trypsin-EDTA, redissolved in 10 ml of Medium, applied 
onto a Neubauer-counting chamber (Marienfeld) and all four aquares were counted 
under a microscope according to manufacturer’s assignments. The average of cells 
was determined, converted into number of cells/ml and cells were diluted as required 
for the different assays. 
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4.4.7 Statistics 
Results are expressed as mean ± SE of the indicated number of experiments. IC50-
values for MTT assay were calculated using Origin 8GPro. Statistical analysis 
comparing a treatment condition to the appropriate control was performed between 
two groups and analyzed using two-sided unpaired t-test. The statistical tests were 
applied student’s t test in Microsoft excel. 
Significances: *: P < 0.05, **: P < 0.01 and ***: P < 0.001. 
4.4.8 MTT assay 
MTT assay was performed as described in the literature [153]. Briefly, cells were 
seeded in a 96-well plate at a density of 40000 cells/100 µl and allowed to adhere for 
6 h. Then cells were treated with test compounds in 100, 25, 20, 15, 10, 7.5, 5 and 
2.5 µM in the absence or presence of 30 µM H2O2. Cells incubated with 0.2 % 
DMSO, which was used as solvent for the tested compounds, served as control. 
After incubation for 24 h the medium was removed, 150 µl MTT (0.5 mg/ml in 
medium) were added and incubated for 40 min. Then MTT was removed and cells 
were lysed by addition of 200 µl DMSO. The absorbance was measured at a 
wavelength of 550 nm with 690 nm used as reference wavelength. Each 
concentration was tested in hexaplicate and each experiment was repeated at least 
three times on different days. A preliminary experiment showed that the appropriate 
solvent control containing 0.2 % DMSO had no statistically significant effect on the 
cell viability and thus all calculated cell viabilities are expressed relative to 0.2 % 
DMSO. IC50 values were calculated using OriginPro8.5. 
A control experiment performed in the absence of cells ensured that no undesired 
interaction between the test compounds or H2O2 and MTT itself was observed. In a 
preliminary experiment H2O2 was tested in different concentrations and 30 µM H2O2 
was found to reduce cell viability to approximately 50 % and was chosen to simulate 
the event of OS. 
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4.4.9 Caspase-3 assay 
Caspase-3 assay was performed analogously to a literature procedure [100]. Briefly, 
cells were seeded in a 96-well plate at a density of 40000 cells/100 µl and allowed to 
adhere for 6 h. Then cells were treated with test compounds (5 µM or 10 µM for 
compounds 1-3 and 5; 0.2 µM and 2 µM for compound 20; 20 nM and 200 nM for 
compound 16) in the absence or presence of 10 µM H2O2. Cells incubated with  
0.05 % DMSO, which was used as solvent for the test compounds, served as control. 
After incubation for 3 h, 6 h, 9 h and 24 h, cells were placed on ice, washed twice 
with ice-cold PBS and lysed by the addition of 20 µl of lysis-buffer. For complete 
lysis, cells were frozen overnight at a temperature of -78°C. For the following 
caspase-3 assay, cell lysate was split and transferred into two 96-well plates: 10 µl of 
the lysed cells were used for the caspase-3 assay and 5 µl of the lysed cells were 
used for the determination of the protein concentration via Bradford assay. For the 
caspase-3-assay, 90 µl of substrate containing 50 µM DEVD-AFC was added to  
10 µl of lysed cells treated with compounds in the presence or absence of 10 µM 
H2O2. The generation of free AFC was measured at a wavelength of 485 against a 
reference wavelength of 535 nm (with AFC in concentrations from 0.20 mM to 10 mM 
serving as standard curve). Bradford-assay was performed using a ready-to-use 
Biorad Protein assay Kit solution and BSA (from 0 µg/ml to 30 µg/ml) as standard. 
The amount of AFC released was divided by the amount of the protein and caspase-
3 activities were calculated as folds compared to the appropriate solvent-treated 
control. Each concentration was tested in triplicate and each experiment was 
repeated at least three times.  
In a preliminary experiment, cell lysates of actinomycin D treated (200 ng/ml) cells 
were treated with 10 µM of test compounds and the caspase-3 assay was performed 
as described. The compounds did not interact with any of the substrates of the 
caspase-3 assay. 
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4.4.10 Griess assay 
The Griess assay was performed according to a literature procedure [28]. Briefly, 
cells were seeded in a 96-well plate at a density of 80000 cells/200 µl. After allowing 
the cells to adhere for 6 h, cells treated with the test compounds in the presence or 
absence of 100 ng/ml LPS (ultrapure from E. coli, K12 strain-TLR 4 ligand, 
Invivogen) and DMSO in the appropriate concentration was used as control. After 
incubation for 20 h, 100 µl of the supernatant were transferred into a 96-well plate 
and 90 µl of sulfanilamide and 90 µl of N-(1-naphthyl)-ethylene-diamine were added 
to quantify nitrite as a metabolite of •NO. NaNO2 was used for the standard curve on 
the same plate. The absorbance at 550 nm was measured using a microplate reader 
against the background of 690 nm. For the determination of cell viability, MTT assay 
was performed as described above. Each concentration was tested in triplicate and 
each experiment was repeated for at least three times. In a preliminary experiment 
different concentrations of LPS (50 ng/ml-1 µg/ml) were tested to determine the 
effective concentration of LPS. 
To make sure that the effects observed were not an interaction of the test 
compounds with Griess reagents themselves, the same assay was performed in the 
absence of cells using the •NO-donors diethylamine nonoate diethylammonium salt 
(DEA) or S-nitroso-N-acetyl-D,L-penicillamine (SNAP). Briefly, 10 µM or 100 µM of 
test compounds were added to a solution containing 100 µM DEA or 100 µM SNAP 
and allowed to incubate for 15 min (DEA) or 7 h (SNAP). The amounts of •NO 
released were not statistically significantly changed in the presence of the test 
compounds. 
4.4.11 ROS assay 
ROS assay was performed as described in the literature [6] using DCF-DA. The non-
fluorescent cellpermeable fluorescein easily diffuses into the cell, where it is 
hydrolysed enzymatically by some intracellular esterases to non-fluorescent 
dichlorodihydrofluorescein. In the presence of reactive species, 2′,7′-dichloro-
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dihydrofluorescein (DCF) is oxidised to the fluorescent dichlorofluorescein. The 
emitted fluorescence is directly proportional to the concentration of reactive species 
[110, 114]. Cells were seeded at a density of 80000 cells/200 µl in a 96-well plate 
and allowed to adhere for 4 h. Then, 100 µl of the medium were removed and 100 µl 
of the test compounds were added to give final concentrations of 5, 10, 25, 50, 75, 
100 and 150 µM. Cells were incubated at 37°C for 25 min. Afterwards the complete 
medium was removed, cells were washed with warm HBSS and 200 µl of 20 µM 
2′,7′-dichlorodihydrofluorescein diacetate in HBSS were added. After incubation for 
25 min, cells were washed with HBSS, 200 µl HBSS were added and cells were 
stimulated with 1 µM or 50 µM H2O2. Cells only treated with DMSO, dye and stimulus 
served as control. The fluorescence was followed for 40 min in a fluorescence reader 
(Wallac Victor 2) at a temperature of 37°C using the excitation filter set at 485 nm 
and the emission filter set at 535 nm. Each concentration was tested in triplicate and 
each experiment was repeated at least three times. In a control experiment different 
concentrations of PMA and H2O2 were tested and 1 µM PMA and 50 µM H2O2 were 
found to differ significantly from the cells treated only with dye. Another control 
experiment, in which cells were only incubated with the test compounds and stimuli in 
the absence of dye, showed no fluorescence, proving that neither test compounds 
nor stimuli induced fluorescence by themselves.  
4.4.12 Proliferation assay 
Prior to use, ECIS-96-well plate (96W10E+) was pre-incubated with medium 
overnight. Cells were seeded at a density of 7000 and 10000 cells/well in a 96-well 
ECIS plate and allowed to adhere for approximately 6 h. Untreated cells, DMSO-
treated cells and LPS-treated (100 ng/ml) cells served as controls. After the 
attachment, cells were treated with 5 µl of the test compounds to give final 
concentrations of 2.5 µM, 10 µM and 25 µM by pausing the experiment. After 
addition of the compounds, impedance was continued recorded every 15 min for 72 h 
using multi-frequency option at an ECIS apparatus (ECIS®Z, Applied Biophysics). A 
common 96-well plate was treated simultaneously and served for the MTT assay. 
Each concentration was tested in triplicate and experiments were repeated three 
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times. Optical changes were controlled via microscope every 24 h and at the end of 
the ECIS-assisted assay, cell viability of the analogously treated plate was confirmed 
using MTT assay (as described above). All experiments were repeated at least three 
times. 
4.4.13 Staining of cell nuclei 
Nucleus staining was performed according to literature [154]. Cells were cultured in 
24-well plates on a coverslip. After allowing the cells to adhere for 4 h, cells were 
treated with the test compounds for 9 h. Then, medium was removed, cells were 
washed once with 500 µl PBS and cells were fixed by the addition of 300 µl 
paraformaldehyde (3.7 % in PBS). After incubation for 10 min, cells were washed 
twice with 500 µl PBS and exposed to 500 µl DAPI (0.5 µg/ml) for 10 min in the dark. 
Afterwards, cells were washed with PBS and fixed onto a microscope slide. Cells 
were observed under a fluorescence microscope (Zeiss Axiovert 25 microscope) and 
supportingly, pictures were taken. For each sample, at least 150 cells were counted 
and the ratio of apoptotic cells to the total number of cells was expressed as 
percentage. Each concentration was tested in duplicate and experiments were 
repeated three times. 
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Caspase assay 
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Caspase-3-assay for compounds 1 (A), 3 (B), 5 (C) and 16 (D) after treatment with 10 µM 
(compounds 1,3 and 5) or 0.2 µM (compound 16) for 3, 6, 9 and 24 h in the absence (white bars) 
or in the presence of 10 µM of H2O2 (grey bars). Significances are expressed relative to the 
appropriate control. Data show means of four independent experiments and error bars 
represent SE. 
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Griess assay 
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Griess assay for compounds 1 (A), 2 (B), 4 (C), 5 (D), 12 (E), 14 (F), 15 (G) and 16 (H) in RAW 
264.7 cells. Panels show the amount of •NO released by cells treated with the test compounds 
in the concentrations stated in the absence (white bars) or presence (grey bars) of 100 ng/ml of 
LPS. Data show means of three experiments, error bars represent SE. Significances are 
expressed to the relative control. 
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Griess assay for compounds 18 (I), 19 (J), 20 (K) and nq (L) in RAW 264.7 cells. Panels show 
the amount of •NO released by cells treated with the test compounds in the concentrations 
stated in the absence (white bars) or presence (grey bars) of 100 ng/ml of LPS. Data show 
means of three experiments, error bars represent SE. Significances are expressed to the 
relative control. 
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ROS assay for compounds 1 (A) and 3 (B) in RAW 264.7 cells. Data show relative fluorescence 
in cells incubated for 40 min with compound in the presence of H2O2 (___) or PMA (….) 
compared to H2O2 or PMA treatment alone. Data show means of four experiments, error bars 
represent SE. 
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ROS assay for compounds 16 (A), 17 (B), 18 (C), 19 (D), 20 (E) and nq (F) in RAW 264.7 cells. 
Data show relative fluorescence in cells incubated for 40 min with compound in the presence 
of H2O2 (___) or PMA (….) compared to H2O2 or PMA treatment alone. Data show means of four 
experiments, error bars represent SE. 
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